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SUMMARY
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The prevention of immune complex p rec ip i ta t ion  (PIP) is the phenomenon 
whereby immune complexes form ed at or near equivalence in serum are held in 
solution and an immune p rec ip i ta te  does not fo rm . PIP is mediated by the 
complem ent system via ac t iva t io n  o f the classical pathway. The fo rm a tion  and 
d e p o s i t io n  o f  c i r c u la t in g  im m un e  co m p le xe s  is an im p o r ta n t  cause o f  
im m uno log ica lly  mediated tissue in ju ry . The com plem ent system through the 
PIP mechanism the re fo re  acts to prevent the fo rm a tion  o f these large insoluble 
complexes which m igh t deposit in tissues and thereby cause disease. My 
hypothesis was tha t  i f  PIP was im portan t in inh ib i t ing  the fo rm a tion  o f these 
ph log istic  complexes then one m ight expect there to be defects in PIP in 
patients w ith  immune complex disease. I the re fo re  developed an assay and 
proceeded to measure PIP in the sera of patients w ith  rheum atic  disease in 
which immune complexes were im p lica ted  in disease pathogenesis.
The sera o f fo r ty  seven per cent of patients w ith  seropositive rheumatoid 
a r t h r i t i s  (R A )  f a i le d  to  p re v e n t  th e  p r e c ip i t a t io n  o f  a n t ig e n  - a n t ib o d y  
complexes. This was not due to hypocomplementaem ia suggesting tha t  the 
im pa irm en t o f PIP in these sera was due to the presence o f an inh ib i to r o f PIP.
An assay to  measure th is inh ib i to ry  a c t iv i ty  was developed. Inh ib ito ry  a c t iv i ty  
was found in the m a jo r i ty  o f  patients w ith  seropositive RA in both sera and 
synovial f lu id .  Sera from  patients w ith  seronegative a r th r i t is  contained l i t t le  or 
no inh ib i to ry  a c t iv i ty .  In seropositive RA sera in h ib i to ry  a c t iv i ty  was inversely 
corre la ted  w ith  PIP. Inh ib ito ry  a c t iv i ty  in the serum did not corre la te  w ith  
ind ices  o f  g e n e ra l is e d  disease a c t i v i t y  ( a r t i c u la r  in d ex ,  e r y th r o c y te  
sedim enta tion  ra te  (ESR), haemoglobin, wh ite  ce ll count or p la te le t^  In the 
synovial f lu id  (SE) inh ib i to ry  a c t iv i ty  did not co rre la te  w ith  SE pro te in  content 
or wh ite  ce ll count and only weakly w ith  a localised jo in t  a c t iv i ty  score. 
However, the leve l o f inh ib i to ry  a c t iv i ty  was associated w ith  the presence of
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the e x tra -a r t ic u la r  fea tures o f  RA being highest in those patients w ith  nodular 
disease and especially in RA patien ts  whose disease was com plica ted by skin or 
m ajor organ vasculit is .
A lthough s ign if ican t levels o f inh ib i to ry  a c t iv i ty  were only found in sero­
p o s i t iv e  R A th e  c o r r e la t io n  b e tw e e n  in h ib i t o r y  a c t i v i t y  and Ig M -R F  (as 
measured by ELISA) was poor. Some patients sera displayed high levels of 
inh ib i to ry  a c t iv i ty  and low IgM -RF and vice versa.
The p u r i f ica t io n  of the molecule(s) responsible fo r  in h ib i to ry  a c t iv i ty  was 
c a r r ie d  o u t .  I n h ib i t o r y  R A  se rum  was s u b je c te d  to  IgG Sepharose 
c h ro m a to g ra p h y  and subsequen t gel f i l t r a t i o n  on S ephary l S300. Ig M -R F  
co-chromatographed w ith  inh ib i to ry  a c t iv i ty  at a l l stages of the pu r i f ica t io n  
procedure.
However, studies on the mechanism of action o f the in h ib i to r  o f PIP in RA sera 
showed tha t  IgM -RF was not alone responsible fo r  the phenomenon in whole RA 
serum. The inh ib i to r  of PIP reduced C4 consumption by antigen - antibody 
complexes but pu r if ied  IgM -RF did not display tha t  capac ity ; fu r the rm ore  
pur if ied  IgM -RF inh ib ited  PIP to a greater ex ten t than the same amount of 
IgM-RF in RA serum.
To d e l in e a te  these aspec ts  o f  i n h ib i t o r y  a c t i v i t y  m ore  c le a r ly  f u r t h e r  
p u r i f ica t io n  procedures were developed. Inh ib ito ry  a c t iv i t y  was shown to exist 
in the higher m olecular weight frac t ions in both RA and normal serum when 
these sera were subjected to sucrose density gradient u lt ra cen tr i fu g a t io n .  
Inh ib ito ry  a c t iv i t y  was expressed d i f fe re n t ly  in RA and normal serum and this 
f ina l expression of inh ib i to ry  a c t iv i ty  in serum was dependent on the modulating 
influences o f  various antagonists found in the whole serum. Furthe r p u r if ica t io n
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using small columns of IgG Sepharose revealed tha t  the m a jo r i ty  o f  inh ib i to ry  
a c t iv i t y  bound to the column and could be eluted w ith  0.4M NaCI (normal
serum) or 2M guanidine hydroch loride (RA serum). SDS-PAGE analysis of the 
pro te in  bands revealed a constant band representing a pro te in  o f MW 60,000 
Daltons. I have suggested tha t  this p ro te in  was responsible fo r  the inh ib it ion  of 
PIP found in RA and normal serum.
In the f ina l chapter 1 have discussed the s ign if icance of my findings and the
role o f  PIP in immune complex processing in health and disease in the l igh t  of
recent work by o ther authors in this f ie ld . The fa i lu re  to  prevent immune
p rec ip i ta t io n  in RA serum may have pathogenetic s ign if icance  as indicated by 
the close re la t ionsh ip  w ith  reduced PIP and the e x tra -a r t ic u la r  m an ifesta tions 
of the disease. Fu rthe r studies are suggested to address th is  problem including 
prospective studies on the na tu ra l h is to ry  of inh ib i to ry  a c t iv i t y  in the Individual 
RA pa t ien t,  the e ffe c ts  of disease m od ify ing  drugs (eg gold, pen ic il lam ine and 
chloroquine) on the process and the re lationsh ip  between the inh ib i to r o f PIP 
and IgM -RF. PIP is only one aspect of a h ighly com p lica ted  physiological 
phenomenon whereby immune complexes are processed and sa fe ly  disposed of by 
the re t icu loendo the l ia l system in man. The requirem ent fo r  continued studies at 
basic leve l is stressed in both normal and patholog ica l sera in order to  place in 
perspective the role of inh ib i to ry  molecules In the PIP reaction .
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CHAPTER ONE
INTRO DUC TION
15
PREFACE
The experim en ta l work conta ined in this thesis is concerned w ith  the specific  
in te rac t io n  o f immune complexes w ith  the com plem ent system. I have 
concentra ted  on the phenomenon of com plem ent mediated prevention  of 
immune complex p re c ip i ta t io n ,  a consequence of the in te rac t io n  between 
immune complexes and com plem ent whereby the complexes rem ain  small and 
soluble and the fo rm a t io n  of large insoluble la t t ic e s  is prevented (S ch if fe r l i ,  
B a r to io t t i  &  Peters, 1980). In this in troduc t ion  I w i l l  survey the general 
background to the studies conta ined in this thes is . The experim enta l work 
conta ined herein was commenced in 1983, and against this background o f 
previous work in th is f ie ld  I was able to fo rm u la te  my ideas fo r  fu r th e r  
research in this area leading up to my own observations which are set out in 
the f i r s t  results section.
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INTR O D U C TIO N
When an in d iv id u a l  is exposed to  an a n t ig e n ,  s p e c i f i c  a n t ib o d ie s  are 
syn th e s ise d  w h ic h  i n t e r a c t  w i th  the  in c i t in g  a n t ig e n ,  u n i t in g  w i th  i t  
n o n -c o v a ie n t ly  to  fo r m  im m u n e  co m p le x e s .  Th is  n o rm a l  phenom enon  is 
designed to bene fi t  the host by e l im ina t ing  and/or neutra lis ing  the antigens. 
There are however some c ircumstances where the fo rm a tion  o f  immune 
complexes is d e tr im en ta l to the host. These h arm fu l e ffec ts  o f immune 
complexes were f i r s t  noted by von P irguet (1911), who, when studying the 
course o f serum sickness, proposed tha t  the in te rac t io n  of antigen w ith  host 
antibody in the c ircu la t io n  produced tox ic  fac to rs . He re la ted  the production
of these tox ic  fac to rs  to the onset and the course o f the serum sickness
reaction . O ther workers made s im ila r observations (Longcope, 1915; Rich & 
Gregory, 1943; Hawn &  Janeway, 1947).
In the 1950's the d e f in i te  pathogenetic  ro le  o f the immune complexes was 
demonstrated by the experim ents o f Germuth (1953), Germuth & McKinnon 
(1957) and Dixon and associates (Dixon et al, 1958; Dixon, Feldman & 
Vazquez, 1961). The orig ina l theory o f von P irguet was confirm ed and
expanded using the experim enta l rabb it  model of 'one-shot' serum sickness. 
The onset of generalised vasculit is  and g lom eru lonephrit is  in this model
c o - in c id e d  w i th  the  appearance  o f  so lub le  im m u n e  c o m p lexe s  in the
c ircu la t io n  of the rabbits , at the same t im e  serum complem ent a c t iv i ty
decreased and immune complexes were deposited at the sites of tissue in ju ry 
(Dixon, 1963).
Many fac to rs  involved in immune complex fo rm a tion ,  rem ova l and loca lisa tion
have been c la r i f ie d  by in vivo and in v i t ro  experim ents.
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Form ation  and Fate o f Immune Complexes
Most na tu ra l ly  occurr ing  antigens are m u lt iva le n t  and antibody molecules 
possess a t least two antigen-b ind ing sites. When complexes are fo rm e d , 
e x te n s iv e  c r o s s - l in k in g  may o c c u r  le a d in g  to  the  f o r m a t io n  o f la rg e  
aggregates of reduced so lub i l i ty .  These large aggregates would be d i f f i c u l t  to 
remove i f  fo rm ed in the tissues and, i f  formed in the c ircu la t io n ,  would tend 
to  p re c ip i ta te  in the blood vessels. Insoluble complexes appear to be of 
cen tra l im portance  in the production  of immune com plex-m edia ted  tissue 
in ju ry and the evidence fo r  this comes from  several sources outlined below. 
The com plem ent system plays an im p o rta n t  role in the in f la m m a to ry  reactions 
induced by these insoluble complexes. Jn vivo an t igen-an tibody complexes are 
form ed at three general anatom ica l sites viz (1) the reac tion  of antibody 
w ith  f ixed  s tru c tu ra l antigens eg a ce ll surface membrane, or basement 
membrane, (2) the reac tion  of antibody w ith  antigen which is secreted or 
in jected in to  the in te rs t i t ia l  f lu ids, (3) the reac tion  o f antibody w ith  soluble 
antigens found in the c ircu la t io n .
(1) The basement membrane is one such f ixed s tru c tu ra l antigen against which 
immune responses may be d irec ted . An example of antibasement membrane 
antibody-induced disease is Goodpasture's syndrome characterised c l in ica l ly  by 
g lo m e r u lo n e p h r i t i s  and p u lm o n a ry  h a e m o rrh a g e ,  a n o th e r  is a n t i - t u b u la r  
basement membrane antibody tu b u lo - in te rs t i t ia l  nephrit is  (Wilson & Dixon, 
1976). In these s ituations where the antigen is insoluble (basement membrane) 
one ends up w ith  an insoluble complex.
(2) The Arthus reac tion  is the c lassical experim enta l fo rm  of the reaction  
between antibody and antigen secreted or in jected in to  the in te rs t i ta l  f lu ids 
(A rthus, 1903; Cochrane &  Janoff,  1974). In this reac tion  antigen is in jected 
in trade rm a lly  in to  immunised animals and reacts w i th  antibody in and around
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the blood vessels which carry  the c ircu la t in g  antibody to the site  of the 
in jected antigen. The reac t ion  is a vasculit is  which is due to  the fo rm a tion  of 
immune complexes in the region of the vessel w a ll .  The ensuing in f lam m a to ry  
response occurs secondary to the a c t iva t io n  o f m ed ia to r systems which are 
ac t iva ted  by the complexes (Cochrane <5c Jano ff,  1974). The A rthus reac tion  is 
produced nruch more e f fe c t iv e ly  by p re c ip i ta t in g  antibody as opposed to 
n o n - p r e c ip i t a t in g  a n t ib o d y  (C o c h ra n e  & W e ig ie ,  1958). S e q u e n t ia l  
imm unofluorescence studies have demonstrated tha t  fo l low ing  the deposition 
o f immune complexes and com plem ent components in the vessel wa ll there is 
a ce l lu la r  in f lu x  o f neutrophils  in i t ia l ly  but a f te r  8 hours mononuclear cells 
appear and are p redom inant by 24 - 48 hours.
(3) C ircu la t in g  soluble antigens can react w ith  antibody to  fo rm  immune 
complexes which themselves continue to c ircu la te . The eventual fa te  of these 
c irc u la t in g  complexes d ic ta tes  whether the complexes become pathogenic or 
not. It  can be envisaged tha t  any animal must a t a l l  t im es be constantly  
exposed to exogenous and/or endogenous antigens wh ich  on most occasions 
must gain access to the c ircu la t io n .  Antibody reac ting  w ith  these c ircu la t ing  
antigens fo rm s immune complexes and in the vast m a jo r i ty  o f instances these 
antigen conta in ing  immune complexes are disposed o f harmlessly by normal 
p h y s io lo g ic a l  m e ch a n ism s .  In some cases, h o w e v e r ,  c i r c u la t i n g  im m un e  
complexes become trapped in one or more vascular or f i l te r in g  s truc tu res  of 
the body and induce in f la m m a to ry  reactions and subsequent immune complex 
disease (Dixon, 1963; Cochrane &  Dixon, 1978). Vascular f i l te r in g  systems 
include the glomerulus, choroid plexus, synovium, skin and uveal t ra c t  and 
subsequently they all have a high degree of blood f lo w  per u n it  mass of 
tissue. Thus th e ir  p o ten t ia l to trap  large quantit ies  of immune complexes in 
the ir  vascular walls  is g reat. Immune complexes may the re fo re  cause disease 
by v ir tu e  o f th e ir  b locking o f these f i l te r in g  mechanisms and the ensuing
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in f la m m a to ry  response can be seen as a p ro tec t ive  mechanism to remove the 
complexes from  tha t organ thus restor ing its  func t ion . However, on the other 
hand excessive or persisting in f lam m ation  by i tse lf  w i l l  fu r th e r  damage the 
organ. 1 w i l l  now b r ie f ly  discuss the reaons why this m igh t occur and the 
fa c to r s  w h ic h  d e te rm in e  the  fa te  o f  c i r c u la t in g  im m u n e  co m p le x e s .
F a c to rs  w h ic h  in f lu e n c e  the  fa te  and b io lo g ic a l  a c t i v i t i e s  o f  im m un e  
complexes include the nature of the antibodies and antigens involved and on 
the molar ra t io  of the two reactants. The immunoglobulin  class o f the 
antibody determines the antibody's valency fo r  a spec if ic  antigen as we ll as 
i ts  a b i l i t y  to  in t e r a c t  w i t h ,  and b ind to ,  c e l lu la r  Fc re c e p to rs .  The 
im m u n o g lo b u l in  c lass also d e te rm in e s  the  im m une  c o m p le x 's  a b i l i t y  to  
ac t iva te  the complem ent system. The av id ity  o f the antibody fo r  the union of 
spec if ic  antibody and antigen is also im portan t in in f luenc ing  the fa te  of the 
immune complex. The production o f high amounts o f  antibody of high av id ity  
or a f f in i t y  in mice allows fo r  accelerated clearance o f the antigen from  the 
c ircu la t io n  compared w ith  mice which produce low amounts of low a f f in i t y  
antibodies (Alpers, Steward & Sooth ill, 1972).
The im portance o f the nature o f the antigen in in fluenc ing  immune complex 
disposal is i l lus tra ted  by experiments using univalent and m u lt iva le n t  antigens. 
When un iva len t antigens are in jected in to  the c ircu la t io n  of an animal which 
contains spec if ic  antibodies small complexes are fo rm ed, where each antigen 
forms a separate antigen-antibody bond w ith  a binding s ite  on an antibody 
molecule. No la t t ic e  is formed and these complexes remain in the c ircu la t ion  
fo r  long periods w ith o u t  tissue deposition (Schmidt, Kaufm an & Butle r, 1974). 
On the other hand m u lt iva le n t  antigens such as prote ins when combined w ith  
the ir  spec if ic  antibodies do fo rm  large la t t ices , the vary ing composition of 
the resu ltan t immune complex depending on the m olar ra t io  of the reactants
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(Haakenstad & Mannik, 1974).
The most im po rtan t  fac to r  determ in ing  the fa te  and b io log ica l a c t iv i t ie s  of 
immune complexes is the ra t io  of antigen to antibody in the immune complex. 
Larger immune complexes are in general rap id ly  removed from  the c ircu la t ion  
(Mannik e t al, 1971; Haakenstad & Mannik, 1974). Immune complexes formed 
at large antigen excess are typ ica l ly  very small conta in ing antigen and 
antibody in the ra t io  A g^Ab^. They o ften  c ircu la te  fo r  long periods but 
because of the ir  size do not f ix  complement we ll and generally are unable to 
in i t ia te  in f la m m a to ry  processes. Immune complexes formed w ith  a large 
excess o f  antibody over antigen are very large and insoluble. A lthough being 
very capable of f ix ing  complement and having ph log is tic  po ten t ia l the ir  rapid 
p h a g o c y to s is  ensures th a t  t h e i r  p h lo g is t ic  p o te n t ia l  is l im i t e d .  Im m une  
complexes o f  in te rm ed ia te  size ly ing between these tw o extremes, formed in 
m odes t a n t ig e n  excess are so lu b le  bu t  n o t  ra p id ly  p h a g o cy to se d .  These 
c o m p le xe s  can f i x  c o m p le m e n t  and thus t h e i r  p h lo g is t ic  p o te n t ia l  is 
considerable. This im p o rta n t  role of the size of the immune complex and its 
ph log is tic  po ten t ia l was c learly  shown by Dixon (1963) in the experim enta l 
model o f  chronic serum sickness in the rabb it  where progression of disease 
was only seen when the immune complexes were soluble. The size o f  the 
immune complexes was varied by changing the dose o f antigen. Progression of 
the disease could be arrested by e ither lowering the dose of antigen to give 
a n t ib o d y  excess co m p lexe s  or ra is in g  the  dose to  g ive  a n t ig e n  excess 
complexes (Dixon, 1963). However i t  should be noted tha t immune complex 
g lom eru lonephrit is  only occurred in those rabbits  which made p rec ip i ta t ing  
antibodies. Renal disease only occurred in those rabbits  in which immune 
complexes were fo rm ed at equivalence or in antibody excess (Dixon et al, 
1961). I f  the rabbits  were maintained in permanent antigen excess renal 
disease did not develop.
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Immune Complex Deposition and Tissue Injury
The development o f an immune complex disease is also dependent on the 
magnitude and duration of antigen exposure. The po ten t ia l exists fo r  chronic 
immune complex fo rm a tion  in s ituations where there is long te rm  antigen 
exposure such as in chronic in fections or w ith  autoantigens. The nearest 
experim enta l model to  this s itua t ion  in humans is probably chronic serum 
sickness (Cochrane & Dixon, 1978). A t  any given t im e  the concentra t ion  of 
immune complexes in the c ircu la t io n  depends on the ra te  of immune complex 
fo rm a tion  and on the ra te  of immune complex removal. Complexes formed at 
e q u iv a le n c e  are  u s u a l ly  la rg e  and i f  in je c te d  in t ra v e n o u s ly  are ra p id ly  
removed from  the c ircu la t io n  by the l ive r  (Haakenstad, Case &  Mannik, 1975). 
Thus one can postu late tha t  such complexes can only produce tissue damage 
|n  v ivo i f  they are allowed to c ircu la te^  ie i f  the ir  removal from  the 
c ircu la t ion  by the re t icu loendo the l ia l system is impaired.
It  is conceivable tha t  large insoluble complexes may be form ed w ith in  the 
m ic roc ircu la t io n  and deposited loca lly . In experiments where rabbits  or pigs 
were pre-immunised w ith  p ro te in  antigens, the in jec t ion  of small amounts of 
antigen d ire c t ly  in to  the renal a rte ry  resulted in acute g lom erulonephrit is  
(Gabbiani, Badonnel & Vassalli, 1975; Shigematsu et al, 1979) However, in 
another study rabbits  maintained in permanent antigen excess over prolonged 
pe r iods  n eve r  deve lo p ed  g lo m e r u lo n e p h r i t is  (Boyns & H a rd w ic k e ,  1968). 
Therefore i t  would appear tha t  large immune complexes form ed at or near 
equivalence by p re c ip i ta t in g  antibodies are inc r im ina ted  in the pathogenesis of 
some types o f experim enta l g lom eru lonephrit is  or vasculit is .
I t  has been demonstrated in experim enta l animals tha t  release of vasoactive 
amines and increased vascular perm eab il i ty  are prerequis ites fo r  immune 
complex deposition (Cochrane, 1963; Kn iker & Cochrane, 1968) and tha t  large
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immune complexes o f 195 or g reate r are necessary fo r  induction o f vasculit is  
(Cochrane & Hawkins, 1968; Wilson &. Dixon, 1971). Henson & Cochrane (1971) 
described a mechanism in the model of acute experim enta l serum sickness in 
the  ra b b i t  w h e reb y  im m une  c o m p le x  d e p o s i t io n  was m e d ia te d  by a 
c o m p le m e n t  in d e p e n d e n t ,  le u k o c y te  dependen t p rocess . The m echan ism  
involved the degranulation of basophils sensitised w ith  IgE antibody and 
antigen w ith  subsequent release of a p la te le t aggregating fa c to r  (PAE). This 
RAF subsequently caused aggregation o f  and release of vasoactive amines 
from  p la te le ts  (Benveniste, Henson & Cochrane, 1972). PAF is present in 
human basophils (Benveniste, 1974) and s im ila r mechanisms may operate in 
man. The anaphylatoxins C3a and C5a produced a f te r  complem ent ac t iva t ion  
by immune complexes also increase perm eab il i ty .  Vasoactive amines are 
released from  p la te le ts  a f te r  the d irec t In te rac t ion  o f immune complexes w ith  
the p la te le t  Fc or complem ent receptors in experim enta l animals as we ll as 
a f t e r  d i r e c t  o r in d i r e c t  ly s is  o f  p la te le ts  by im m u n e  c o m p le x  induced  
complem ent ac t iva t io n  (Henson & Cochrane, 1971). I t  is o f  in te res t to note 
tha t depletion of p la te le ts , the princ ip le  reservo ir of vasoactive amines, 
prevents the development of immune complex disease in the rabb it  (Kn iker & 
Cochrane, 1968).
When immune complexes are deposited along vascular basement membranes 
the in f la m m a to ry  response which is evoked is la rge ly  dependent on the 
b io log ica l a c t iv i t ie s  produced by complement ac t iva t io n .  These b io logical 
a c t iv i t ie s  are generated and mediated by e ither the immune complex f ixed  
complem ent components or by flu id-phase ac tiva ted  com plem ent components 
and t h e i r  f r a g m e n ts .  The b io lo g ic a l  a c t i v i t i e s  p roduced  secondary  to  
complem ent ac t iva t io n  includes increased vascular pe rm eab il i ty ,  chemotaxis, 
immune adherence and lysis of cells. The cleavage product of C5 (C5a) is the 
m ajor chem otaxin  which promotes an in f lux  of in f la m m a to ry  cells to the s ite
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of immune complex deposition. The anaphylatoxin a c t iv i ty  occurs via the 
binding o f  C3a and C5a to mast cells and basophils w ith  the subsequent 
re le ase  o f  v a s o a c t iv e  am ines  (H u g l i  &c M u l le r - E b e rh a r d ,  1978). Im m une  
adherence is the process in which immune complexes conta in ing C3b bind to 
spec if ic  receptors on various ce ll types, including neutrophils , resu lt ing in 
phagocytosis. Neutroph ils  may release lysosomal enzymes thus increasing 
tissue in ju ry  (Cochrane &  D ixon, 1978). This sequence o f events operates as a 
general mechanism of immune complex mediated tissue in ju ry  in experim enta l 
animals. It should be noted tha t  depletion of com plem ent by cobra venom 
fa c to r  or dep le tion o f  neutrophils  can prevent the development o f  necrotis ing 
a r te r i t is ,  but the g lom eru lonephrit is  can s t i l l  occur (Henson &. Cochrane, 
1971). A lthough com plem ent may not always be necessary fo r  the production 
of the lesions o f immune complex disease, the results of the cumulated 
studies of immune complex induced tissue lesions in experim enta l animals 
im p lica ted  com plem ent a c t iva t io n  as playing a m ajor ro le in the pathogenesis 
of immune complex mediated tissue in jury (Cochrane & K o f f le r ,  1973).
The Com plement System
A t th is point 1 would l ike  to b r ie f ly  rev iew  the com plem ent system as this 
w i l l  a llow fo r  easier understanding of the com plem ent- im m une complex 
in terac tions described below.
Com plem ent a c t iv i t y  is the resu lt o f the sequentia l in te rac t ion  o f a number 
o f plasma and ce ll membrane associated proteins. There are tw o pathways for 
c o m p le m e n t  a c t i v a t io n ,  the  c la s s ic a l  and the  a l t e r n a t i v e .  The c la s s ic a l  
pathway is ac t iva ted  by antigen-antibody complexes (immune complexes) of 
the IgG and IgM classes, while  the a lte rna t ive  pathway is ac t iva ted  in the 
absence o f  a n t ib o d y  by a v a r ie t y  o f  agen ts  in c lu d in g  b a c te r ia l  
i ipopolysaccharides, virus in fec ted  cells, protozoa, aggregated immunoglobulins.
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cobra venom fa c to r  and C3 neph rit ic  fa c to r .  A c t iv a t io n  of e ithe r pathway 
ieads to the generation of m u lt i-m o lecu la r  enzymes which w i l l  a c t iva te  the 
th ird  (C3) and the C5 components of complement. These enzymes are called 
C3 convertases and C5 convertases respective ly .
The classical pathway is ac t iva ted  by the binding o f  C1 to antigen-antibody 
complexes (conta in ing IgM or IgG^, IgG^ or IgG^ antibody molecules). C1 is a 
macrom olecu iar complex composed o f three proteins C1q, C1r and C1s 
(Cooper, 1985). C lq  is the recogn it ion  unit which binds to  immunoglobulin and 
undergoes 'a confo rm ationa l change leading to ac t iva t ion  of C i r  to its 
enzym atica l ly  ac tive  fo rm  C1r, which then enzym atica l ly  activa tes  C Is  to 
become an ac tive  enzyme C1s. C1s is the ac tive  s ite  of m acro-m o lecu ia r C1 
and has tw o  natura l substrates C4 and C2. This ac tive  C l  then cleaves the 
next two components, C4 and C2, in sequence. A c t ive  C1 produces a l im ited  
p ro te o ly t ic  cleavage in the oL -chain of C4, separating a 6000 molecular 
we ight peptide, C4a (Schreiber & Muller-Eberhard, 1974). The remainder of 
the molecule, C4b, is able trans ien t ly  to  bind to antigen-antibody complexes 
via a lab ile  binding s ite . This a b i l i ty  o f  C4b to bind to surfaces is due to the 
presence of an in terna l th io les te r group in C4. C4b binds to surfaces (eg 
immune complexes) by covalent bond fo rm a tion  and thus serves to ta rge t the 
rest of the com plem ent sequence to tha t  surface. C4b also possesses a Mg^^ 
dependent binding site  fo r  C2 and this C2 is cleaved by ac t iva ted  C l  to y ie ld 
two fragm ents, C2a and C2b. C2 binds to C4b via the C2b fragm ent which 
remains bound to C2a by non-covalent bonds. The enzym atic  site of this 
molecule is contained in the C2a (Nagasawa & Stroud, 1977). C4b2a is the C3 
cleaving enzyme (C3 convertase) generated by classical pathway ac tiva t ion .
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The a lte rna t ive  pathway C3 convertase is form ed when C3b binds to fa c to r  B, 
in the presence o f  ions, to  fo rm  C3bB. B is then cleaved by D to fo rm
C3bBb which is the unstable a lte rna t ive  pathway C3 convertase. This enzyme 
is unstable because Bb rap id ly  decays from  i t .  However the enzyme is
stabil ised by the binding of P to C3b which prevents the decay of Bb from
the complex (Fearon &  Austen, 1975) This complex C3bBbP is called the
properdin stabil ised C3 convertase (C3bBbP). Thus tw o  C3 convertases are 
fo rm e d  one f ro m  c la s s ic a l  p a th w a y  a c t i v a t io n  (C 4b2a) the  o th e r  f ro m  
a lte rna t ive  pathway ac tiva t ion  (C3bBbP).
C3 is cleaved to  release a small peptide C3a. The remainder of the molecule 
C3b contains a lab ile  binding site which l ike  C4b allows C3b to bind to 
surfaces (eg antigen-antibody complexes or polysaccharides). The mechanism 
of binding of C3b to surfaces is the same as tha t  fo r  C4b. C3 contains an 
in terna l th io les te r bond (Tack et al, 1980) and the cleavage of C3 by the C3 
convertase results in the appearance o f  a single th io l  group (Janatova e t al, 
1980). The transfe r of an acyl group from  the th io l  to  an hydroxyl group in 
the  a c c e p to r  m o le c u le  re s u l ts  in c o v a le n t  bond fo r m a t io n  (P angburn  & 
M ulle r-Eberhard , 1980; Tack et al, 1980). Again i t  w i l l  be evident tha t this 
a b i l i ty  o f C3b to bind to surfaces allows fo r  the subsequent complement
a c t iv i ty  to  be localised close to the site  o f ac t iva t ion .
C3b is a product of the enzym atic  action of C3 convertases on C3 while  at 
the same t im e  being a cons t ituen t of the a lte rna t ive  pathway C3 convertase. 
Thus a positive feedback mechanism exists which would continue to cleave C3 
u n t i l  the supply of C3 or B became exhausted. This does not occur because of 
the presence o f the con tro l p ro te in  fa c to r  I and its c o - fa c to r  H. I in the 
presence of H w i l l  cleave the ok chain of C3b to fo rm  C3bi which can no 
longer bind B and thus fo rm  a C3 convertase.
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The te rm ina l sequence is ac t iva ted  by the cleavage o f C3 by C4b2a and 
C3bBbP. As stated above C3b binds to its  ta rge t (eg immune-compiex) by its 
labile binding s ite . Ciose binding of the C3b to the C3 convertase changes the 
sp ec i f ic i ty  o f the enzyme to  tha t of a C5 convertase. C5 is cleaved to 
release C5a (MW 12,000) and the C5b which is the remainder of the moiecule 
binds to  ce ll membranes via a labile  binding site , however, th is  binding of C5b 
is not covalent (Law, L ich tenberg  & Levine, 1980) but binding to  C6 helps to 
stabil ise the binding o f C5b in its active s ta te . C7 binds to C5b6 fo rm ing  
C5b67 which is inserted in to  l ip id  membranes. Reaction w ith  C8 to  fo rm  the 
C5b“ 8 complex allows fo r  pa r t ia l  penetration of the l ip id  membrane. C9 then 
binds to CB to fo rm  the c y to ly t ic  C5b-9 complex which results in osmotic 
lysis o f the ce ll as proposed by Mayer (1972).
The B io log ica l A c t iv i t ie s  o f Complement
A pa rt f rom  the c y to ly t ic  e f fe c t  of the complement cascade many other 
b io lo g ic a l  a c t i v i t i e s  are g e n e ra te d  d u r ing  c o m p le m e n t  a c t i v a t io n .  These 
a c t iv i t ie s  are im portan t in the expression of the in f la m m a to ry  events which 
take place fo l low ing  complem ent immune complex in terac tions.
Increased Vascular P erm eab il i ty
The breakdown products C4a, C3a and C5a are anaphylatoxins. C5a which is 
the most potent acts, as does C3a, to release h istam ine f ro m  mast cells and 
basoph i ls .  C3a re leases  s e ro to n in  f r o m  p la te le t s  (Johnson, H u g l l  & 
Mulle r-Eberhard, 1975). C3a and C5a can induce smooth muscle con trac t ion  in 
the absence of h istam ine. The anaphylatoxic a c t iv i t ie s  o f  C3a and C5a are 
inh ib ited by carboxypeptidase N.
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Chemotaxis
C3a and C5a which has been degraded by carboxypeptidase N are
pow erfu l chemotaxins. They w i l l  a f fe c t  neutrophils, eosinophils and monocytes 
(F e rn a nd e z  e t  a l,  1978) C3bBb is c h e m o ta c t ic  f o r  p o ly m o rp h o n u c le a r  
leukocytes (Ruddy, Austen & G oetz l, 1975).
Leukocytosis
The peptide C3e, derived from  the oL chain o f C3, causes an in i t ia l  
leukopenia and then a leukocytosis. The mechanism is thought to  be by C3e 
mediated m ob il isa t ion  of neutrophils from  the bone m arrow  (Rother, 1972; 
M cC a ll e t  ai, 1974).
Solubilisation o f Immune Complexes and Prevention o f Immune P rec ip ita t ion  
These tw o aspects of com plem ent function  w i l i  be discussed in a ia te r 
section.
Opsonisation
One o f  the most im p o r ta n t  b io log ica l functions of com plem ent is opsonisation, 
the process whereby antigen-antibody complexes or o the r partic les  are coated 
w ith  C3b. These opsonised part ic les  can bind to  receptors fo r  C3b (CR1) 
found on a number of ce ll surfaces including polymorphonuclear leukocytes, 
mononuclear phagocytes and B lymphocytes. There are also receptors fo r  C3bi 
and C3dg ( (X^D) which are fu r th e r  breakdown products o f  C3b. C3bi binds to 
CR3 and CR1 and C3dg (O^D) bind to CR2. When the p a r t ic le  is coated w ith  
C3b alone adherence is promoted, however, when IgG antibody in addition 
coats the pa r t ic le  ingestion is enhanced. C3b ac ting  on C3b receptors on 
macrophages results in the enhanced in tra ce i lu la r  k i l l in g  o f bacte ria  (Lei jh  et 
ai, 1979).
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Up u n t i l  the early  1970's com plem ent had always been thought of as being 
d e tr im en ta l and playing a s ign if ican t pathogenetic ro le in the production of 
tissue in ju ry  in immune complex diseases. In human immune complex disease 
much evidence has been accrued to support this concept of complem ent being 
the major e f fe c to r  mechanism o f immune complex mediated tissue damage. 
The f in d in g  o f  h y p o c o m p le m e n ta e m ia  in p a t ie n ts  w i th  im m une  co m p ie x  
disease (Franco & Schur, 1971; Schur, 1975; Whaley &  E l-Ghobarey, 1981) and 
the detec tion  o f com plem ent components in the involved tissues go a long 
way to support this idea (Rodman et ai, 1967; K o f f le r  e t ai, 1969; Verroust et 
al, 1974).
However in the past 15 years or so our views on the ro le  of complement in 
immune complex disease have been a ltered by the observations tha t patients 
w ith  inherited  compiem ent de fic iency syndromes have a high incidence of 
immune compiex disease.
Immune Complex C learing Mechanisms
I have discussed the reasons and possible mechanisms whereby c ircu la t ing  
immune complexes are deposited in tissues thereby causing disease. This must 
only happen when there is a breakdown of the normal mechanisms whereby 
immune complexes are cleared from  the c ircu la t ion .  In experim enta l animals 
immune complexes conta in ing IgG antibodies, when in jected in travenously are 
cleared f rom  the c ircu la t ion  main ly by the non-parenchymal cells of the l ive r  
(Mannik & Arend, 1971). IgG immune complex entrapm ent in the l ive r  is 
mediated m ain ly  by in te rac t ion  w ith  ce l lu la r Fc receptors (van Es, Daha & 
K i j ls t ra ,  1979). I t  can be envisaged tha t i f  the re t icu loendo the l ia l system 
became overloaded w ith  immune complexes the complexes may then deposit 
in the tissues (Haakenstad & Mannik, 1974) and in i t ia te  ac tive  disease.
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Studies on the clearance of IgM coated e ry throcytes  f ro m  the c ircu la t ion  have 
emphasised the im portance o f complem ent in the clearance process. When 
e ry th rocy tes  are sensitised w ith  IgM antibody th e ir  fa te  in the c ircu la t ion  is 
quite  d i f fe re n t  f rom  tha t of e ry th rocy tes  sensitised w ith  IgG. Un like  IgG 
sensitised cells, m vivo com plem ent ac t iva t ion  is c r i t ic a l  fo r  the clearance of 
the IgM sensitised cells (Frank e t al, 1977). The cells are cleared when C3b is 
deposited on the ir  surface a f te r  complement a c t iva t io n  and they are then 
sequestered by the Kuppfer cells in the l ive r .  This hepatic  loca lisa tion  of 
sequestered e ry th rocy tes  is very d i f fe re n t  from  the splenic clearance seen in 
the rem ova l o f IgG sensitised e ry throcytes  f rom  the c ircu la t io n .  Fo llow ing the 
hepatic  sequestration o f IgM coated e ry throcytes , they are then released back 
into the c ircu la t io n  because o f the action o f fa c to r  I and FI on the ce ll bound 
C3b which is cleaved to  C3bi and then subsequently to  C3c and C3dg(oL2D). 
The C3dg coated e ry th rocy tes  then are released back in to  the c ircu la t ion  
where they continue to  c ircu la te  w ith  a h a l f - l i fe  equal to tha t o f  unsensitised 
cells.
Com plem ent appears im po rtan t  in the clearance o f p a r t icu la te  antigens from  
the c ircu la t io n  (Brown, Lachmann & Dacie, 1970) but whether i t  a f fe c ts  the 
e l im ina t ion  of c ircu la t in g  immune complexes is somewhat controvers ia l.  Large 
immune complexes greater than 3ÜS are more read ily  endocytosed by adherent 
macrophages i f  complem ent is present (van Snick &  Masson, 1978). The 
d e g ra d a t io n  o f  so lub le  im m u n e  co m p iexe s  is enhanced  by c o m p le m e n t  
(K i j ls t ra ,  van Es & Daha, 1981). However com plem ent is not essential fo r  the 
a ttachm ent of soluble immune complexes to macrophages in suspension (Arend 
âx Mannik, 1972) nor does com plem ent appear to  m ediate  the blood clearance 
o f  IgG c o n ta in in g  so lu b le  im m une  c o m p le x e s  when these  are in je c te d  
in travenously (Bockow &  Mannik, 1981). Skogh & Stendahl, (1983) when
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studying the blood clearance o f small IgG immune complexes found tha t the 
clearance of these immune complexes from  the c ircu la t io n  was actua lly  
re tarded by fresh normal mouse serum and not by com plem ent depleted mouse 
serum.
Although these above studies cast some doubt on the ro le of complement in 
the e l im ina t ion  of c ircu la t ing  immune compiexes a body of evidence has 
grown in recent years which has established complem ent as having a centra l 
ro le in immune complex processing and the subsequent safe disposal of 
po ten t ia l ly  ph log is t ic  immune complexes in the c ircu la t ion .  C entra l to  this has 
been the recogn it ion  o f  inherited défic iences of the com plem ent components. 
It  is only in recent years tha t  the widespread a v a i la b i l i ty  of reagents w ith  
which ind iv idua l complem ent components can be measured has allowed these 
complem ent component defic iencies to be recognised. Individuals de f ic ien t  in 
complem ent have a p red ilec t ion  to development of disease and certa in  
syndrom es  appear a s so c ia te d  w i t h  p a r t i c u la r  c o m p le m e n t  co m p on e n t 
defic iencies (Agnello , 1978; Rynes, 1982). In Table 1.1 I have lis ted the cases 
reported up to 1983, this table being taken f rom  tha t  of S ch i f fe r l i  & Peters 
(1983(a)). A scerta inm ent bias is o f  course inev itab le  especially when dealing 
w ith  small numbers, complem ent being measured in people presenting w ith  
immunologica l disease much more frequent ly  than in the general population. 
However even a llow ing fo r  this, scru t iny  of Table 1.1 allows some general 
conclusions to be drawn. In fec t ion  is much more common and widespread in 
p a t ie n ts  w i th  c o m p le m e n t  d e f ic ie n c ie s  thus  e m phas is ing  the  m a jo r  
an t im ic rob ia l roie of complem ent. However, pa tien ts  w ith  defic iencies of the 
e a r ly  a c t in g  co m p on e n ts  o f  the  c la s s ic a l  p a th w a y  seem p rone to  the  
d e v e lo p m e n t  o f  im m u n e  c o m p le x  m e d ia te d  d isease, th is  seems to  be 
p a r t icu la r ly  the case fo r  defic iencies o f C4 and the C l  subcomponents.
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Component
TABLE 1.1
Number w ith  Associated Disease
homozygous
defic iency
Classicai pathway
C lq
C i r  or C Is
C4
C2
C 1-inh ib ito r
15 
8
16 
66
7500
IC disease In fec tion
14
6
14
38
2%
)
) many 
) pyogenic 
) in fections 
)
C3 and a lte rna t ive  pathway 
C3 
B /D
Properdin
Eac I 
H
11
3
1
1 (HUS)
10 pyogenic
(+ N e is s e r ia )  
2 (+ 3 d ied  o f  
fu lm inan t 
in fections)
4 pyogenic
Membrane a ttack  complex
C5 12
C6 17
C7 14
C8 14
C9 Many
1
2
1
2
no disease 
associated
9)
10)
6) Neisseria 
8)
TABLE 1.1
R e p o r te d  cases o f  c o m p le m e n t  d e f ic ie n c ie s  and a sso c ia te d  diseases 
H pa r t ia l  de f ic iency  <.10%
IC d isease = SEE, S E E - l ike  syndrom es , g lo m e r u lo n e p h r i t i s ,  v a s c u l i t is  
HUS = H aem o ly t ic -u raem ic  syndrome
(taken f rom  S ch i f fe r l i  &. Peters, Lancet, 1983)
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I have stated previously tha t  complement ac tiva t ion  is a major e f fe c to r  
m echan ism  o f  in f la m m a t io n  in im m un e  c o m p le x  m e d ia te d  t issue  in ju r y .  
A lthough this concept s t i l l  holds true the evidence gleaned from  studies of 
complement de fic iency syndromes has led us to reappraise the ro le of 
complem ent in immune complex disease and also puts fo rw a rd  the idea tha t 
normal com plem ent func t ion  p ro tec ts  against the development of immune 
complex associated disease.
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The Role of Complement in Immune Complex Clearance
(1) The In te rac t ion  of Opsonised Immune Complexes w ith  Complement 
Receptors
Opsonisation is the coating of antigen-antibody complexes or ac tiva to rs  o f the 
a lte rna t ive  pathway w ith  large numbers of C3b molecules and is a major 
b io log ica l function  of complem ent. The process of opsonisation perm its  more 
e f f ic ie n t  clearance of complexes by the f ixed  macrophage system. The fa te  of 
opsonised complexes is dependent on the ir  in te rac t ion  w ith  spec if ic  receptors 
fo r  C3b found on the surfaces of various cells.
The com plem ent recepto r (CR1) is a g lycopro te in  w ith  four major a l lo typ ic  
forms, m olecu lar weights being 160, 190, 220 and 250 kD (Fearon, 1980; 
Fearon, 1984; Ross & Medof, 1985). The major ligand fo r  CR1 is C3b and it  
binds especia lly w e ll when the C3b is present in c lusters. CR1 is found on 
p o ly m o rp h o n u c le a r  le u k o c y te s ,  m acrophages , B ly m p h o c y te s ,  some T 
lymphocytes, dend rit ic  re t ic u la r  cells in germ inal centres and g lomerular 
podocytes. In primates CR1 Is also found on e ry th rocy tes  and i t  would appear 
tha t 90-95 per cent of CR1 is found on the surface o f  e ry throcytes  in the 
c ircu la t ion  of humans (Siegel, L iu  & G le icher, 1981). In v i t ro  complement 
reacted immune compiexes a ttach  main ly  to the CR1 found on e ry throcytes  
(S ch if fe r l i  & Peters, 1983(b)). In vivo immune complexes bind to  ery throcytes  
when in jected in to  the aortas o f  baboons and monkeys. The binding of 
opsonised immune complexes to e ry th rocy te  CR1 is a transport mechanism 
whereby immune complexes are carried  safely to the f ixed  macrophage 
system (C ornaco ff  et ai, 1983). Immune complexes formed in the ex tra  
vascular spaces are probably removed via the lym phatics  and then trapped in 
the regional lymph nodes (Pepys, 1976).
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In studies in monkeys C o rnaco ff  et a l, (1 98 3 )  showed tha t  under normal 
c i r c u m s ta n c e s  im m u n e  c o m p lexe s  w ere  bound to  e r y th r o c y te s  by a 
complem ent dependent mechanism, transported to the l ive r  and then stripped 
from  these e ry th rocy tes . Fa ilu re  of this mechanism occurred in animais which 
had been depleted o f com plem ent and instead o f being cleared by the l ive r  
the complexes were found w ide ly  d is tr ibu ted  in the body (Waxman et al, 
1984). Immune complex binding to  e ry throcytes  is the re fo re  thought to be a 
p ro te c t ive  mechanism which transports immune complexes to sites o f  safe 
disposal.
The mechanism whereby complexes are transfe rred  f rom  ery th rocy tes  to 
macrophages is obscure. I t  may involve enzym atic  removal or i t  may be 
re la ted  to the high density o f Fc receptors and CR1 on macrophages. This 
w i l l  provide s tronger binding fo r  the complex than the re la t ive ly  low density 
CR1 on the e ry th rocy tes  and may a llow fo r  p re fe re n t ia l  uptake o f  the
complex by the macrophage. I t  should also be remembered tha t the binding of 
immune complexes to  e ry th rocy tes  is a re la t iv e ly  trans ien t phenomenon in as 
much tha t CR1 also has a potent inh ib i to ry  func t ion  in the complement 
cascade being a c o - fa c to r  fo r  fa c to r  I in the cleavage of C3b to C3bi and 
subsequently to C3dg (Medof et al, 1982; Medof & Prince, 1983). C3dg is thus 
le f t  a ttached cova len tly  to  the immune complex but C3dg does not bind to 
CR1 and the  im m un e  c o m p le x  is then  re le a se d  f ro m  the  r e c e p to r .
The range o f the numbers o f  C R I 's  on the e ry th rocy tes  of normal individuals 
is large (200 to 1,000 per ce ll)  (Ross & Medof, 1985). Reduced numbers of 
CR1 have been found on the e ry throcytes  o f patien ts  w ith  SLEJ in i t ia l ly
thought to be an inherited  de fec t (Wilson e t ai, 1982) i t  has now been shown 
tha t  low CR1 numbers on e ry throcytes  occurs secondarily  to the disease
process (W alport et al, 1985; Holme et al, 1986). Reduced binding o f immune
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complexes to C R I has been observed in various diseases including rheum ato id  
a r th r i t is ,  SLE, haematolog ica l neoplasia and cold agg lu tin in  disease (Miyakawa 
et al, 1981; Tay lor et al, 1983).
(2) The In te rac t ion  of Complement w ith  Immune Complexes 
In recent years i t  has become clear tha t complem ent can in te rac t  w ith  
immune complexes and cause profound changes in the properties o f the 
immune complex. These changes occur in the so lub i l i ty ,  composition and 
aggregation of the complexes (M il le r  & Nussenzweig, 1975; Casali & Lam bert,  
1979; S ch i f fe r l i  et al, 1980). Insoluble antigen-antibody complexes become 
soluble when incubated w ith  serum (M il le r  & Nussenzweig, 1975) and immune 
complexes form ed at equivalence or in antibody excess do not p rec ip i ta te  but 
are held in so lution (S ch if fe r l i  e t al, 1980). Both these phenomena termed 
immune complex so lubil isa tion  and the prevention of immune p rec ip i ta t ion  
respective ly  are brought about by complem ent ac t iva t ion .  I w i l l  now describe 
these phenomena in turn  and discuss the ir  possible re levance to immune 
complex disease.
Solubilisation of Immune Complexes
In his c la s s ic a l  paper o f  1941 H e id e lb e rg e r  w hen  s tu d y in g  c o m p le m e n t  
incorpora tion  in to  p rec ip ita tes  form ed from  pneumococcal polysaccharides and 
rabb it antibody noted tha t,  somewhat unexpectedly, the amount of bound 
complem ent per complexed antibody actua lly  decreased as the amount of 
added serum  in c re ase d . The e x p la n a t io n  o f  th is  phenom enon  was no t 
fo r thcom ing  u n t i l  1975 when M i l le r  and Nussenzweig described soiubil isa tion 
of an t igen-an t ibody  aggregates. Since this observation several papers have 
appeared which have defined the mechanism of so lubil isa tion o f immune 
p rec ip ita tes  and demonstrated the rad ica l a lte ra t ions  which take place in the 
physical and b io log ica l properties of immune complexes on in te rac t io n  w ith
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complem ent.
The so lubil isa tion phenomenon is a general phenomenon and many kinds of 
Ag-Ab complexes form ed w ith  soluble antigen can pa r t ic ip a te .  Antibodies of 
IgG, IgA and IgM from  several mammalian species can be involved although 
the e ff ic ien cy  of the serums show some species d if fe rences. Complement can 
solubilise p rec ip i ta tes  form ed w ith  the F(ab ' ) 2  f ragm ent but less e f f ic ie n t ly  
than w ith  the whole immunoglobulin  molecule (M il le r  & Nussenzweig, 1975). 
The ra te  of so lubil isa tion  depends on the amount o f  immune complexes, the 
properties of antigen and antibody, the composition of the complexes and the 
conditions of incubation. P rec ip ita tes  form ed a t or near equivalence can be 
solubilised most e f f ic ie n t ly  (M il le r  & Nussezweig, 1975) and the a f f in i t y  of 
the complexed Ab fo r  Ag is very im portan t suggesting tha t the p r im ary  
an t igen-an t ibody  bond is im p lica ted  in the so lubil isa tion  process (Czop &. 
Nussenzweig, 1976). Solubilisation is a complem ent dependent phenomenon, 
h ea t- in a c t iva t io n  o f serum (56°C fo r  30 minutes) or t re a tm e n t  of serum w ith  
EDTA, zymosan or cobra venom fa c to r  w i l l  abrogate the solubil is ing a c t iv i ty  
o f tha t  serum (M il le r  &  Nussenzweig, 1975).
The so lub il isa tion  phenomenon has an absolute requ irem en t fo r  the a lte rna t ive  
pathway of com plem ent. Sera which had been depleted of the a lte rna t ive  
p a th w a y  co m p o n e n ts ,  D, B or P w e re  unab le  to  s u p p o r t  s o lu b i l is a t io n .  
Replacement of the missing component resulted in the solubil is ing capacity  of 
the  serum  b e co m in g  n o rm a l ( M i l le r  & N u sse zw e ig ,  1975). In s im i la r  
experiments using C 3 -d e f ic ie n t  human serum (Czop &  Nussenzweig, 1976) or 
fa c to r  D-depleted or properd in-deple ted serum (Takahashi et al, 1978) a ll o f 
these components of the a lte rna t ive  pathway were found to be essential. More 
recent work using pur if ied  a lte rna t ive  pathway components (C3, B, D, P, FI 
and I) has re-emphasised the essential ro le o f the a lte rna t ive  pathway in this
37
process . O m iss io n  o f  the  c o n t r o l  p ro te in s  e i t h e r  H or I r e s u l te d  in 
inappropria te  f lu id  phase turnover of 03  and so lubil isation did not occur 
(Fu jita , Takata & Tamura, 1981).
The classical pathway is not essential fo r  so lubil isa tion, sera de f ic ien t in 04  
or 0 2  were able to support so lubil isa tion but the onset was delayed and the 
ex ten t o f  the reaction  was reduced (Czop & Nussenzweig, 1976; Takahashi et 
a l,  1978). 0 3 - d e f i c i e n t  se rum  does n o t  su p p o r t  s o lu b i l is a t io n  (C zop  &  
Nussenzweig, 1976) but sera de f ic ien t  in 05  or 0 6  does (Takahashi e t al, 
1976). This suggests tha t the complem ent components beyond 0 3  are not 
involved in the reaction . Up to 95% of the solubilised complexes can be 
p rec ip i ta ted  by antiserum to 03  showing tha t 0 3  is bound to the complex 
(Takahashi, Takahashi &  Hirose, 1980).
The k ine tics  of the so lubil isa tion process have been studied. Deposition of 03b 
on the surface o f the immune complex occurs f i r s t .  This can occur rap id ly  i f  
the immune complex can f ix  01 , the in i t ia l  03b deposition tak ing piace due 
to  c la s s ic a l  p a th w a y  a c t i v a t io n  (Takahash i e t  a l,  1976). The phase o f  
a m p li f ica t io n  begins once the f i r s t  few  molecules o f 03b  are deposited on the 
complexes w ith  the assembly of the a lte rna t ive  pathway 03  convertase 
(03bBbP) on the complex. More molecules o f 0 3  are cleaved and increased 
deposition of 03b  on the complexes ensues. Massive deposition of 03b leads 
to  d is ru p t io n  o f  the  im m u n e  c o m p le x  l a t t i c e  and s o lu b i l is a t io n  occu rs  
(Takahashi, Tack & Nussenzweig, 1977). 03b deposition by classical pathway 
alone is in su ff ic ien t  to produce solubil isa tion. I t  has been suggested tha t the 
in te rac t ion  of 03  w ith  antigen-antibody complexes during so lubil isation results 
in the fo rm a tion  of an ester bond, the 03b binding sites possibly being located 
on amino acid residues in the Fd region of the IgG molecules and the 03b 
b in d in g  to  a n t ig e n  v ia  e s te r  bonds (T a k a ta ,  T a m u ra  &  F u j i t a ,  1984).
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When large quantit ies  o f C3b have been deposited on the complex the f ina l 
phase o f  the so lubil isa tion process begins. Sucrose density gradient studies on 
the p re c ip i ta t ion  of rad io- labe lled  antigen w ith  ammonium sulphate (f ina l 
cone 50%) show tha t most o f the soluble antigen is present in the fo rm  of 
immune complexes (Takahashi et al, 1980) C3, C4 and P are found in 
solubilised complexes (Takahashi et al, 1978) and the m olar ra t io  of C3b to 
antibody is approx im ate ly  1:1 (Takahashi et al, 1977). The size of solubilised 
co m p lexe s  is h e te ro g e n e o u s ,a  la rg e  p a r t  o f  the  co m p lexe s  show ing  
sedimentation co -e ff ic ien ts  between 11S to g reate r than 195.
The mechanism of so lubil isation seems best explained by the in te rca la t ion  
hypothesis advanced by M il le r  <5c Nussenzweig (1975). B r ie f ly  i t  states tha t 
during the in te rac t ion  o f  immune complexes w ith  excess compiem ent a large 
amount of C3 is incorporated in to the immune complex la t t ic e ,  combining 
w ith  antibody and thus tending to decrease the a f f in i t y  of antigen combining 
sites on the antibody molecule. There is breakage o f a few  antigen-antibody 
bonds and a reorganisation of the la t t ic e  takes place favouring  production of 
sm aller aggregates. In favour o f this hypo the tica l mechanism is the fa c t  tha t 
degradation products of antigen and antibody have not been found (Czop & 
Nussenzweig, 1976). Solubilisation does not occur in the absence of C3 and C3 
levels in sera corre la te  w e ll  w ith  so lubil isation in ind iv idual sera (Czop & 
N ussenzw e ig ,  1976). In c o rp o ra t io n  o f  la rg e  q u a n t i t ie s  o f  C3b in to  the  
antigen-antibody la t t ic e  occurs during the so lub il isa tion  process and the 
degree o f so lubil isa tion  appears dependent on the amount of C3b available 
(Takahashi et al, 1977). Incubation of complexes w ith  the monovalent Fab 
fragm ents of antibodies to the immunoglobulin in the complex can m im ic  
so lubil isa tion; in contras t 75 antibody and F(ab ' ) 2  fragm ents to the antibody 
in the  c o m p le x  p re v e n te d  s o lu b i l is a t io n .  T h is  p rocess  w ou ld  fa v o u r  
c ro s s - l in k in g  o f  the  a n t ib o d y  and thus p ro m o te  p r e c ip i t a t io n  (C zop  &
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Nussenzweig, 1976).
Some evidence can be presented to explain the mechanism whereby C3b 
e ffec ts  so lubil isa tion. The resu lt o f the early experiments o f M i l le r  (1977) 
support the mechanism of the reduction of the a f f in i t y  of antibody fo r  
antigen w ith  subsequent d issociation o f the complex as a possible means of 
C3b induced so lubil isa tion. Indeed insoluble complexes form ed w ith  high 
a f f i n i t y  a n t ib o d y  are s o lu b i l is e d  m ore  s lo w ly  th a n  co m p le x e s  c o n ta in in g  
antibody w ith  low a f f in i t y  fo r  the antigen (Takahashi et al, 1978) suggesting a 
role fo r  p r im ary  antigen-antibody bond d isruption. Fc -Fc  in terac tions are 
im po rtan t  in immune p rec ip i ta t ion  (M oller, 1979) and C3b fragm ents may 
in te r fe re  w ith  la t t ic e  fo rm a tion  by inh ib it ing  these Fc -Fc  in teractions. The 
overa ll so lub i l i ty  of the immune complex may be m od if ied  by the sheer 
numbers of C3b molecules which bind to the immune complex tending to 
favour d issociation of the immune complex.
Solubilisation o f p re fo rm ed immune complexes is a phenomenon studied ]n 
v i t r o . Whether th is phenomenon occurs in vivo is open to debate. I f  indeed i t  
does how im portan t is i t  in health or disease? Solubilisation occurs as a 
general phenomenon under physiological conditions and w ith  a va r ie ty  of 
antigen-antibody systems both from  human and animal sera (Takahashi et al, 
1980). In v iv o  s o lu b i l i s a t io n  m u s t be im p o r ta n t  in c le a r in g  la rge  
antigen-antibody complexes which are form ed or found deposited in the 
tissues and this concept is supported by the observation of the delayed
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clearance of complexes from  the g lomeruli o f decomplemented rabbits  w ith  
acute serum sickness (B a r to lo t t i  & Peters, 1978). I t  has been suggested tha t 
so lubil isa tion of complexes by C3 may be im portan t fo r  the generation of 
B-m em ory cells based on experim enta l evidence showing a small proportion  of 
solubilised complexes taken up and retained in the germ inal centres of the 
spleen (Malasit, B a r to lo t t i  ^H um phrey , 1983). Solubilisation is one of the 
p ro tec t ive  mechanisms against the occurence o f large aggregates in the body 
which would a lmost ce r ta in ly  cause tissue damage. For th is  to  be im portan t i t  
must be assumed tha t antigen-antibody immune p rec ip i ta tes  are formed 
and/or deposited and then are acted upon by com plem ent end thus solubilised. 
This seems an un like ly  occurence and i t  is d i f f i c u l t  to conceive o f many 
situations where antigen-antibody immune p rec ip ita tes  are form ed in the 
presence of an in ta c t  complem ent system. In the vast m a jo r i ty  o f instances 
antigen-antibody complexes must be formed in the presence of complement 
(S ch if fe r l i  et al, 1980).
S ch if fe r l i  and his colleagues (1980) argued tha t the ac tion  of complement on 
immune compiexes at the t im e  o f  the ir  fo rm ation  was l ike ly  to be more 
im portan t than the action  o f complement on pre fo rm ed complexes. They 
carried  out studies on immune complex fo rm a tion  in the presence of fresh 
serum and were able to show tha t com plem ent prevented the fo rm a tion  of 
immune p rec ip ita tes . In this study complexes fo rm ed a t equivalence or in 
antibody excess in the presence o f human serum did not p rec ip i ta te  but 
remained soluble fo r  up to 2 hours.
This phenomenon of p revention o f immune p rec ip i ta t ion  had been encountered 
by several workers previously. Heidelberger noted tha t  "pa rt icu la t ion  was 
g reatly  delayed in the tubes conta in ing ac tive  com plem ent" in his studies of 
complement f ix a t io n  (Heidelberger, 1941). L a te r  workers, during a ttem p ts  to
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develop double radio-immunoassay techniques, noted inh ib i to ry  a c t iv i ty  in 
normal serum and a t t r ibu te d  i t  to  the complement system (Morgan, Sorenson 
& Lazarow, 1964; Grant, 1968) It was also noted tha t BSA anti-BSA immune 
complexes did not p rec ip i ta te  when formed at equivalence in the presence of 
fresh serum at 37°C. Fo llow ing isolation these immune complexes were found 
to conta in  C lq ,  C i r ,  C Is  and C3 in addition to antigen and antibody (Casali & 
Lam bert,  1979).
S c h i f f e r l i  and h is c o l le a g u e s  c a l le d  p re v e n t io n  o f  im m un e  p r e c ip i t a t io n  
inh ib it ion  of immune p re c ip i ta t ion  (IIP). I have p re fe rred  to use the te rm  
prevention of immune p rec ip i ta t io n  (PIP) because this thesis contains work on 
an inh ib itor(s) of this process. I t  is fa r easier to  discuss an inh ib i to r of 
prevention o f  immune p re c ip i ta t ion  ra ther than an in h ib i to r  of inh ib it ion  of 
immune p rec ip i ta t ion .
Complement m ediated prevention of immune p rec ip i ta t io n
Immune p re c ip i ta t io n  was prevented by fresh normal serum via ac t iva t ion  of 
the complem ent system. This e f fe c t  of human serum was blocked by prior 
t re a tm e n t o f  the serum w ith  EDTA or by heating to 56°C fo r  30 minutes, 
procedures which would abrogate complement func t ion  (S ch if fe r l i  et al, 1980). 
Serum which had been depleted o f  B or P, thus being able only to  sustain 
c la s s ic a l  p a th w a y  a c t i v a t io n ,  was h ow e ve r  ab le  to  p re v e n t  im m un e  
p rec ip i ta t ion .  Immune complexes form ed in Mg^^ conta in ing E G TA-trea ted  
serum displayed an early  phase o f p re c ip i ta t ion  which was then fo l lowed by a 
phase of reso lub il isa tion  (S ch if fe r l i ,  Woo & Peters, 1982). The importance of 
the classical pathway in the prevention of immune p re c ip i ta t io n  phenomenon 
is fu r th e r  emphasised by the observation tha t excessive immune p rec ip i ta t ion  
is known to occur in sera which are de f ic ien t in C lq ,  C4, C2 and C3
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(S ch if fe r l i  e t al, 1980; S ch if fe r l i  e t  al, 1982) but not in sera which are 
d e f ic ien t in C5 or C7 (Naama et al, 1983). These findings again underline the 
im portance o f the classical pathway in this phenomenon and show tha t the 
te rm ina l components beyond C3 (C5-C9) are not required fo r  the process. As 
in the complem ent mediated solubil isa tion of p re fo rm ed p rec ip ita tes  C3 
a c t iva t ion  and binding is the im portan t step in the prevention o f immune 
p re c ip i ta t io n  phenomenon.
The role of C l  in prevention of immune p rec ip i ta t ion  is in teresting . Pur if ied  
C l  is able to block the early aggregation of immune complexes and appears 
to be the f i r s t  line o f  defence against immune p rec ip i ta t io n  (S ch if fe r l i  e t al, 
1982; Naama et al, 1984). The C l  molecule is bound to  the Fc portion  of 
immunoglobulins and probably in te r fe res  w ith  Fc-Fc in terac tions by s te r ic  
h indrance. These Fc-Fc  in terac tions are probably the main mechanism by 
which aggregation o f  immune complexes occurs (M olle r, 1979). However when 
the C l molecule was dissociated in to its subcomponents by the removal o f 
c a lc iu m  an im m e d ia te  a g g re g a t io n  o f  the  im m une  co m p le xe s  was seen 
(S ch if fe r l i  e t  al, 1982). This was due to the e f fe c t  o f C lq  which remained 
f ix e d  to  the  im m u n o g lo b u l in s  enhanc ing  the  in te r a c t io n s  be tw e e n  the  
complexes (Agnello, Winchester & Kunkel, 1970). These opposite e ffec ts  o f C l  
and C lq  have been reported  in o ther s ituations including the C lq  induced 
agg lu t ination  o f  IgG coated la tex  partic les  and enhanced agg lu tination  by 
rheum ato id  fa c to r  (Haiigren, Stalenheim &  Venge, 1979; Hallgren, 1979). Both 
of these reactions were abrogated by pur if ied  whole C l .
The use o f ind iv idual pur if ied  complement components have allowed fo r  
precise dissection o f the roles of the classical and a lte rna t ive  pathways in the 
prevention of immune p re c ip i ta t io n  reaction  (Naama et al, 1984; Naama et 
al, 1985). The anti-aggregationa l properties o f  C l  were confirm ed. No e f fe c t
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on immune p re c ip i ta t io n  was noted w ith  C4 or C2 alone, but when present 
w ith  C3 at the same concentrations as in normal serum, immune p rec ip i ta t ion  
did not occur. When the six a lte rna t ive  pathway components (C3, B, D, P, H 
& I) were present immune p rec ip i ta t ion  occured but th is  was fo l lowed by a 
phase of reso lub il isa t ion . A dd it ion  of the a lte rna t ive  pathway components to 
the components of the classical pathway did not a llow  fo r  more e f fe c t iv e  
prevention of immune p re c ip i ta t ion  than the classical pathway components by 
themselves (Naama et al, 1985). This study indicates tha t  the a lte rna t ive  
pathway is o f secondary importance to the classical pathway in the prevention 
o f  im m une  p r e c ip i t a t io n  r e a c t io n  in c o n t ra s t  to  the  s i tu a t io n  w i th  
so lubil isation of p re form ed immune prec ip ita tes.
A t th is point i t  is w o rth  making o ther comparisons of these two complement 
m e d ia te d  phenom ena  (v iz  s o lu b i l is a t io n  and p re v e n t io n  o f  im m un e
prec ip i ta t ion ) .  Solubilisation is more e f f ic ie n t  when complexes are formed in 
antigen-excess whereas prevention o f immune p re c ip i ta t io n  is more e f f ic ie n t  
fo r  an t ibody- excess complexes (S ch if fe r l i  e t al, 1980). The size of the
complexes produced a f te r  the tw o  reactions were s im ila r .  Sucrose gradient 
u l t ra ce n tr i fu ga t io n  revealed the size to  be approx im ate ly  25S which is s im ila r 
to the size of the complem ent solubilised Immune complexes (Takahashi e t  al,
1980). Norm al serum could m a in ta in  about tw en ty  t im es more complexes in 
solution by the process of prevention of immune p re c ip i ta t io n  compared to 
so lubil isa tion (S ch if fe r l i  et al, 1980). This may have relevance to the greater 
b io log ica l im portance of prevention of immune p re c ip i ta t ion  compared to 
so lubil isation in the processing of immune complexes in v ivo .
The m e ch an ism  o f  p re v e n t io n  o f  im m une  p r e c ip i t a t io n  in v o lv e s  the  
a ttachm ent o f C3b to immune complexes. Rad io- labelled C3 studies have
shown tha t the m olar ra t io  o f  C3b to IgG in the soluble complexes is 2:5
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(Naama et al, 1985), and immune p rec ip i ta t ion  experiments have shown tha t 
over 90% of immune complexes form ed in serum are p rec ip ta ted  by an ti-C 3  
antiserum. Antisera  to C lq ,  C4 and C2 p rec ip ta ted  much smaller proportions 
of immune complexes (Naama et al, 1985). Fu rthe r work in this f ie ld  has 
shown th a t  fragm ents of C3 and C4 are incorporated in to  the soluble immune 
complexes (the C3 fragm ents which were incorporated were C3b, iC3b, C3c 
and C3d). Some o f these fragm ents were bound cova len t ly  w ith  heavy chains 
of IgG antibody molecules. I t  was considered by these workers (Hong e t ai, 
1984) tha t the fo rm a tion  of covalent bonds between IgG and C3 and probably 
C4 was essential fo r  the prevention of immune p re c ip i ta t io n  process. The 
covalent linkage between IgG and C3 did not appear to be an ester bond 
(Hong e t  al, 1984) although this type o f  bond was reported  to be the linkage 
b e tw e e n  IgG and C3 when p re fo rm e d  p r e c ip i ta te s  w ere  d isso lved  by 
complem ent (Takata et al, 1984).
I t  is c lear the re fo re  tha t the immune complex la t t ic e  is g rea tly  m odif ied  
fo l low ing  the in te rac t ion  of antigen and complem ent f ix in g  antibody in body 
f lu ids. A large number o f C3b molecules are bound to an immune complex 
through a c t iva t io n  of the classical pathway fo l low ed  by rapid engagement of 
the a l te rna t ive  pathway (via the C3b feedback loop) w ith  the resu lt tha t large 
la t t ices  are not formed and immune p rec ip i ta t ion  is prevented.
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Hypothesis and proposed investiga tion
If the phenomenon o f  prevention o f immune p rec ip i ta t io n  is im po rtan t in the 
handling and safe disposal o f these c ircu la t ing  immune compiexes then a 
fa i lu re  of this mechanism would be expected to be associated w ith  immune 
complex diseases. The most extrem e example of th is would be hered ita ry  
defic iency o f  one or more of the classical pathway complem ent components, 
and indeed these are associated w ith  a high incidence o f immune complex like 
diseases (see Table 1.1). However complement de fic iency states are rare in 
the general population, Hasslg and colleagues (1964) found 14 individuals from  
41,083 m i l i t a r y  r e c r u i t s  w i t h  p e r s is te n t ly  u n d e te c ta b le  t o t a l  h a e m o ly  t i c  
complem ent, a frequency o f 0.03%. Torisu and his colleagues (1970) found 
only 37 of 42,000 normals to have low CH5D levels. Since genetic  defic iencies 
of com plem ent proteins are there fo re  probably quite  rare in the general 
population, studies have tended to concentrate  on p a t ien t  populations. O f 545 
patients w ith  rheum atic  disease Glass et al (1976) found one C2 de f ic ien t 
h o m o z y g o te  and 10 d e f in i t e ,  5 p ro ba b le  and 4 poss ib le  C2 d e f ic ie n t  
heterozygotes. Among 509 contro ls  w ithou t rheum atic  disease only 6 possible 
heterozygotes were found. This gave an estimated frequency o f 1.2% fo r  the 
n u l l  gene in the  ge n e ra l p o p u la t io n .  P a t ie n ts  w i th  s y s te m ic  lupus 
e ry th e m a to s u s  had the  h ig he s t f re q u e n c y  (5 .9% ) o f  C2 d e f ic ie n c y .
It  is c lear tha t  hered ita ry  complement de fic iency states are rare even when 
patien t populations, w ith  th e ir  considerable ascerta inm ent bias, are screened.
Up u n t i l  the work contained in th is thesis was s tarted  in 1983 no studies had 
been undertaken to measure prevention of immune p re c ip i ta t ion  in disease. 
The work o f S ch i f fe r l i  and his colleagues (S ch if fe r l i  e t al, 1980; S ch if fe r l i  et 
a l,  1982; S c h i f f e r l i  & P e te rs ,  1982* S c h i f f e r l i  &. P e te rs ,  1983(b)) had 
concentrated on e luc ida ting  the deta iled mechanisms of the reaction  but no
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work on the c l in ica l re levance, i f  any, o f  prevention of immune p rec ip i ta t ion  
had been undertaken. The aim the re fo re  of my in i t ia l  work was to measure 
p re v e n t io n  o f  Im m une p r e c ip i t a t io n  in  d iseases a s s o c ia te d  w i th  im m un e  
complex fo rm a tion .
If  p revention o f  immune p re c ip i ta t io n  (PIP) was im po rtan t  in th is respect and 
as inherited  defects o f complem ent are rare one m igh t expect there to be 
other defects  in PIP in patien ts  w ith  immune complex disease. I f  indeed this 
was the case I planned to examine the mechanism whereby this occurred and 
also to  study the deta iled  c l in ica l features o f  each disease to ascerta in which 
c l in ica l features m igh t be most strongly associated w ith  the fa i lu re  of 
prevention of immune p re c ip i ta t ion .  The sera o r ig ina l ly  chosen were from  
patients w ith  system ic lupus erythematosus (SLE) and g lom eru lonephrit is  (GN). 
I also included osteoarthrosis as a disease con tro l being an example o f a 
non - in f lam m ato ry  rheum atic  disease. However in rou tine  c l in ica l p rac tice  
these diseases (SLE and GN) are re la t ive ly  rare and I the re fo re  decided to  
look more closely a t sera from  patients w ith  rheum ato id  a r th r i t is ,  which is a 
c o m m o n , se r ious  rh e u m a t ic  d is o rd e r  in w h ic h  im m u n e  co m p lexe s  are 
im p lica ted  in disease pathogenesis.
A lthough there is no doubt tha t  ce il mediated immune responses play an 
im portan t ro le in the pathogenesis o f rheumatoid synovitis , humoral immune 
m echan ism s  are  a lso in t im a t e l y  in v o lv e d  in  the  d isease p rocess . The 
h is topatho log ica l features of the rheumatoid synovium w ith  p ro l i fe ra t io n  of 
lin ing cells and intense ce l lu la r in f i l t r a te  which includes (in established 
rh e u m a to id  s y n o v i t is )  la rg e  num bers  o f  ly m p h o c y te s ,  p lasm a c e l ls ,  
m acrop ha ges  and o cc a s io n a l g e rm in a l  c e n t re  f o r m a t io n  t e s t i f i e s  to  the  
im p o r ta n c e  o f  c e l lu la r  im m une  m echan ism s in the  rh e u m a to id  process 
(Sokoloff, 1979). In rheum ato id  synovitis in i t ia l ly  there is congestion and
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oedema most marked at the in terna l surface of the synovium and these 
changes are associated w ith  the development o f e ffus ion  in to  the jo in t  space. 
Small numbers of polymorphs em igra te  w ith  the oedema f lu id .  In early  lesions 
especially, the p r inc ipa l in f i l t r a t in g  ce ll is a small lym phocyte . Many o f the 
lymphocytes in the synovial in f i l t ra te s  are T cells (Van Boxel & Paget, 1975). 
Studies using OKT4 and 0 K T 8  antibodies have shown tw o types of T ceils, 
namely he lper- inducer and suppressor-cytotoxic, in the synovium (Duke et al, 
1982; Kurosaka & Z i f f ,  1983). In la te  lesions the m a jo r i ty  of in f i l t ra t in g  cells 
are plasma cells (P ia t le r  et al, 1976) which synthesise rheum ato id  fac to r  
(Nowoslawski & Brzosko, 1967).
The late lesions are marked by gross synovial th icken ing, p ro l i fe ra t io n  of 
synovial f ib rob las ts  and synovial lin ing  cells. M u lt i-nuc lea ted  g iant cells may 
be seen (G rim ley & Sokoloff, 1966). This chronic in f la m m a to ry  tissue which 
extends over the a r t icu la r  ca rt i lage  is called pannus and is accompanied by 
ca rt i lage  destruct ion. Chondrolysis may occur because of pannus induced 
disturbance of normal ca r t i lage  n u tr i t io n  or because o f  the e laboration of 
p r o te o ly t i c  enzym es  f r o m  p o ly m o rp h s  and o th e r  c e l ls  in the  c h ro n ic  
in f la m m a to ry  tissue.
In the synovial f lu id  however, there is evidence of an acute in f lam m a to ry  
reaction  w ith  a predom inantly  neutroph il accum ulation and plasma exudation. 
H u m o ra l  im m une  m echan ism s th e r e fo r e ,  e s p e c ia l ly  in v o lv in g  im m une  
complexes, are also considered to be im portan t in rheum ato id  a r th r i t is  
patholog ica l processes. The concept tha t antigen-antibody complexes m ight 
mediate rheum ato id  synovitis is supported by the dem onstra tion o f  phagocytic 
synovial l in ing  cells and polymorphonuclear leukocytes showing cytop lasm ic 
g ranu les  c o n ta in in g  im m u n o g lo b u l in s ,  a n t i - Ig G s  ( rh e u m a to id  fa c to r s )  and 
complem ent components (Hollander e t al, 1965; K insella , Baum & Z i f f ,  1969;
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Kinsella, Baum & Z i f f ,  1970; Vaughan et al, 1968). Fu rthe r evidence fo r  this 
notion came from  the demonstrations of decreased haem o ly t ic  complement 
levels in rheum ato id  synoviai f lu ids (Hedberg, 1963; Pekin & Zva if le r ,  1964). 
The immune complex nature of the molecules responsible fo r  this decreased 
synoviai f lu id  com plem ent was recognised and rheum ato id  fa c to r  was also 
shown to  be a part o f the synovial f lu id  immune complex (Winchester, Agnello 
& Kunkel, 1970; Winchester, 1975).
The experim enta l model of antigen-induced a r th r i t is  o r ig ina l ly  described by 
Dumonde and Glynn (1962), where chronic synovitis in rabb its  was Induced by 
in traderm a l im m unisation w ith  f ib r in  in Freund's com plete  adjuvant fo l lowed 
in 2 to 3 weeks by an in t ra -a r t ic u la r  in ject ion  o f f ib r in ,  showed tha t immune 
complexes could mediate  a rheum ato id - l ike  synovitis . An identica l chronic 
synovitis could be induced by antigens such as ovalbumin and bovine serum 
albumin in jected in to  the jo in ts of previously sensitised animals (Consden et 
al, 1971; Cook & Jasin, 1972). The h is to log ica l fea tures described by Dumonde 
and G lyn n  in c lu d e d  h y p e rp la s ia  o f  s y n o v ia l  l in in g  c e l ls ,  i n f i l t r a t i o n  o f 
synovium w ith  plasma cells and lymphocytes, pannus fo rm a tion  and bone 
erosions and were s im ila r  in many respects to rheum ato id  a r th r i t is  synovitis . 
Subsequent s tud ie s  on a n t ig e n —induced  a r t h r i t i s  have d e m o n s t ra te d  the  
re ten t ion  of rad io- labe lled  antigen in the menisci o f a r th r i t ic  rabbits  w i th  the 
im m unofluorescent dem onstra tion of antibody and C3 in the same location  as 
the antigen (Jasin e t al, 1973). Indeed immune complexes have been found in 
the hyaline a r t ic u la r  ca rt i lage  in a m a jo r ity  of patien ts  w ith  rhqumatoid 
a r th r i t is  (Cooke e t al, 1975; Ishikawa, Smiley & Z i f f ,  1975).
C ircu la t in g  immune complexes are also found in rheum ato id  a r th r i t is  patients 
(Luthra et ai, 1975; Zubler e t al, 1976; Hay e t al, 1979) and the potentia l 
pathogen ic ity  o f c ircu la t in g  complexes has been discussed above. The presence
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of systemic hypocompiementaem ia in some patien ts  w ith  rheum ato id  a r th r i t is  
(H unde r & M c D u f f ie ,  1973) and the  h y p e rc a ta b o l is m  o f  c o m p le m e n t  
components in many others (Kaplan e t al, 1980; K r ic k  et al, 1978) suggest 
tha t  c ircu la t in g  immune complexes may play a ro le in RA w ith  and w ithou t 
the e x tra -a r t ic u la r  m anifesta tions o f the disease. The se lf  association of IgG 
and IgM rheum ato id  fac to rs  is w e ll described (Pope, T e lle r  & Mannik, 1974) 
and may be responsible fo r  a proportion  of c ircu la t ing  immune complexes in 
p a t ie n ts  w i t h  rh e u m a to id  a r t h r i t i s  (Pope, Y osh in o ya  &  M c D u f f y ,  1981). 
C ircu la t ing  immune complexes in patients w ith  rheum ato id  a r th r i t is  may fo rm  
cryoglobulins. IgM rheum ato id  fa c to r  and less frequen t ly  IgG rheum ato id  
fac to r  conta in ing cryoglobulins appear to  be associated w ith , and may indeed 
m e d ia te  rh e u m a to id  v a s c u l i t is  (W eism an &  Z v a i f l e r ,  1975). Us ing  the  
polyethylene g lyco l p re c ip i ta t io n  technique over ha lf  o f the sera from  patients 
w ith  rheumatoid a r th r i t is  (32 of 63) contained immune complexes. This 
compared w ith  only 2 of 52 normal contro ls who had immune complexes 
detectab le  in th e ir  sera (Barnett e t al, 1979). Using a p la te le t  aggregation 
assay c ircu la t ing  immune complexes were found in approx im ate ly  25% of 
seropositive rheum ato id  a r th r i t is  sera (Norberg, 1974). A pa rt  f rom  these 
studies which were carried  out on patients w ith  established disease other 
studies have shown tha t  c ircu la t in g  immune complexes can be detected in 
patients w ith  very early  disease and even many months before the actual 
diagnosis of rheumatoid a r th r i t is  can be made (Jones e t al, 1981). The 
importance o f this study is tha t  there are obviously abnormal c ircu la t ing  
immune complexes r ig h t  at the very inception of disease. From the foregoing 
I the re fo re  fe l t  ju s t i f ied  in looking at rheum ato id  a r th r i t is  as an immune 
complex disease although 1 have taken cognisance of the evidence tha t  there 
is an ongoing ce l l-m ed ia ted  reaction  in the rheumatoid synovium along side 
the type 3 reaction .
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The presence of c ircu la t in g  immune complexes in rheum ato id  a r th r i t is ,  o ften  
early  in the disease, taken w ith  the evidence o f system ic hypercatabolism of 
complem ent, raises the question o f whether there is a fa i lu re  o f clearance of 
these c o m p le x e s .  D e fe c t iv e  r e t i c u lo - e n d o th e l ia i  f u n c t io n  in  rh e u m a to id  
a r th r i t is  has been reported by W ill iams and colleagues (1979). In this study 
only 13 patients were studied but the authors could re la te  the levels of 
c ircu la t in g  immune complexes and splenic func t ion  to disease a c t iv i ty ;  there 
was a lso an in ve rse  r e la t io n s h ip  b e tw e e n  le v e ls  o f  c i r c u la t in g  im m un e  
complexes and splenic func t ion  suggesting a causal re la tionsh ip . However 
other studies have not been able to substantiate these findings (Gordon e t al, 
1981; Henderson et al, 1981). In teresting ly , in v i t ro  studies (Hurst & Nuki,
1981) have shown a s e le c t iv e  im p a i rm e n t  o f  c o m p le m e n t -m e d ia te d  
phagocytosis in patien ts  w ith  rheum ato id  a r th r i t is  w ith  vasculit is  but not in 
those w ith o u t  vasculit is . Fc recepto r function  was normal in a ll patients. 
Elkon and associates have shown, using heat-damaged e ry th rocytes , defects  in 
clearance in SEE and various vasculit ides (Elkon et al, 1980). Ind irec t methods 
o f assessing the function  of the re t icu lo -endo the lia l system by studying its 
capacity  to c lear e ry th rocy tes  coated w ith  IgG (Rh-D) antibody (splenic Fc 
mediated c learance) and e ry throcy tes  sensitised w ith  IgM antibody (usually 
human IgM anti-b lood  group substance A) and C3 (hepatic clearance) have 
shown de fec t ive  re t icu lo -end o the lia l function  in pa tien ts  w ith  various immune 
complex diseases (Frank et al, 1983) but in rheum ato id  a r th r i t is  the role of 
re t icu lo -endo the lia l blockade In pathogenesis remains unclear. As discussed 
above complem ent reactions w ith  immune complexes are im portan t in the 
processing and de livery  o f immune complexes to the re t icu lo -endo the lia l 
sys tem  fo r  sa fe  re m o v a l .  C o m p le m e n t  m e d ia te d  p re v e n t io n  o f  im m un e  
p rec ip i ta t ion  by m ain ta in ing  complexes small and soluble and by in i t ia t in g  
opsonisation whereby the complexes are coated w ith  C3b, is cen tra l to this 
clearance process. I t  is clear tha t tissue damaging immune complexes are
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made when p rec ip i ta t ing  antibodies are formed (Dixon e t al, 1961). Therefore 
the a b i l i ty  o f complem ent to keep complexes soluble is o f c r i t ic a l  importance.
C e rta in ly ,  a t least some o f the manifesta tions of rheum ato id  a r th r i t is  may be 
mediated by immune complexes (eg vasculit is) and the fa c t  tha t immune 
complexes in serum can be detected very early on in the  disease suggests tha t 
immune complexes may be im portan t in mediating the early  features o f the 
disease. The presence o f insoluble immune complexes in the c ircu la t ion  and 
the synovial f lu id  may in part be due to the fa i lu re  of normal clearance 
mechanisms.
The w o rk  in th is  thes is  co nce rns  s tud ie s  w h ic h  1 c a r r ie d  o u t  b e tw e e n  
1983-1986 concerning the investiga tion  o f complem ent mediated prevention of 
immune p re c ip i ta t io n  (PIP) in rheum atic  diseases. For the reasons discussed 
above 1 focussed on rheum ato id  a r th r i t is  and a ttem p ted  to re la te  the findings 
in serum and synovial f lu id  to the c l in ica l and labora to ry  features o f  disease. 
If ,  as has been postulated, a de fec t o f  PIP did exist in RA serum or synovial 
f lu id  what was its  nature and its mechanism of action? I f  a fa i lu re  of PIP did 
exist In RA was i t  re la ted  to any spec if ic  c l in ica l or labora to ry  aspect o f  the 
disease? These were the questions which I set out to  answer at the beginning 
of this work.
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CHAPTER TWO
M ATERIALS & METHODS
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I have arranged this chapter in three parts, namely:
(1) C lin ica l methods
(2) Experim enta l methods
(3) S ta t is t ica l methods.
The chapter is arranged in sections and subsections and enumerated as 
fo llows:
2.1, 2.2, 2.3, the f igure  a f te r  the point denoting the section.
The figure  a f te r  the second point indicates the subsection eg 2.1.1, 2.1.2, 
2.1.3 etc.
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Reagents Obtained C om m erc ia l ly
Gelatin  (Merck)
P ur if ied  agarose (BDH)
Sheep e ry th rocy tes  (Gibco)
Bovine serum albumin (Sigma)
Freund's com plete  adjuvant ]
Freund's incom plete  adjuvant ]
Tyrosine (Sigma)
Phenylmethylsu lphonyl f luo r ide  (PMSF) (Sigma)
Soyabean tryps in  in h ib i to r  (SBTI) (Sigma)
Pepsin (Sigma)
Trypsin (Sigma)
RA la tex test (Wellco test, Wellcome)
125- I  (Rad iochemical Centre , Amersham)
Tween-20 (Sigma)
o-phenylene-d iam ine (OPD) (Sigma)
TEMED (BDH)
A cry lam ide  ]
B isacry lam ide ]
Antibodies
P e rox ida se  la b e l le d  g oa t  a n t ih u m a n  a n t ib o d ie s  (C a p p e l l  L a b o ra to r ie s ,  
Pennsylvania).
(1) F(ab ')^ anti-human chain ] (Cappell
(2) F(ab')^ anti-human cLchain ] Laboratories
(3) F(ab ' ) 2  anti-human IgG ] Pennsylvania)
Sheep antihuman IgM ] (Scottish Antibody 
Sheep antihuman IgG ] Production U n it)
Chromatography Reagents 
DEAE cellulose (DE52) (Whatman)
Dowex 1x8-200 (A ld r ich  Chemica l Co)
Sepharose 4B ]
Sephadex G-200 ] Pharmacia 
Sephacryl S300 ]
A l l  o ther general labora to ry  reagents used fo r  solutions and buffe rs  were 
Analar grade and were obtained f rom  BDH Chemicals.
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2.1 C L IN IC A L  METHODS
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2.1.1 C o llec t ion  and preparation of b io log ica l m a ter ia ls  
Serum samples
Blood was co llec ted  by venepuncture and allowed to c lo t  at 37°C fo r  30 
m in u te s  and f o r  one hou r on ice  fo r  c lo t  r e t r a c t i o n  to  o c c u r .  A f t e r  
ce n tr i fu g a t io n  at 2000g fo r  10 m inutes the serum was separated and stored in 
aliguots at -70°C.
Synovial f lu id  samples
Synovial f lu id  (SF) was co llec ted  f rom  the knee jo in t  of patien ts  undergoing 
the rapeu t ic  arthrocentes is . This was carried  out under loca l anaesthesia and a 
s t r ic t  aseptic procedure was employed. The volume of SF aspirated was 
recorded.
Samples were cen tr i fuged  at 2000g fo r  10 minutes to  remove any cells and 
pa r t icu la te  debris. The supernatants were divided in to  aliguots and stored at 
-7GFC.
C lin ica l studies - pa t ien t details
2.1.2 Measurement o f PIP in patien ts ' sera (see Chapter 3, Section 2) 
In this study blood was co llec ted  from  32 patien ts  w ith  systemic lupus 
erythematosus (SLE) (Cohen et al, 1971), 75 patients w i th  classical or de f in ite  
rheum ato id  a r th r i t is  (RA) (Ropes et al, 1958) who were seropostive fo r  
rheum ato id  fa c to r  as measured by haemagglutination and 11 w ith  RA who 
were seronegative fo r  rheum ato id  fa c to r .  Also included were 9 patients w ith  
psor ia t ic  a r th r i t is ,  12 w ith  ankylosing spondylit is  and 8 w ith  degenerative jo in t  
disease (os teoarth r it is ) .  A l l  these patients attended a routine  rheumatology 
ou t-pa t ien t  c l in ic .  Blood was also co llec ted  f rom  a group o f patients w ith  
g lom eru lonephrit is :- !^ ,  w ith  membranous g lom eru lonephrit is  (GN), 2 w ith  foca l 
GN and 1 w ith  acute pos t-s trep tococca l GN. The diagnosis of GN was based
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on renal biopsy findings. Blood samples were also obtained from  25 healthy 
labora to ry  personnel, 13 male and 12 fem ale. These served as normal contro ls.
2.1.3 Measurement of inh ib it ion  o f PIP in sera o f  patients su ffe r ing  from  
rheum atic  disease (See Chapter 3, Section 4)
In this study sera was obtained from  25 normal labora to ry  personnel (see 
above). Ser\jfl\was prepared f rom  venous blood obtained fro m  130 patien ts  w ith  
seropositive RA (Ropes et al, 1958), 25 w ith  seronegative RA, 5 w ith  psor ia t ic  
a r th r i t is  and 6 w ith  ankylosing spondylit is. Synovial f lu id  (SF) was obtained 
from  13 patients w ith  RA as described above. Venous blood was obtained from  
these patien ts  at the t im e  of arthrocentesis.
2.1.4 The re la tionsh ip  between inh ib it ion  of PIP ( inh ib ito ry  a c t iv i ty )  and 
c l in ica l features of disease.
Study A
2.1.4(a) Twenty-n ine  patients who underwent therapeutic  arthrocentesis o f the 
knee jo in t,  were divided in to  the fo l low ing  three groups: group A-1 included 15 
patients w ith  RA positive fo r  IgM -RF, group A - I I  included 8 RA patien ts  who 
were seronegative fo r  IgM -RF and group A - l I I  included 6 patients w ith  
miscellaneous a r th r i t id es  (2 psor ia t ic  a r th r i t is ,  2 reac t ive  a r th r i t is ,  1 sarcoid 
a rth ropa thy  and 1 pyrophosphate arthropathy). C lin ica l evidence o f generalised 
disease a c t iv i ty  and a c t iv i ty  w ith in  the jo in t  to be aspirated were assessed 
prio r to  arthrocentesis.
C lin ica l assessment of disease a c t iv i ty
G e n e ra l is e d  d isease a c t i v i t y  was assessed by re c o rd in g  the  d u ra t io n  o f  
morning s t if fness (minutes), pain score (scale 0-3) where 0 = no pain and 3 = 
severe pain and a r t ic u la r  index o f jo in t  tenderness (R itch ie  et al, 1968).
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The degree of in f lam m a tion  in an aspirated knee jo in t  was assessed c l in ica l ly  
by using a cum ula t ive  index (scale 0 - 12). This index comprised assessments 
of pain, synovial hypertrophy, tenderness and effus ion (each scored on a scale 
0 - 3).
L a b o ra to r y  assessm ent o f  d isease a c t i v i t y  in c lu d e d  the  m e a s u re m e n t o f  
haemoglobin (Hb), wh ite  ce ll count (WCC), p la te le t  count and e ry th rocy te  
s e d im e n ta t io n  ra te  (m m  in f i r s t  hou r,  W e s te rg re n ) .  T o ta l  h a e m o ly t ic  
complem ent (CH50) was measured by haem olyt ic  assay (see 2.2.14(b) and C3, 
C4 and Fac to r B by nepheiometry (see 2.2.14(a) IgM -RF, IgA-R F and IgG-RF 
was measured in serum by ELISA (see 2.2.7(d).
Synovial f lu id  analysis included measurement of volume aspirated (mis), WCC, 
to ta l  p ro te in , C3, C4, Fac to r B^ CH50 and rheum ato id  fa c to r  (IgM, IgA and 
IgG-RFs) by ELISA (see 2.2.7(d).
Study B
2.1.4(b) F i f ty -e ig h t  consecutive patients w ith  de f in ite  or classical RA (Ropes 
et al, 1958) were divided in to  the fo l low ing  three groups according to the 
presence or absence o f  e x tra -a r t ic u la r  features o f RA. Group B-I included 20 
RA  patien ts  w ith  a r t icu la r  disease alone; group B-11 included 18 RA patients 
w ith  subcutaneous nodules, and group B -lI I  included 20 patients w ith  RA 
com plica ted  by system ic vasculit is .
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2.2 EXPER IM EN TAL METHODS
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2.2.1 Assays to measure the complem ent mediated prevention o f immune 
p re c ip i ta t io n  (PIP) and inh ib it ion  of PIP (see Chapter 3, Sections 1-4) 
Reagents
1. GVB^^ pH 7.4. This was made as described (2.2.14(b).
2. Phosphate buffe red  saline (PBS) pH 7.4 
1753. I-BSA
4. anti-BSA antiserum
5. T r ich lo roa ce t ic  acid (TCA) 20%
6. BSA (5m g/m l)
Phosphate bu ffe red  saline (PBS) pH 7.4
8g o f sodium ch loride, 1.21g of potassium phosphate and 0.34g o f potassium 
hydrogen phosphate was dissolved in 500mls w a te r and made up to a f ina l 
volume of 1 l i t re .
T r ich lo ro a ce t ic  Ac id  (TCA, 20% W/V)
20g o f t r ich lo ro ace ta te  was dissolved in w ater to  a f ina l volume o f  lOOmls. 
BSA (5m g/m l)
lOOmg of BSA (Sigma) was weighed out and dissolved in 20mls o f PBS pH 7.4. 
F ina l concen tra t ion  o f BSA was 5m g/m l.
1 25' I-BSA
125BSA was rad io labelled w ith  I by a m o d if ica t io n  o f the ch loram ine T 
method described by McConahey & Dixon (1966). The procedure was as 
fo l lows;
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Reagents
2mg BSA (in Im i  solution)
(1mCi)
PBS pH 7.4 
10% BSA in PBS 
Ch lo ram ine-T  5m g/m l.
0 .5m g/m l Tyrosine dissolved in 0.01M NaOH.
10% TC A
Dowex 1 x 8 - 200 Anion exchange resin.
Method
A Dowex s lu rry  was prepared by soaking Dowex beads 1:1 v /v  in deionised 
water overn igh t.
A 10ml graduated p ipe tte  was used as a column. A f te r  insertion o f a small 
p lug o f  g lass w oo l the  c o lu m n  was f i l l e d  w i t h  th e  D ow ex s lu r r y  to  
a p p ro x im te ly  6m ls . The co lum n  was e g u i l ib r a te d  w i t h  PBS, pH 7 .4 .
Reaction
1252mg of BSA (in 1ml solution) was added to v ia l conta in ing  1 mCi of I. 10|j1 
of ch lo ram ine-T  (50jjg) was then added. The v ia l was mixed fo r  40-50 seconds 
and the reac tion  stopped by the addition o f 50|j1 (25pg) tyrosine. The reaction  
m ix tu re  was applied to the Dowex column and the reaction  v ia l washed out 
w ith  a small volume o f PBS. These washings were also applied to the column. 
350{j1 f rac t ions  were co llec ted  in small tubes f ro m  the bo ttom  of the column 
and the d is tr ibu t ion  of the ra d io a c t iv i ty  determ ined by removing 5pl a liguot 
fo r  counting. The tubes conta in ing the peak o f the ra d io a c t iv i ty  were pooled.
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125To determ ine the ra t io  of p ro te in  bound to free I,
10jjl o f labelled p ro te in  pool was added to each of two capped m icrofuge 
tubes to  which had been added 200jj1 of 10% BSA, 1 ml o f 20% TC A was then 
added to  each tube. A f te r  cen tr i fuga t ion  in a m icrofuge at 10,000 rpm fo r  10 
mins, the supernatants were separated from  the p ro te in  pellets. Supernatants 
and pelle ts were counted in a ^  counter (Packard Model 800C) and the 
p e rc e n ta g e  o f  ac id  p r e c ip i ta b le  r a d io a c t i v i t y  was c a lc u la te d  as fo l lo w s .
_______________ counts in pe l le t - background_________________
(counts in pe l le t  - background) + (counts in supernatant-background
A c id -p rec ip i tab le  ra d io a c t iv i ty  was usually 95-97%.
The concen tra t ion  o f BSA in the labelled BSA pool was measured by reading 
OD^gQ o f the sample in a spectrophotom eter. The concen tra t ion  of BSA in 
the sample was ca lcu la ted using the ex t inc t ion  c o -e f f ic ie n t  fo r  BSA (0.667 fo r  
a Im g /m l solu tion o f BSA at 28Gnm). The volume of the labelled BSA pool 
was usually 1.7 to 1.8mls.
Using the above described labell ing procedure the recovery of labelled BSA 
was usually 0.98 to 1.1 m g /m l.
Specific A c t iv i t y  of  ^^^1-labelled BSA
125The a m o u n t  o f  r a d io a c t i v i t y  w h ich  was in c o rp o ra te d  in to  the  1-
labelled BSA was ca lcu la ted by d iv id ing the amount of ra d io a c t iv i ty  in 1 ml of 
125the I-BSA solution by the BSA concentra t ion . The results were expressed 
as cpm /jjg  pro te in , or jjCi/jug pro te in  as pCi = 1.5 x 10^ cpm.
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Anti-BS A  antiserum
Antiserum to BSA was prepared by the immunisation of rabbits . For p r im ary  
imm unisation 1 mg of antigen was emuls if ied in Freund's complete adjuvant 
and in jected subcutaneously and in tram uscu la r ly  in to  several sites. A f te r  6, 8 
and 10 weeks the immune response was boosted by fu r the r  in tram uscular 
in jections o f 1mg o f  antigen em uls if ied  in Freund's incom plete adjuvant. Ten 
days a f te r  the f ina l in jec t ion  the animals were bled and the antiserum was 
hea t- inac tiva ted  (56°C fo r  30 min) p r io r  to storage in aliquots at -20°C.
Testing of antiserum
The antiserum was tested using double-diffus ion in agarose gel (Ouchterlony, 
1958). When antigen and antiserum are placed in adjacent wells cut in agarose 
they w i l l  d if fuse towards each other. A line of p re c ip i ta te  is seen when the 
antigen and antibody meet at equivalence.
Equipment and Reagents
Glass plates 80mm x 80mm
H orizon ta l tab le
Gel punch
Vacuum pump
Drawn out cap i l la ry  tubing
Moist chamber
Agarose
Isotonic veronal bu ffe red  saline (pH 7.4) conta in ing EDTA (10m m ol/ l)  and 
sodium azide (0.02%)
Boiling w a ter bath
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Method
A glass p late was ca re fu l ly  cleaned w ith  detergent and rinsed thoroughly in 
deionised w a te r and then 95% alcohol. I t  was allowed to dry at room 
tem pera tu re . 1.5g agarose was dissolved in lOOmls o f veronal b u f fe r  by boiling 
in a bo t t le  in the w a ter bath. The agarose was dispensed in 10ml aliquots and 
stored a t 4°C un t i l  used. A 10ml a liquo t was melted by boil ing and the 
agarose p ipe tted  onto the glass p la te  on a level tab le. The gel was allowed to 
set at room tem pera ture .
Seven wells each 3mm in d iam eter were punched in to  the agar using a p lastic  
tem p la te  and a gel punch. The arrangement o f the wells was one cen tra l we ll 
surrounded by six periphera l wells. The distance between the centre  of the 
cen tra l w e ll  and the centre  of the periphera l wells was 10mm.
The wells were ca re fu l ly  loaded to the brim  using a drawn out cap il la ry  tube. 
The cen tra l we ll contained BSA ( Im g /m l) .  The periphera l wells were f i l le d  
w i th  s e r ia l  d ou b l in g  d i lu t io n s  o f  a n t is e ru m  ( f ro m  u n d i lu te d  to  1:32).
The loaded p la te  was placed in a moist chamber at room tem pera ture  to 
a llow d if fus ion  to occur over 24-48 hours. The gel was viewed using incident 
l igh t against a dark background. A line of p re c ip i ta t ion  between the centra l 
we ll and the periphera l wells was noted. This was most marked w ith  the 
undiluted antiserum and became fa in te r  as the antiserum was d ilu ted . A single 
line was noted con f irm ing  tha t  the antiserum was m onospecif ic . The d ilu t ion  
of antiserum which produced a s t i l l  v isible line of p re c ip i ta t ion  w ith  the 
antigen in the cen tra l well was used as an ind ication  of the amount of 
spec if ic  antibody which was present in the antiserum.
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Q uan t ita t ive  p rec ip i t in  curve fo r  immune complexes
BSA anti-BSA immune complexes formed at equivalence were used in the PIP 
assay. In order to  determ ine the quantit ies o f BSA and anti-BSA required a 
quan t i ta t ive  p re c ip i t in  curve was prepared. Serial doubling d ilu tions of BSA 
(2mg - 5pg in 250|j1 PBS) were set up in a row  of nine tes t tubes. An equal 
volume o f antiserum (250jjl) was added to each tube. The tube contents were 
m ixed and then incubated at 37°C fo r  1 hour, and overn ight at 4°C. The 
immune p rec ip i ta tes  were separated by cen tr i fug a t ion  (2000g fo r  30mins at 
2°C), washed three t im es in ice cold PBS and redissolved in 100^1 of sodium 
hydroxide (100m m ol/l) . The amount of p ro te in  in each tube was determ ined by 
the Fo lin  phenol method (see on).
The results were p lo tted  as shown in Fig 2.1. The tube conta in ing the greatest 
amount o f p re c ip i ta te  was the equivalence point. This tube contained 350|jg of 
BSA. Subtracting th is from  the to ta l  p rec ip i ta te  value (jjg of pro te in) gave me 
the amount of antibody in the complex which at equivalence should be a ll the 
antibody. In th is  experim ent 805jjg of antibody had p rec ip i ta ted  in this tube. 
This gave a m olar antigen antibody ra t io  at equivalence to be 1 to 2.3. This 
ra t io  of BSA to anti-BSA was used in my assays to  measure PIP and inh ib it ion  
of PIP.
2.2.1(a) Assay to measure the prevention of immune p rec ip i ta t ion  (PIP) 
The assay used was a m od if ica t ion  of tha t described by S ch iffe r l i  and 
colleagues (1980).
Equal volumes 50[j1 of serum and GVB^^ were m ixed in a tes t tube, to which 
1 255pl 1-BSA (1.75 jjg) was added. The m ix tu re  was warmed to 37°C in a
w ater bath, a f te r  which lOpl anti-BSA (4|jg antibody) were added, the 
contents m ixed w e ll and the incubation continued. In the in i t ia l  k ine tic
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Figure 2.1
Q uan t ita t ive  p re c ip i t in  curve of BSA and anti-BSA antibody. The arrow denotes 
the equivalence po in t,  the tube of maximum p re c ip i ta t io n .  To the r ig h t  of this 
point immune complexes are in antigen excess and to the le f t  they are found in 
antibody excess.
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studies, 25|j1 aliquots o f the m ix tu re  were removed a f te r  15, 30 and 60 
minutes. Once the conditions of the assay had been established, a single 
a liquot (50|j1) was removed a f te r  60 minutes. The a liquots were added to 
Eppendorf tubes conta in ing 1ml ice cold phosphate-buffered saline (PBS). The 
tubes were cen tr i fuged  (Beckman M icro fuge) fo r  5 minutes and 250jul o f  the 
supernatant removed fo r  counting ra d io a c t iv i ty .
Contro l tubes included (1) to ta l  ra d io a c t iv i ty  p rec ip i ta ted  by antibody in the 
absence o f  serum (100yl GVB^^ 5|j1 ^^^I-BSA, lOpl anti-BSA. (2) input
(115jj1 GVB^^ , 5pl ^^^I-BSA) and (3) TCA prec ip itab le  counts (50^1 BSA 
(5mg/m l), 5pl ^^^I-BSA, 60[j1 20% TCA). The percentage of complexes which
remained soluble was ca lcu la ted as fo llows:
, , , c.p.m. in serum supernatant - c.p.m. in b u f fe r  supernatant
A l l  assays were perform ed in duplicate .
2 .2 .1 (b ) Assay to  m easure  the  in h ib i t i o n  o f  p re v e n t io n  o f  im m un e  
p r e c ip i t a t io n  ( in h ib i t io n  o f  P IP), (see C h a p te r  3^ S ec t io n  3). 
Preparation of pool of normal serum
10ml blood was co llec ted  by venepuncture from  20 normal healthy volunteers. 
Each sample was allowed to c lo t at room tem pera ture  fo r  30 minutes and was 
then  p laced  on ice  f o r  1 hour fo r  c lo t  r e t r a c t i o n  to  o c c u r .  A f t e r  
ce n tr i fuga t ion  (200g fo r  10 minutes) the serum was separated from  each 
sample and pooled. The pool was made into small a liquots and stored a t -70°C 
un t i l  needed.
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A quan t i ta t ive  p re c ip i t in  curve as previously described \A/as constructed in
125order to determ ine the equivalence point. From this curve 0.5pg of I-BSA 
in 5yi end lO jjl anti-BSA d ilu ted  1:6 were the quantit ies  used in this assay.
The normal serum was t i t ra te d  in order to  determ ine the d i lu t ion  which would
175inh ib it  p re c ip i ta t io n  of complexes (0.5pg I-BSA in 5yjl and lO jjl anti-BSA
dilu ted 1:6), by between 70 and 90%. The procedure adopted fo r  the assay was
to m ix  50|j1 of d ilu ted  normal serum (usually 1:3 in GVB^^ ) w ith  50jjl o f test
serum (e ither fresh or fo l low ing  hea t- inac tiva t ion  fo r  30 min at 56“ C) and
125 I-BSA (0.5^g in 5pl) and then to warm the m ix tu re  to 37°C. Follow ing the 
addition o f anti-BSA (lOpl 1:6 d ilu t ion) the incubation was continued at 37°C 
fo r  1 hour, a f te r  which an a liquot(50jj l)  was removed and transfe rred  to an 
Eppendorf tube conta in ing ice cold PBS (1ml). Fo llow ing  cen tr i fug a t ion  fo r  5 
min (Beckman M icrofuge), 250^1 of the supernatant were removed and the 
ra d io a c t iv i ty  counted using an au tom atic  ' y  counter. C on tro l tubes included
(1) ra d io a c t iv i ty  p rec ip i ta ted  by antibody in the absence of serum (100|ji
GVB^^ , 5pl ^^^I-BSA, lOpl anti-BSA), (2) maximum possible PIP by serum
alone (50pl d i lu ted  normal serum, 50pl GVB^^ , 5pl ^^^I-BSA lOjjl anti-BSA)
1 7 5  7 +  1 7 5
and (3) to ta l  I-BSA input ( I IO j j l  GVB , 5pl I-BSA). The contro l tubes
were processed in an identica l fashion to  the assay tubes.
Each assay was perform ed in duplicate , and when the results o f rep lica te  
tubes varied by more than 5% of the mean the assay was repeated. Results 
were ca lcu la ted  using the fo rm u la :
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, . . . . . .  . cpm test supernatant - cpm bu ffe r  supernatant% Inh ib it ion  = 1- ^—:— ;-----------— r----------------u TZ  . .xlOOcpm serum con tro l supernatant - cpm b u ffe r  supernatant
The day to day va r ia t ion  in the assay was between 1 and 11% (mean 5.5%).
2.2.2 P u r i f ica t ion  o f inh ib i to ry  a c t iv i ty  from  RA Serum 
IgG Sepharose chromatography 
RA serum (15mls) was d ilu ted  in an equal volume o f EDTA (20 mmol/1, pH 
7.5) and passed over a column (1 cm x 40cm) of IgG Sepharose. The IgG 
Sepharose column was previously equ ilib ra ted w ith  veronal bu ffe red  saline 
d ilu ted 1:1 w ith  dextrose solution (5% w /v ) pH 7.5. Fo llow ing  app lication of 
the sample the column was washed w ith  equ il ib ra t ion  b u f fe r  un t i l  no fu r th e r  
p ro te in  was e luted.
The bound m a te r ia l was eluted in 2 stages. F irs t ly  w ith  VBS contain ing 400 
m m ol/1  N a C I  pH 7.5 and secon d ly  w i th  VBS c o n ta in in g  g u a n id ine  
hydrochloride (2 mmol/1) pH 7.5.
The column frac t ions  were screened fo r to ta l  p ro te in  (GD^gg)» inh ib it ion  of 
PIP ( inh ib ito ry  a c t iv i ty )  and rheum ato id  fac to r  a c t iv i ty  by haemagglutination 
and radio-immunoassay fo r  IgM -RF.
Sephacryl S300 gel f i l t r a t io n  chromatography
The frac t ions  conta in ing the inh ib i to ry  a c t iv i ty  were pooled and concentrated 
using vacuum dialysis. This concentrated pool was dialysed against acetate  
bu f fe r  (100 mmol/1 pH 3.5). 1 ml of this concentra te  was applied to a 
Sephacryl S-300 column (1.6 cm x 90 cm) which had been equ il ib ra ted w ith  
the aceta te  b u f fe r .  The column fractions were co llec ted  and neutralised w ith
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Tris-base 1 mmoi/1. The frac t ions  were screened fo r  to ta l  p ro te in , inh ib it ion  
o f PIP ( inh ib ito ry  a c t iv i ty )  and rheum ato id  fa c to r  by haemagglutination and 
radio-immunoassay fo r  IgM rheum ato id  fa c to r .
2.2.3 Isolation o f inh ib i to ry  a c t iv i ty  f rom  serum by sucrose gradient u l t ra ­
c e n tr i fu g a t io n  of R A  serum and normal serum and subsequent a f f in i t y  
chromatography.
D is c o n t in u o u s  sucrose  g ra d ie n ts  ( 4 m l ; 20% - 40% ) w e re  p re p a re d  in 
po lya llom er u l t ra cen tr i fu ge  tubes and the serum sample (0.5ml) was layered 
on top. The tubes were centr i fuged  at 40,000 rpm in an u lt ra cen tr i fu ge  
(B eckm an  M o d e l L6) f o r  16 hours  a t 4°C  (155 ,000  x g). F o l lo w in g  
ce n tr i fu g a t io n  six frac t ions  o f  equal volumes (750pl) were co llec ted  through a 
hole p ierced in the bottom  of the tube. The frac t ions  were extensively 
dia lysed a t 4°C in a glass beaker conta in ing 2 l i t re s  phosphate bu ffe red  saline, 
(PBS, pH 7.4). The dialysis was repeated w ith  three changes of PBS. This 
ensured th a t  each f ra c t io n  was free  from  sucrose p r io r  to screening using the 
fo l low ing  assays;
1 P ro te in  content using the Fo lin  phenol method
2 IgM and IgG content by rad ia l imm unodiffus ion
3 Inh ib ito ry  a c t iv i t y  as previously described
4 IgM rheum ato id  fa c to r  a c t iv i ty  by Rose-Waaler assay and by enzyme 
linked immuno-assay (ELISA).
IgG - Sepharose chromatography 
S im i la r  sucrose  f r a c t io n s  w e re  poo led  and s u b je c te d  to  f u r t h e r  p ro te in  
f ra c t io n a t io n  on small (2ml) columns of IgG sepharose. 1ml frac t ions  were 
co l lec ted . Bound m a te r ia l was e luted in two steps.
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1. 0.4M NaCl
2 2M g u a n id in e  h y d r o c h lo r id e .  F ra c t io n s  w e re  assayed fo r  in h ib i to r y
a c t iv i ty  and IgM rheum ato id  fa c to r  by Rose-Waaler t i t r a t io n  and ELISA,
2.2.4 E f fe c t  of trypsin  and SBTI on inh ib ito ry  a c t iv i ty .
This experim ent was designed to  assess whether (1) the inh ib i to ry  a c t iv i ty  was 
sensitive to the enzyme tryps in  and (2) whether the inh ib i to ry  a c t iv i ty  was a 
tryps in - l ike  enzyme. One hundred m ic ro l i t re s  o f serum was incubated a t 37°C 
fo r 1 hour w ith  100|jg tryps in . A t  the end of the incubation period 200jjg 
soybean trypsin  inh ib i to r  was added to arrest proteolysis. Controls included 
serum w ith  SBTI (200[jg) and tryps in  (100|jg), added in tha t  order p r io r  to 
incubation, serum incubated w ith  SBTI (200^g) alone, and serum alone. The 
samples were tested fo r inh ib i to ry  a c t iv i ty  at the end of the incubation 
period.
2.2.5 The e f fe c t  of PMSF on inh ib i to ry  a c t iv i ty
PMSF is a serine protease in h ib i to r  and this experim ent was designed to 
assess whether the in h ib i to r  o f PIP was a serine protease, PMSF (Sigma) 
dissolved in d im e thy l form am ide  (1m ol/ l) ,  was added to inh ib i to ry  serum to 
give a f ina l concentra t ion  of 1 mmol/1. Contro ls incloitded serum trea ted  w ith  
d im ethy l fo rm am ide  alone, and serum alone. Fo llow ing  Incubation fo r  1 hour 
at 37°C, inh ib i to ry  a c t iv i t y  was assayed.
2.2.6 K ine t ics  of inh ib i to ry  action
This assay was used to study the k inetics o f the inh ib i to ry  action o f RA 
serum, RA synovial f lu id  or pur if ied  IgM-RF on PIP. A liquo ts  (50pl) o f  normal 
serum (d ilu ted 1:3) in GVB^^) were added to a series o f test tubes. To the
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f i r s t  tube 50pi of inh ib i to ry  serum (or synovial f lu id  or IgM -RF) were added at 
t im e  0. To a ll the tubes ^^^ I-B5A  (5|j1 conta in ing 0.5^g ^^^I-BSA) was added 
and the tubes were warmed to  37“ C. A t  t im e  0 anti-BSA (10|j1 d ilu ted  1/6)
was added to a ll six tubes and the incubation continued at 37°C, Inh ib ito ry
serum (or synovial f lu id  or IgM -RF 50pl) was added to  tube 2 a f te r  5 m inutes, 
and to tubes 3, 4, 5 and 6 a f te r  in terva ls  o f 15, 30 and 60 minutes. Each tube 
was incubated fo r  60 minutes a f te r  the addition o f the in h ib i to ry  m a te r ia l.  A t  
the end of the incubation an a liquot o f 50|j1 of the m ix tu re  in each tube was 
removed and trans fe rred  to an Eppendorf tube conta in ing  1 ml ice cold PBS.
The Eppendorf tubes were cen tr i fuged  fo r  5 minutes (Beckman M icrofuge) and 
250|j1 o f  the supernatant was removed and the ra d io a c t iv i ty  counted in an 
au tom a tic  y  counter. The con tro l tubes which were processed in an identica l 
fashion were (1) ra d io a c t iv i ty  p rec ip i ta ted  by antibody in the absence of
serum (lOOjjl GVB^^, 10|j1 anti-BSA, 5pl ^^^I-BSA) (2) maxim um  possible PIP 
by serum alone (50pl d ilu ted  normal serum, 50pl GVB^^, lOpl anti-BSA and 5^1 
 ^^^I-BSA) (3) to ta l  ra d io a c t iv i ty  input (11 Dpi GVB^^ and 5|j1 ^^^I-BSA).
Results were ca lcu la ted  thus:
inh ib i to ry  a c t i v i t y  (%)=1-  t=Gt. _suRernatant-CRm b u f fe r  supernatant ^100
cpm serum contro l supernatant-cpm  b u ffe r
supernatant
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2.2.7 Measurement of rheum ato id  fa c to r
Rheumatoid fa c to r  was measured by several d i f fe re n t  techniques. For some 
assays the Rose-Waaler test was used, fo r  others a radio-immunoassay and 
la te r I developed an ELISA assay to measure rheum ato id  fac to r  classes (IgM, 
IgG and IgA).
2.2.7(a) R A -L a te x  test
This screening test uses la tex partic les coated w ith  human IgG and comes 
available in k i t  fo rm  (W ellcotest: Wellcome). Rheumatoid fa c to r  contain ing 
serum or synovial f lu id  was mixed d ire c t ly  w ith  the serum (or recommended 
serum d ilu t ion ) on a clean glass slide. Gentle m ix ing  was carr ied  out using a 
s m a ll  w ooden s t i c k .  I f  r h e u m a to id  f a c t o r  was p re s e n t  m a c ro s c o p ic  
agg lu tination  were observed at 2 minutes.
2.2.7(b) Rose-Waaler test
This test is more t im e  consuming but does give a q uan t i ta t ive  value fo r  RE in 
terms o f serum t i t r e .
M ater ia ls
Sheep red blood cells in Alsevers solution.
Antisheep red blood ce ll antiserum. The d ilu t ion  used is t i t ra te d  and is one 
th ird  the m in im um  agg lu t inating  dose.
P lastic  round bo ttom  m ic ro t i t re  plates 
Phosphate bu ffe red  saline (PBS, pH 7.4)
56°C w ater bath 
37°C waterba th
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37°C incubator
Procedure
1. The sheep red cells were washed three t im es in PBS and a 2% suspen­
sion in PBS was made. A 1% suspension of con tro l unsensitised cells 
was made by m ix ing equal volumes of the 2% suspension and PBS.
2. The antibody-sensitised ce ll suspension was made by m ix ing  equal
volumes o f  2% suspension and PBS conta in ing the lowest subagglutinat- 
ing d i lu t ion  of rabb it anti-sheep cell antiserum. The m ix tu re  was 
incubated fo r  30 minutes in a shaking 37°C w a ter bath.
3. The test sera and test samples were h e a t- in a c t iv a te d  (56°C fo r  30
minutes) in a w a te r  bath. Two drops o f concentra ted washed sheep red 
cells were added to 0.5ml of each test sample. This was done to absorb 
out any anti-sheep red ce ll a c t iv i ty .  A f te r  incubation fo r  1 hour at 
37°C the tubes were spun and the supernatant was taken fo r  testing.
4. The test and con tro l sera were t i t ra te d  by doubling d ilu tions from  1
in 2 to 1 in 2048 in m ic ro t i t re  plates.
5. C on tro l (unsensitised) cells were added to the f i r s t  tw o  rows of wells,
sensitised cells were added to the remain ing wells.
6 The plates were mixed w e ll on a mechanical p la te  shaker, le f t  a t  room
tem pera tu re  fo r  30 minutes and the sedimentation pa tte rn  was then 
read.
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Results
A confluent layer o f red cells over the bottom  of the we ll Indicated 
agg lu t ination  ie, the presence o f  rheum ato id  fac to r .  The t i t r e  was taken as 
the highest d i lu t ion  o f  tes t serum which showed d e f in ite  agg lu tination . The 
f i r s t  tw o  row s  o f  w e l ls  ( c o n t ro ls )  showed a n e g a t iv e  r e a c t io n  ie , no 
agg lu t ina tion  (red ce ll button  at bo ttom  of well). The inherent e rro r in any 
doubling d i lu t ion  assay is one d ilu t ion  on e ithe r side of the recorded t i t r e .
2.2.7(c) Radioimmunoassay fo r  IqM-RF
Reaqents PBS (pH 7.5)
PBS conta in ing 0.05% Tween 20 (PBS-Tween)
Gelatin  (0.1%) in PBS 
 ^^^ I-P (ab ' ) 2  anti-human IgM 
Human IgG (5^jg/ml) in PBS
Radio-immunoassay wells were coated w ith  human IgG and then washed in
PBS conta in ing 0.05% Tween 20; (PBS-Tween, pH 7.5). The unreacted sites
were 'b locked' w ith  ge la t in  (0.1%) and the wells rewashed. A f te r  the test
m a te r ia l (IDOpl) was added, the wells were incubated overnight at room
tem pera ture  (RT). The wells were then washed three t im es w ith  PBS-Tween 
125and I- labe lled  F(ab')^ fragm ents of anti-human IgM added. A f te r  a fu r th e r  
incubation period (4 hours at RT) the wells were rewashed and the bound 
counts measured using an au tom a tic  gam ma-counter. A standard curve using 
d ilu tions o f  a sample o f RA serum contain ing a known concentra t ion  o flgM -- 
RF was included in each series of assays. Each assay was perform ed in 
dup lica te ; only results vary ing by less than 5% of the mean were accepted. 
Results were expressed as un its /m l.
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2.2.7(d) Measurement of rheum ato id  facto rs  by enzyme linked immunoassay 
(E L IS A ) (T h is  was a m od if ica t ion  o f the  m e th o d  d e sc r ibe d  by 
Eaith  et al, 1982)
IgM, IgG and IgA-R E were measured using a m ic ro -EL ISA  technique. For the 
IgM-RF and IgA-R F assays, Dynatech plates were coated w ith  human IgG, but 
fo r  Ig G -R F  assay p la te s  w ere  c o a te d  w i th  r a b b i t  IgG . P r io r  to  the  
measurement o f  IgG-RF, sera and synovial f lu ids were digested w ith  pepsin 
(see b e lo w ) .  P e rox ida se  la b e l le d  g oa t  a n t i -h u m a n  ch a in ,  a n t i - h u m a n  
chain and anti-human IgG^F(ab ' ) 2  antibodies (Cappell^Pennsylvania) were 
used to  de tec t the presence of RF of the d i f fe re n t  classes.
ELISA fo r  IqM -RF
A Dynatech p la te  w ith  f la t  bottomed wells was used. The wells were coated 
w ith  human IgG (5pg/ml), lOOpl per well and incubated overnight at room 
tem pera ture  (RT). The p la te  was washed 3 t imes w ith  PBS-Tween. The 
unreacted sites were blocked by adding 200pl of 0.1%B5A in PBS to each 
w e ll.  The p la te  was le f t  at RT fo r  a t least 1 hour before being washed again 
w ith  PBS-Tween. The test sample (eg serum) was loaded on to the p la te  
100|.il/well in various d ilu tions. The p la te  was then le f t  a t RT overnight. A f te r  
washing 3 t imes w ith  PBS-Tween, lOOpl peroxidase labelled conjugate F(ab ' ) 2
antR IgM  d ilu ted  1/4000 in PBS-Tween) was added to each w e ll and the plate 
incubated at RT fo r  1 hour. The p late was fu r th e r  washed w ith  PBS-Tween.
The substrate (o-phenylene diamine; (OPD); 17mg) was dissolved in 50mls 
c i t ra te  phosphate b u ffe r ,  (pH 5.4). Just p r io r to addit ion to the washed wells, 
the substrate was ac tiva ted  by the addition of 20^1 of hydrogen peroxide 
(H^Og). 10Ojul o f the ac t iva ted  substrate was added to  each w e ll and the plate 
was incubated in the dark fo r  10 minutes. The colour reaction  was stopped by 
the addition o f 25|j1 4N sulphuric acid to  each w e ll .  The op tica l density at 492
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nm was read using an ELISA reader.
A rheumatoid fa c to r  (5000 un its /m l)  contain ing R A  serum was used as a 
standard. The level o f  IgM-RE had been previously determ ined as 5000 
un its /m l.  This standard was doubly d ilu ted w ith  PBS-Tween from  1/100 to a 1 
in 51,200 d ilu t ion . A standard curve was p lo tted  of foi' each d ilu t ion  of
the standard (y axis) against the logarithm  of IgM -RF un i ts /m l (x axis). A 
sigmoid curve was obtained. Values o f  the tes t samples were then read o f f  
00^21  against the x axis (IgM-RF un its /m l)  u t i l is ing  the s tra igh t line pa r t  of 
the curve. Samples were su itab ly  d ilu ted  so tha t  O D ^ 2 i  readings fe l l  on the 
s tra igh t  line part  o f the curve.
A n o rm a l range was e s ta b l is h e d  using sera f ro m  25 n o rm a l c o n t ro ls .
Seronegativ ity  o f sera was established using sheep ce ll agg lu t ination  test 
( t i t re  1/16 or less) in 50 pa t ien t sera samples. These sera were assayed fo r  
IgM -RF in the above described ELISA. The mean value in un its /m l ± 2 
standard deviations was ca lcu la ted fo r  these seronegative sera. On the basis 
of this, se ronegat iv ity  was taken as less than 800 un its /m l which was 2 
standard deviationsabove the mean fo r  these seronegative sera.
ELISA fo r  IgG-RF
To measure IgG-RF the serum or SF sample must f i r s t  be digested by pepsin 
so tha t  IgG is reduced to  its F(ab ’ ) 2  fragm ents.
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Pepsin digestion of serum and SF samples to FCab')^ fragm ents.
Pepsin aceta te  bu ffe r
A stock aceta te  b u ffe r  lOOmM pFI 3.5. was prepared. This was d ilu ted 1:10 
w ith  w a te r  and pH checked a t 3.5 (lOmM acetate  b u f fe r  pH 3.5). Im g  pepsin 
was added to lOOmls o f the aceta te  bu ffe r.
2 5 0 |j 1 of pepsin aceta te  b u ffe r  was p ipetted  in to a series of labelled B i jou  
bott les . 5|j 1 o f tes t sample (RA serum or synovial f lu id )  was then added to the 
appropriate bo tt le .  A f te r  m ix ing  the bott les were incubated fo r  20 hours at 
37^^C.
A f te r  this t im e  the digests were neutralised b y  the addit ion of 2 5 0 |j 1 of 
disodium hydrogen phosphate in PBS-Tween/80mg/m l) to  each bo tt le .  lOOjjl of 
each digest was loaded on to the ELISA plate.
Measurement o f IgG-RF in serum and synovial f lu id  (SF)
Method
The measurement of IgG-RF by ELISA was s im ila r to  tha t  described above fo r  
the measurement of IgM -RF. However, fo r IgG-RF measurement the wells 
were coated w ith  normal rabb it  serum 100|.il (5 |jg /m l). The samples were 
digested w ith  pepsin as described above p rio r to app lica tion. Peroxidase- 
labelled goat anti-human IgG F(ab ' ) 2  was used as the conjugate (d ilu ted 1:5000 
in PBS). The results were ca lcu la ted as described above fo r  IgM-RF ELISA. A 
normal range was established using sera from  25 normal volunteers. The 
normal range o f the IgG-RF assay was ca lcu lated as less than 30 un its /m l.
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ELISA fo r  IqA -R F
The assay to measure IgA -R F was a m od if ica t ion  of tha t  described above fo r  
IgM -RF. The assay was s im i la r  in a ll respects to tha t  described fo r  IgM -RF 
except tha t the conjugate used was peroxidase labelled FCab')^ an t l- IgA .
The results were ca lcu la ted  as described fo r  IgM -RF ELISA. Using sera from  
25 normal contro ls  the normal range fo r IgA -R F as measured by this assay 
was < 20 un its /m l.
2.2.8 Measurement of p ro te in  
— 280
Prote in  was detected by measuring its absorbance of u l t ra  - v io le t  l ig h t  at 
280nm (O D ^ g ^ ) .  Th is  is the  s im p le s t  m e th o d  f o r  m e a su r ing  p ro te in  
concentra t ion  and was used in my experiments to give an approximate 
e s t im a te  o f  t o t a l  p ro te in  c o n c e n t r a t io n .  (O D ^g g  = mg p r o te in /m l ) .
Fo lin  phenol method
This method was a m o d if ica t io n  of the method described by (Lowry et al, 
1951). I t  is a m ore  a c c u ra te  m e tho d  fo r  p ro te in  e s t im a t io n  than  UV 
absorbance.
M ater ia ls  Fo lin  so lution A
Fo lin  so lu tion B 
Fo lin  so lution C
2g Sodium carbonate
20mg Sodium potassium ta r t ra te
M ake up to  lOOmls w i th  0.1 N sodium
hydroxide.
0.15% Copper sulphate pentahydrate  
5mls A + 0.1ml B
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This is made up fresh each t im e .
Fo lin  solution D Com m erc ia l Folin and C ioca lteu 's  Reagent.
Standard: BSA 1m g/m l in PBS.
Method
A standard curve was constructed by adding d i f fe re n t  (25, 50, 100, 150^1) 
volumes o f  stock BSA solution to a series o f test tubes. To a ll tubes were 
added 2mls of Folin  solution C fo llowed by 20|j1 o f  Fo lin  solution D. To a 
fu r th e r  series o f tubes lOOjjl o f  p ro te in  sample to be measured was added to 
each tube. 2mls Folin  C and 200|j1 Folin D were then added to  each tube.
The negative con tro l consisted of a tube conta in ing 2mls o f  Fo lin  solution C, 
lOOpl of b u f fe r  and 200|j1 o f Folin  so lution D.
The Folin  reac tion  is t im e  dependent, so a f te r  m ix ing  on a vortex the tubes 
were allowed to stand fo r  30 minutes and the OD^gg in each tube read in 
the order in which the reaction  was s tarted . The standard curve (OD^gg v 
p ro te in  concentra t ion) was p lo tted  and the concen tra t ion  of p ro te in  in the 
test sample was ca lcu lated.
2.2.9 Prepara tion  of IgG from  normal human serum
Reaqents
(1) S a tu ra te d  a m m o n iu m  s u lp h a te .  Th is  was made by d isso lv in g  767g
ammonium sulphate to a f ina l volume of 1 l i t r e  deionised water,
tem pera ture  25°C, (4.1 M olar solution).
(2) 40% ammonium sulphate was prepared by adding 4 parts o f saturated
ammonium sulphate to 6 parts deionised w ater .
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(3) 10m m o]/l potassium phosphate b u ffe r  pH 8.0
(4) DE52 equ il ib ra ted  in the above bu ffe r.
(5) Phosphate buffe red  saline (PBS) pH 7.2
Method
40mls of sa tura ted ammonium sulphate was added w ith  s t i r r in g  to  60mls of 
human serum. The m ix tu re  was le f t  overn ight at 4°C and then spun at 10,000g 
fo r  30 minutes at 4°C. The pe lle t  was resuspended in lOOmls of 40% 
ammonium sulphate^ recen tr i fuged^ and the pe l le t  redissolved in 20mls of 
500m m ol/ l sodium ch loride  in 10m m ol/ l phosphate b u f fe r ,  pH 8.0. The sample 
was dialysed tw ice ,  f i r s t ly  against 2 l i t res  of 10mmol/1 phosphate pH 8.0 at 
4°C fo r 2 hours and secondly against another 2 l i t re s  fo r  16 hours at 4°C. 
A f te r  rem ova l o f any p re c ip i ta te  by cen tr i fuga t ion  a t 10,000g fo r  30 minutes 
at 4^ ’C, the sample was applied to  a 14x5cm column of DE52 equ il ib ra ted in 
the same b u f fe r .  The column was washed w ith  10m m ol/ l phosphate b u ffe r  pH 
8.0 and 10ml frac t ions  co llec ted . The exclusion peak conta in ing the IgG was 
pooled and concentra ted  by p re c ip i ta t io n  w ith  an equal volume o f  saturated 
ammonium sulphate. The m a te r ia l was cen tr i fuged  and the pe l le t  dissolved in 
lOmls of 500 mmol/1 NaCl in PBS. I t  was fu r th e r  dialysed against PBS and 
stored at -20°C t i l l  used.
The p u r i ty  of the IgG prepara tion  was tested by SDS-PAGE under reducing 
and non-reducing conditions. A single band MW 150I<D was seen on the 
u n red u ced  g e l .  A f t e r  r e d u c t io n  w i th  5 -m e rc a p to e th a n o l  tw o  bands 
corresponding to the heavy and l ig h t  chains of IgG were noted.
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2.2.10 A c t iv a t io n  o f Sepharose 48 by cyanogen bromide (CNBr) and coupling 
of Sepharose 4B w ith  human IqG 
This procedure was a m od if ica t ion  o f the one described by Goetz l & Metzger 
(1970).
(1) B uffe rs  -3 l i t res  o f 0 .1m ol/ l NaHCG^ pH 8.0
-2 l i t res  of 4M NaOH
(2) Sepharose 4B (lOOmls)
(3) Human IgG - dialysed against NaHCO^ 0.1 mol/1 pH 8.0
(4) Scintered glass funnel and Buchner f lask.
Method
Sepharose 4B was washed f ive  times in deionised w a te r  and resuspended in 
lOOmls w a ter .
lOOg CNBr was dissolved in 1 l i t re  of deionised w a ter .  Sepharose 4B was 
added and the m ix tu re  s t ir red  slowly w ith  a m agnetic  s t i r re r .  The pH was 
brought up to 11 and maintained there by adding 4M sodium hydroxide. The 
pH eventua lly  s tabil ised at 11. The reaction  took approx im ate ly  5 minutes to 
reach com pletion .
The cyanogen-bromide ac tiva ted  Sepharose was poured in to  a Buchner funnel 
which was packed w ith  crushed ice and attached to  a vacuum flask. A f te r  
extensive washing w ith  3 l i t res  of ice-co ld  sodium bicarbonate (0 .1m ol/ l ;  
pH8.0), 100ml of human IgG (20mg/m l) in sodium bicarbonate pH 8.0 were 
mixed w ith  the Sepharose beads in a sealed beaker and the s lu rry ro ta ted  
gently  overn ight at 4°C. A f te r  cen tr i fuga t ion  lOOOg at 4°C fo r  10 minutes the 
supernatant was taken fo r p ro te in  estim ation  and i t  was ca lcu lated tha t  93%
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of the IgG was bound to the beads. The IgG Sepharose was resuspended in an 
equal volume o f monoethanolamlne (1 mol/1 pH 8.0) and the s lu rry  was ro ta ted  
at room tem pera tu re  fo r  1 hour to  b lock the unreacted pro te in  binding sites.
F u rthe r  washes were carr ied  out, three times in each of the fo l low ing ; 
a c e ta te  b u f f e r  (1 0 0 m m o l / l ,  pH 3.0) c o n ta in in g  sod ium  c h lo r id e  1 m o l/1 ; 
phosphate b u f fe r  (10m m ol/ l,  pH 7.5) conta in ing 1m o l/ l sodium chloride. The 
beads w ere  s to re d  a t  4°C  in PBS c o n ta in in g  0 .01%  sodium  a z id e .
2.2.11 P re p a ra t io n  o f  FCab')^ f ra g m e n ts  o f  n o rm a l  hum an IqG, and 
the IqG frac t ions  of an t i- IqM  antiserum 
M ater ia ls
0.1M sodium aceta te  b u f fe r  pH 4.5 
Human IgG (20m g/m l in aceta te  bu ffe r)
2M tr is
Tris bu ffe red  saline (TBS) lOmM t r is -H C l pH 7.3 conta in ing 0.15M 
sodium ch loride.
Pepsin ( lO m g/m l in aceta te  bu ffe r)
Sephadex G-200 (Pharmacia) equ il ib ra ted in TBS and packed in to  a
1.6 cm x 100 cm column.
Method
Pepsin solution (100 |j1) was added to 2.5ml IgG solution. A f te r  gentle m ix ing  
the solution was incubated overn ight (16 hours) at 37“ C. 300|j1 t r is  (2M) was 
added to neutra lise the solu tion which was then cen tr i fuged  at 2000g fo r  10 
minutes to remove any p rec ip i ta te .  The supernatant was applied to the 
Sephadex G-200 column and e lu ted w ith  TBS. 2.5ml fra c t ions  were co llec ted  
and the  p ro te in  c o n c e n t r a t io n  m o n i to re d  by the  abso rbance  a t  280nm .
2-0•up
g<
0*5
pFc Peptides
20 40
Fraction number
60 80
Fiqure2.2
Chromatography of pepsin digested human IgG on a Sephadex G-200 column 
in t r is  bu ffe red  saline (TSB).
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Undigested IgG w i l l  be e luted just p r io r to  the m a jo r F(ab ' ) 2  peak (Fig 2.2) 
Every th ird  f ra c t io n  was tested by SDS-PAGE and only those conta in ing 
F (a b ' ) 2  w e re  used. The f r a c t io n s  c o n ta in in g  F (a b ' ) 2  w e re  poo led  and 
concentra ted to  5mls using vacuum dialysis.
2.2.12 Sodium docecyl sulphate po lyacry lam ide gel e lectrophoresis 
(SDS-PAGE)
SDS-PAGE analysis of prote ins described in th is  thesis was based on the 
method of Weber & Osborn, 1975. SDS binds to prote ins and because o f its 
strong negative charge, the m o b i l i ty  of SDS-protein complexes on SDS-PAGE 
is determ ined by the m o lecular weight of the p ro te in . The reducing agent 
2 -m e rc e p to e th a n o l  was used to  d is s o c ia te  p o ly p e p t id e  cha ins  l in k e d  by 
d is u lp h id e  b r id g e s .  T h e r e fo re ,  SD S-PAG E, when run  und e r re d u c in g  and 
non-reducing condit ions reveals the m olecular w e igh t of the pro te in  and its 
polypeptide chain s truc tu re .
Equipment
Power pack 
Glass tubes 
E lectrophoresis tank
Buffers :
Solution A
1 mol/1 sodium phosphate b u ffe r ,  pFl 6.5,
219.6g/I sodium hydrogen phosphate dodecahydrate,
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Solution B
10% (100g) sodium laury l sulphate in 1 l i t re  of wa ter.
Solution C
A cry lam ide /b isacry lam ide  m ix tu re .  30g acry lam ide  and 
»
800mg N ,N  -m ethy lene-b isacry lam ide  made up to lOOmls 
w ith  w a ter .  Stored at 4°C.
Method
A f te r  sealing the bo ttom  ends o f the gel tubes w ith  P ara f i lm  they were 
placed v e r t ic a l ly  in a rack. 5% gels were used fo r  most p ro te in  analysis work 
in th is  thesis. To make 5% acry lam ide gels 10mls o f so lu tion C was added to 
43.4mls o f w a te r .  6mls of solution A and 60pl o f so lution B were then added 
sequentia lly. F ina lly  30|j1 o f  TEMED (BDH) [N, N, N N te tram e thy lene - 
diamine) and 60mg o f ammonium persulphate was added, to ta l  f ina l volume 
being 60mls. The m ix tu re  was s lowly s t ir red  throughout. The gel m ix tu re  was 
added to  the tubes w ith  a Pasteur p ipe tte  to  w ith in  10mm of the top. The gel 
so lu tion was ca re fu l ly  overlayed w ith  w ater end the gel a llowed to polymerise 
at room tem pera tu re  fo r  1 hour.
The w e ll b u f fe r  was made up by adding IGOmls of so lu tion  A to lOmls of 
so lution B and making up to 1 l i t re  w ith  water.
The pro te in  sample b u f fe r  contained the fo l low ing  reagents:
Reducing Non-Reducing
Solution B 0.5 m l 0.5 m l
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2mercaptoethanol 0.5 m l -
G lycero l 1.0 ml 1.0 m l
Solution A 0.05 ml 0.05 ml
0.5% bromophenol blue 0.1 ml 0.1 ml
water 3.3 ml 3.35 ml
The pro te in  sample and sample bu ffe r  were mixed, 1:1v/v. The to ta l  volume 
applied to the gel was usually between 50-75pl. The m ix tu re  was boiled at 
100°C (water bath) fo r  2 minutes p r io r to  loading. The samples were ca re fu l ly  
applied to the top of the gel, the w a ter overlay having been removed. One gel 
conta in ing a m o lecu lar we ight standard was run as a con tro l.
The electrophoresis was run at a constant cu rren t o f  6m A/tube  un t i l  the 
bromophenol blue m arker had m igra ted approx im ate ly  80% down the tube.
The gels were removed from  the glass tubes and a piece of stainles steel w ire  
inserted into the gel to  mark the bu ffe r  f ro n t  (bromophenol blue band).
The gels were f ixed  and stained in test tubes conta in ing 0.1% Coomassie 
b r i l l ia n t  blue in a m ix tu re  conta in ing 5 parts methanol, 1 part g lacia l acetic  
acid and 4 parts  w a te r .  A f te r  incubation 40°C fo r  2-6 hours the gels were 
destained in several changes o f destaining solution (1 pa r t  methanol, 1 part 
g lac ia l ace t ic  acid and 8 parts water).
The distance between the p ro te in  band and the b u ffe r  f ro n t  is proport iona l to  
the logar ithm  of the m olecu lar weight of the pro te in . Using the known 
m olecular w e ight standards in the contro l gel the m olecular we ight of the 
sample pro te in  under study can be determined.
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2.2.13 E s t im a tion  of IgM and IqG concentra t ion  using single rad ia l 
im m unodiffus ion
When an antigen solution is placed in a we ll cu t in an antibody conta in ing gel 
a c ircu la r  immune p rec ip i ta te  is formed around the w e ll.  The area contained 
w ith in  the r ing is p roport iona l to the concentra t ion  of the antigen being
measured. This method was described by Mancini and colleagues in 1965. 
However Fahey and M cKelvey (1965) introduced a m od if ica t ion  of the method 
which allowed fo r  the reading of the plates a f te r  a much shorter t im e .
Equipment and reaqents
1. P e tr i  dishes 35mm in d iam eter
2. The equipment fo r gel p repara tion  and the procedure fo r  preparing the
agarose were the same as tha t  described previously (see Section 2.2.1)
Method
1. A 10ml a liquo t o f  agarose (1.5%) was m elted  in boiling w ater and 
cooled to 56°C in a 56° water bath.
2. An appropria te  volume of antiserum IgM or IgG was prewarmed to 56°C
and ca re fu l ly  m ixed w ith  the agarose to give a f ina l d i lu t ion  o f 1 in 20 
of antibody in agarose. A 1 in 20 d ilu t ion  was chosen fo r  p rac t ica l
purposes because this gave a sa tis fac to ry  size of p rec ip i t in  ring (diam
5 -7 m m ) round a w e l l  to  w h ich  u n d i lu te d  se rum  had been added.
3. A standard tem pla te  was placed under the gel and the well was made
using a 2mm punch. By th is method each Pe tr i dish could accommodate 
19 equid istant wells.
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4. The test m a te r ia l (eg column frac t ions) was loaded into the wells to  the 
brim  using a drawn out cap il la ry  tube. A new tube was used fo r  each 
sample.
5. The gels were placed in a moist chamber a t room tem pera ture  on a
hor izon ta l surface and d if fus ion  allowed to proceed fo r  24 or 48 hours.
6. A f te r  tha t t im e  the plates were read inverted  using incident l igh t
against a dark background. A measuring m agn if ie r  was used to measure 
the d iam eter of the rings.
7. The presence of IgG or IgM was shown by a r ing  of p rec ip i ta t ion
round the we ll.  The d iam eter o f  the ring was measured in mm and the 
p la te s  w e re  read  a t  24 hours f o r  IgG and 48 hours f o r  IgM .
This technique was used to de tec t the presence o f IgM and IgG in column
frac t ions  and sucrose grad ien t frac t ions , se m i-q u an t i ta t ive ly .  No a t te m p t was
made to accura te ly  quan ti fy  IgG or IgM concentra t ion  using contro l standards.
2.2.14 Measurement of Complement
2.2.14(a) Im munochemica l Assays C3, C4 and F ac to r  B.
Serum levels of C3, C4 and B were measured by nephelometry using a 
Beckman ICS Analyser II. This method is an im m unochem ical means of 
m e a s u r in g  se rum  c o m p le m e n t  c o m p o n e n ts .  M o n o s p e c i f ic  p r e c ip i t a t in g  
antisera to ind iv idua l complem ent components are availab le com m erc ia lly .  
The basic p r inc ip le  of nephelom etry is tha t  a l ig h t  beam is passed through a 
glass cuve tte  conta in ing a solution. The l igh t beam passes s tra igh t through 
the cuve tte  i f  the solution is c lear. If there is p a r t icu la te  m a te r ia l in the 
solu tion then some o f  the l ig h t  is de flec ted  as a resu lt  o f impinging on the 
surfaces of the p a r t icu la te  m a te r ia l .  The deflec ted  l ig h t  is measured at r ig h t  
angles to the inc iden t beam. The princip les o f nephelom etry were applied to 
the antigen-antibody reac tion  by Boyden, Bolton &. Gemeroy (1947). Flowever, 
i t  was only w i th  the development of continuous f lo w  nephelometry by Larson, 
Orenstein & R itch ie ,  (1971) tha t this technique gained w ider popu la r ity . 
Monospecif ic  antisera of high a v id ity  and t i t r e  are used. The antibody is 
added at a co rre c t  proport ion  to  the antigen in the serum and an immune 
p rec ip i ta te  is form ed. It is th is p rec ip i ta te  which de f lec ts  the l igh t.  The 
machine measures the peak ra te  of p rec ip i ta t ion  ^measured as the ra te  of 
change o f  l igh t  sca tte r ing  f rom  the t im e  at which the antigen and antibody 
are m ixed. Nephe lom etry  can de tec t p ro te in  concentrations between 1-20 
pg/m l and can give answers w ith in  a few  minutes.
The patterns of com plem ent ac t iva t io n  in indiv idual pa tien ts  can provide the 
physician w ith  useful diagnostic in fo rm a tion . Consumption of C l ,  C4 and C2 
fo l lo w s  a c t i v a t io n  o f  th e  c la s s ic a l  p a th w a y  w he reas  f a c t o r  B, D and 
properdin are u ti l ised  when a lte rna t ive  pathway a c t iva t io n  is occurring. 
Cleavage of C3, C5 and the incorpora tion  o f C6, C7, C8 and C9 in to the 
C5b-9 membrane a tta ck  complex occurs on a c t iva t io n  o f e ithe r pathway.
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Therefore f rom  a c l in ica l point o f  view i t  is im po rtan t  to  measure serum 
levels o f at least one classical, one a lte rna t ive  and one te rm ina l component 
in order to determ ine the pathway o f complement ac t iva t io n  in disease. In 
p ra c t i c e  th is  is a c c o m p lis h e d  by m e a su r ing  C3, C4 and F a c to r  B.
2.2.14(b) Measurement o f Complement - Functional Assays 
Buffe rs  used in assays 
Stock veronal bu ffe red  saline (5 x VB5)
85g of sodium ch loride, 3.75g Sodium-5,5-d iethyl ba rb itu ra te  was dissolved in 
1 l i t re  of deionised w a te r  (solution 1). 5.75g Na5, 5 -d ie thy l ba rb itu r ic  acid 
was dissolved in 600 mis o f w a te r by vigorous s t ir r ing  on a heated magnetic  
s t i r re r  (solution 2). Solutions 1 & 2 were mixed and made up to 2 l i t re s  w ith  
w ater . pFl should be 7.4-7.6
Isotonic EOT A (86 mmol/1)
I I
89.338g of ethylene diamine N, N, N , N te tra  acetic  acid (Sodium salt) was 
dissolved in 1500 mis of w a te r and then made up to 2 l i t res . pFI was 
approx im ate ly  4.5 (solution 1). 24g of sodium hydroxide pellets were dissolved 
in 1500 mis of w ater and then made up to 2 l i t res  (solution 2). Solution 2 
was added to so lu tion 1 un t i l  the pFl was betwen 7.2 and 7.6.
The f ina l m o la r i ty  o f the EOT A was ca lcu lated as fo l lows:
____________ Start ing  volume EDTA______________  X 0 12
S ta r t in g  vo lum e  E D T A  + v o lu m e  o f  NaOFl used
The concen tra t ion  should be 86 mmol/1.
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EGTA E thy leneg iyco l-b is  ( j3-aminoethyl e ther) N, N, N , N - te t ra  ace tic  
acid (Sodium Salt) 100 mmol/1)
38.04g EGTA was added to  500 mis o f w a ter s t i r r in g  constantly  w ith  a 
m agnetic  s t i r re r .  NaOH (10 mol/1) was slow ly added u n t i l  the EGTA was 
dissolved and the pH was 7.4. The solution was made up to 1 l i t r e  w ith  
water.
10% gelat in
lOg ge la t in  (M erck) were dissolved in 100 mis of w a te r w ith  continuous 
s t ir r in g  on a heated m agnetic  s t i r re r .  The ge la t in  so lu tion was made into 10 
mis aliguots in s te r i le  glass universal containers and stored at 2-4°C. When 
reguired fo r  use in bu ffe rs  the universal conta iner was heated in boiling 
w a ter u n t i l  the ge la t in  had m elted.
Calc ium Chloride (30 mmol/1)
3.286g CaClg. hH^O was dissolved in water and made up to a f ina l volume of 
500mls.
Magnesium Chloride (100 mmol/1)
10.165 g of M gC l^ . hH^O was dissolved in w ater and made up to a f ina l 
volume of 500mls.
Isotonic veronal bu ffe red  saline conta in ing ge la t in  and cations (GVB^^). 
200mls. 5 X VB5
lOmls MgClg (100 mmol/1) 
5mls CaC l^  (30 mmol/1)
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10mis 10% gelatin
The m elted  ge la t in  was thoroughly m ixed w ith  lOOmls o f w a ter at room 
tem pera ture  to prevent i t  reso lid ify ing  when added to  the other agents which 
were kept on ice. The so lu tion w a s ^ i^  to 1 l i t re  w ith  w a ter .
Is o to n ic  v e r o n a l - b u f fe r e d  sa l ine  c o n ta in in g  g e la t in  bu t w i t h o u t  c a t io n s
(GVB")
200mls 5 X VB5 
lOmls 10% gelatin
The ge la tin  was m e lted  in boil ing w ater and added to lOOmls of w a te r before 
m ix ing  w ith  5 x VBS. I t  was made up to a f ina l volume of 1 l i t re  w ith  w a te r .
EDTA (40m m ol/ l)  GVB"
232.5mls o f EDTA (86 mmol/1) and 267.5mls GVB“  were mixed together. 
F inal volume was 500mls.
EDTA (10 mmol/1) GVB"
58mls 0.086 mol/1 EDTA was mixed w ith  442mls GVB”  F inal volume was 
500mls.
Isotonic dextrose w ithou t cations (D3W~)
50g of D-glucose was dissolved in w a te r and made up to a f ina l volume o f  1 
l i t re .
Isotonic dextrose conta in ing cations (D5W^^)
50g D-glucose was dissolved in 500mls of w a ter. To this was added 5ml 
CaC l^  (30m m ol/ l)  and 10ml M gC l^  (100 mmol/1) and the solution was made 
up to a f ina l volume o f 1 l i t re .  This bu f fe r  is isotonic and is used to reduce 
the  io n ic  s t re n g th  o f the  b u f fe r s  w i th o u t  m a k in g  th e m  h y p o to n ic .
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D e x tro s e  g e la t in  v e ro n a l  b u f fe re d  sa l in e  c o n ta in in g  c a t io n s  (D G V B ^^ )  
Egual parts o f GVB^^ and DSW^’*’ were mixed toge ther producing a low ionic 
s trength  b u f fe r  (jj-0.D75) conta in ing cations. P ro te in -p ro te in  in terac tions are 
enhanced by the low ionic s trength  and as such increases the sens it iv ity  of 
haem o ly t ic  com plem ent assays.
M q-EGTA
10mls of EGTA (100m m ol/l)
5mls MgC1 ^ (100m m ol/l)
B3mls DGVB”  (3 parts D5W“ : 1 part GVB” ) 
pH 7.4-7.6. F ina l volume lOOmls.
Preparation of H aem o ly t ic  In termediates
Antibody sensitised sheep e ry throcy tes  (EA)
Antibody to sheep e ry th rocy tes  (E) was prepared by the imm unisation of 
rabbits w ith  in ta c t  e ry th rocy tes  or the ir  plasma membranes. The bu ffy  coat 
was removed ca re fu l ly  f rom  sheep E stored in A lsevers solution. The cells 
were washed three t im es in VBS and 1 ml of a 10% suspension (V/V) of E in 
VBS was em uls if ied  in an egual volume of Freund's com plete  adjuvant. The 
im m unisation procedure and schedule was the same as th a t  described fo r  the 
preparation o f antibody to bovine serum albumin (BSA) as described ear l ie r  in 
this section. As a resu lt of this imm unisation schedule the antiserum 
contained antibody which was predom inantly  IgG. The antiserum was heat' 
inac tiva ted  (56°C fo r  30 mins) p r io r to  use.
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Prepara tion  of EA
S uff ic ien t  sheep E was w ithd raw n from  the stock A lsever's so lution and 
cen tr i fuged  at 2000g fo r  10mins at 2°C. A f te r  removal of the supernatant 
plasma and the b u f fy  coat the cells were washed three t imes in 10 volumes 
of EDTA (1 Ommol/1) GVB”  to  give approx im ate ly  a 5% suspension. 1 ml of 
the suspension was added to  29mls of deionised w a te r  and the op t ica l density 
(GD) of the lysate measured using a spectrophotom eter at wavelength 541 nm 
(OD^^^). An OD^^^ o f 0.385 corresponds to a sheep E concentra t ion  of 
1X10 ce l ls /m l.  The volume of the e ry th rocy te  suspension should be adjusted 
to IX IO ^ m l as fo l lows:
Volume E required = In i t ia l  volume X GD measured
0.385
The sheep E in a glass conical f lask was warmed to 37°C in a shaking w ater 
bath. Antibody to sheep E was d ilu ted  in an equal volume of EDTA 
(10m m ol/ l)  GVB”  and prewarmed to 37°C. The d i lu t ion  of antiserum to be 
used in the prepara tion  o f EA is the m in im um  d ilu t ion  which does not 
agg lu tinate  an equal volume of sheep E at a concen tra t ion  of 1X I0 ^ /m l .  This 
t i t r a t io n  is ca rr ied  out on m ic ro t i t r e  plates.
The antiserum was added to the sheep E suspension while  being constantly  
shaken. The m ix tu re  was incubated fo r  a fu r th e r  30 mins in the shaking 
w a ter bath at 37°C.
The EA were then cen tr i fuged  (2GGGg fo r  5 mins at 2°C) washed once in 
EDTA (1 Ommol/1) GVB” , tw ice  in GVB^^, and f in a l ly  resuspended to the ir  
o rig ina l volume in GVB^^. EA can be stored at 0°C fo r  up to 1 week.
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Preparation of rabb it  e ry throcytes
Blood was co llec ted  f rom  the marg ina l ear vein of the rabb it  into an equal
volume o f A lsever's solution and stored at 0°C u n t i l  needed. Rabbit E were
separated from  the plasma and b u f fy  coat by cen tr i fu g a t io n  as described fo r  
sheep E above. The cells were washed three t im es in EDTA (1 Ommol/1)
GVB”  resuspended in the same b u ffe r  and incubated at 37°C fo r  15 mins.
The cells were then washed three t imes in M g-EGTA and stored in this
bu ffe r  at 0°C fo r  up to 2 weeks or un t i l  used.
To ta l H aem oly t ic  Com plement A c t iv i t y  (CH50)
The method used was a m o d if ica t io n  of tha t described by Kent & F ife  (1963).
EA when added to serum are lysed as a resu lt o f ac t iva t ion  of the classical 
pathway and the fo rm a tion  and insertion of the c y to ly t ic  C5b-9 membrane 
a ttack  complex in to the ce ll membranes. A standard suspension of EA is used 
and the a b i l i ty  of serum to lyse the cells can be t i t ra te d .
GVB^"^
EA (5x10®/ml) in GVB^^
Test serum
Method
1. Test sera were d ilu ted  1 in 30 in ice-co ld  GVB^^ and then kept on ice.
2. A row o f  test tubes was set up and to these were added increasing 
vo lum es  o f  d i lu te d  se rum , s ta r t in g  w i th  50^il and in c re a s in g  in 5 0 |j1 
increments to 450|j1. The volumes were adjusted in each tube to 450|j1 by the
95
addit ion of GVB^^. Two con tro l tubes each conta ined 4 5 0 |j 1. GVB^^ (cell 
blank and 100% lysis).
3. 300|j1 of EA was added to each tube.
4. The tubes were removed from  the ice and transfe rred  to  a shaking w ater 
bath at 37°C fo r  1 hour.
5. 2mls of isotonic saline was added to  all tubes except the 100% lysis
contro l.  To th is tube 2ml o f w a te r was added.
6. The tubes were cen tr i fuged  at lOQOg fo r  5 mins at 2°C.
7. The op t ica l density o f the supernatants a t 541 nm (O D^^^) was read using
a spectropho tom eter.
C a lcu la tion  of Results
The proport ion  o f cells which were lysed (y) in each tube was ca lcu lated 
using the fo rm u la :
0 D ^ 4  ^ test - ce ll blank
100% - cell blank
The percentage o f cells which were lysed in each tube is obtained by 
m u lt ip ly ing  y by 100
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Some serum samples can conta in large amounts of haemoglobin and the 
colour o f the serum influences the OD reading. To compensate fo r  this a 
para lle l series o f serum d ilu tions should be made in EDTA (40 mmol/1) GVB” . 
Lysis w i l l  not occur in these tubes and GD of the ir  supernatants should be 
substracted f ro m  the readings of the corresponding tubes in which lysis has 
occurred.
A p lo t o f y (or percent lysis) against the volume of serum in each tube 
produces a s igmoid curve (Fig 2.3(aJ), The cen tra l pa r t  o f  the curve (between 
20% and 80% lysis) is steep and the proport ion  o f cells lysed is sensitive to 
small changes in the amount o f complem ent in the serum. For th is reason 
the end point o f the t i t r a t io n  is taken as 50% haemolysis.
The sigmoid curve may be m a them atica l ly  described using the von Krogh 
equation (von Krogh, 1916).
X = the amount o f serum added to  the tube ( j j l )  and K is a constant which is 
the 50% unit o f com plem ent. A t  the point o f  50% haemolysis 1-y=1, hence x
= K
The value o f K can the re fo re  be obtained by p lo t t in g  log x against log y /1 -y  
(Fig. 2.3(b))
The number o f CH50 un its /m l = in i t ia l  d i lu t ion  x 100. The normal range 
established in the labora to ry  in which this work was perfo rm ed was 150-250 
un i ts /m l.
100%-1
50%-
4503002001000
(a) Volume of serum fil
10.0  -1
100 200 300 400 500
(b) Volume of serum f i l
Figure 2.3
CH50 assay (a) p lo t of percent lysis against volume of d i lu ted  serum. The 
shape o f the curve is sigmoidal, (b) Log-log p lo t o f y /1 -y  against volume of 
d ilu ted  serum. 50% lysis has occurred when y /1-y=1. By drawing a ve rt ica l 
l ine to the x axis th is gave the volume of d i lu ted  serum which had produced 
this amount of lysis.
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A lte rn a t iv e  Pathway CH50 (APH5D)
When rabb it  e ry th rocy tes  are added to human serum lysis occurs because 
they a c t iva te  the a lte rna t ive  pathway to generate the ly t ic  C5b-9 complex. 
(P la t ts -M il ls  &  Ishizaka, 1974).
Method
1. Test serum was d ilu ted  1/25 in M g-EGTA.
2. Increasing volumes o f d ilu ted  test serum were added to a series of
test tubes on ice (10|j1, 20^1, 40^1, 60|j1, 80pl, lOOpl). The volume in
each tube was adjusted to lOOpl by adding M g-EGTA.
3. lOOyl f rom  each tube was trans fe rred  to another series of tes t tubes.
100|j1 o f b u f fe r  was added to each of two co n tro l tubes (ce ll blank and 
100% lysis).
4. 100|j1 o f E^^^ was then added to each tube and the tubes were
incubated in a shaking w a te r bath at 37°C fo r  one hour.
5. 2ml of iso ton ic saline was added to each tube excep t the 100% lysis
tube. This tube rece ived 2ml o f w a ter .
6. The tubes were cen tr i fuged  at lOOOg fo r  5 mins a t 2°C, The op t ica l
density o f the supernatants was read at 414nm (GD^^^).
7. The ca lcu la t ion  of the results was s im ila r  to  tha t  described fo r  the
classical pathway CH50 assay.
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The normal range established in the labora to ry  in which this work was 
perform ed was 185-327 un its /m l
Complement D e f ic ie n t  Sera
Sera from  patients who were genetica l ly  d e f ic ien t  fo r  C2, C5, C7 and 
C1~inhibitor were obtained. These sera were stored in a liquots at -70°C un t i l  
used.
E D T A -tre a te d  serum
Whole serum was d ilu ted  w ith  EOT A (40m m ol/ l)  GVB“  pH 7.4. The f ina l pH 
of the m ix tu re  was 7.4. Ca lc ium  and magnesium ions are chelated by this 
t re a tm e n t and as such the serum is unable to fo rm  the classical or 
a lte rna t ive  pathway C3 or C5 convertases. The E D T A -trea te d  serum was 
unable to lyse EA or rabb it  e ry throcytes .
E G T A 'tre a te d  serum
Serum was d ilu ted  in M g-EGTA (10m m ol/ l EGTA: 5m m o l/ l  M g C I^ )  pH 7.4-7.6 
to give a f ina l concentra t ion  o f  EGTA of 10mmol/1. The f ina l concentra t ion  
of M g^^ ions was 5m m ol/ l.  EGTA se lec tive ly  chelates Ca^'*’ ions thus 
preventing C l  ac t iva t ion  and the re fo re  classical pathway ac tiva t ion . The 
presence of the M g^^ ions perm its  ac t iva t ion  o f the a lte rna t ive  pathway as 
i t  is required fo r  the fo rm a tion  o f  C3bBb. The sens it iv i ty  o f the assays is 
enhanced by the  lo w  io n ic  s t re n g th  o f  the  s o lu t io n s .  M agnes ium  
E G T A -trea ted  serum fa i led  to lyse EA.
Fac to r B-depleted serum (RB)
A glass conical flask conta in ing fresh serum was incubated in a shaking 
w ater bath at 50°C fo r 20 mins. Im m edia te ly  a f te r  this the flask was cooled 
by plunging i t  in to  iced w a te r .  When cooled the RB was divided in to  aliquots
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and stored at -70°C. The fa c to r  B- depleted serum was t i t ra te d  and shown to 
be able to lyse EA, in order to demonstrate tha t  the classical pathway was 
in tac t .  RB fa i led  to lyse rabb it  e ry throcytes .
2.2.15 Measurement o f C4 using C4- de f ic ien t  guinea pig serum
This was based on the method described by G a ither, A i l ing  & Frank (1974)
Reagents
1. DGVB^'^
2. C 4 -de f ic ien t  guinea pig serum dilu ted 1/75 in DGVB^^ C 4-de f ic ien t
guinea pig serum was prepared from  the blood o f  guinea pigs which were
gene tica l ly  d e f ic ie n t  in C4.
, 2 +3. EA (1x1Cr/m l) in DGVB'
Method
1. The test serum was d ilu ted  in DGVB^^ (1/25,000, 1/50,000, 1/100,000, 
1/200,000, 1/400,000, 1/800,000, 1/1600,000)
2. lOOjjl o f  each serum d i lu t ion  was trans fe rred  to a series of tubes on ice.
3. lOOpl o f C4 de f ic ien t guinea pig serum was added to  each tube fo l lowed 
by lOOjjl o f EA. The vary ing additions o f reagents to the contro l tubes is 
shown below. The tubes were incubated at 37°C fo r  1 hour.
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Contro ls DGVB^^ C4 def. serunn EA
Cell blank ZOOyl - 100 jjl
Reagent blank 100 pi 100 pi 100 pi
100% lysis 100 pi 100 pi 100 pi
2ml saline was added to a ll tubes except the 100% lysis con tro l tube to 
which 2ml of w a te r was added. A f te r  cen tr i fuga t ion  (lOOOg fo r  5 min a t 2°C) 
the op t ica l densities o f the supernatants were read at 414nm (GD^^^)
C a lcu la tion  o f Results
GD sample - GD reagent blank 
^ ~ GD 100% - GD reagent blank
% lysis = 100 x y
When y is p lo tted  against the serum d ilu t ion  the curve is concave to  the x 
axis. Based on the shape of the curve Mayer and his colleagues (Borsos, Rapp 
& Mayer, 1961) postulated tha t com plem ent-m edia ted lysis was due to a 
single e f fe c t iv e  h i t  by a complem ent molecule (one-h it theory) ra the r than to 
cum u la t ive  h its . It  fo l lows the re fo re , tha t  i f  the to ta l  number o f e f fe c t ive  
molecules o ffe red  per ce ll = z then the proport ion  of unlysed cells(e) (cells 
w ith  n il h its) w i l l  be e^.
Thus -z = In  (1-y)
or z = - I n  (1-y)
2.0
1.5
1.0
0.5
0
1/feoOT i A oOT 1 /1G 0T
Figure 2.4
Plot of haem olytic titra tio n  for C4. Z was plotted against dilution of C4 used. 
Dilution of serum along x axis, T=thousand, therefore 1 /1001=1/100,000 etc.
E.g. I f  in i t ia l  d iu t ion  of serum was 1/100T, C4 conc^ = ^  x 100T
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When z is p lo tted  against the concentra t ion  of the component o ffe red , a 
s tra igh t  line, passing through the orig in is obtained (Fig 2.4). When z=1 then 
-1n (1-y) and y = 0.623. That is 62.3% of the cells have been lysed. The 
number of e f fe c t iv e  molecules of component in a given volume is found by 
drawing a v e r t ic a l line from  the point on the graph which passes through z=1  ^
to the X axis.
The number o f units of component were ca lcu la ted thus:
In i t ia l  d i lu t ion  x D istance along x axis to in i t ia l  d i lu t ion
Distance along the x axis to  z = 1
In all component assays 100pl of ce ll suspensions were used (EA 1x10 /m l)  ie 
10^ ce lls /tube  and IGOjui o f component o f each d i lu t ion .
The concen tra t ion  of e f fe c t iv e  molecules = units x 10^ /m l.  The results of 
haem o ly t ic  assays are usually expressed as un its /m l.
2.2.16 C4 Consumption assay 
Reagents 
1.
2. B5A
3. A n t i-BS A  antiserum (1:2 d ilu t ion). This antiserum was raised in rabbits .
4. Serum or synovial f lu id  f rom  patients w ith  RA.
Method
A row of tes t tubes was set up in a rack, labelled and set on ice. 50pl of 
test-serum  was mixed w ith  an equal volume o f GVB^^ and 5pl (1.75pg) of 
BSA was added. The m ix tu re  was warmed to 37°C in a w a te r bath. Immune
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complexes were fo rm ed at equivalence by the addit ion o f  lOnl o f  an t i-B5A
(dilu ted 1:2 in GVB^'^).
The tubes were incubated fo r  one hour at 37°C, a f te r  which complement 
a c t iva t ion  was stopped by the addit ion of 1ml ic e -c o ld  EDTA (10m m ol/ l)  
GVB” . Residual C4 content was measured h aem o ly t ica l ly .  Contro ls  included 
two serum conta in ing  tubes w ith o u t  immune complexes. One was incubated 
at 37°C and the other at 0°C. The to ta l  volume in each tube was kept 
constant by the add it ion  o f bu f fe r .
2.2.17 The e f fe c t  of R A  serum and pur if ied  rheum ato id  fa c to r  on the 
consumption o f C4 by immune complexes 
This assay was designed to  examine the e f fe c t  of the tes t m a te r ia l ( f rac t ion  
from  chromatography columns, pu r if ied  IgM -RF, hea t- inac t iva ted  RA serum 
from  which the pur if ied  RE had been prepared) on the a b i l i ty  of immune 
complexes to a c t iva te  the com plem ent system (measured as C4 consumption) 
in normal human serum.
The C4 c o n s u m p t io n  assay was m o d i f ie d  in these e x p e r im e n ts .  F i f t y  
m ic ro l i t re s  o f  normal serum (undiluted), 50pl of tes t m a te r ia l (column 
frac t ions , pu r if ied  RF or hea t- inac tiva ted  (30 mins at 56°C) RA serum) BSA 
(0.5pg in 5pl GVB^^) and anti-BSA(1 Dpi 1:6 d ilu ted  in GVB^^) were m ixed at 
G°C and then incubated at 37°C fo r  one hour. The reac tion  was stopped by 
the add it ion  of 1 ml ice cold EDTA (10m m ol/ l)  GVB“ . Residual C4 content 
was measured using C 4 -d e f ic ien t  guinea pig serum as described above.
The con tro l fo r  C4 consumption by complexes in the presence of RA serum 
was:- 50pl normal serum, 50pi hea t- inac tiva ted  normal serum, BSA and 
anti-BSA. The co n tro l fo r  the e f fe c t  of pu r if ied  RF consisted o f 5Gpl normal
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serum, 50pi GVB^*^, BSA and anti-BSA. O ther contro ls  included identica l 
reaction  m ix tu res  to  which 15pl GVB^^ had been added in place of BSA and 
anti-BSA.
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2.3 STATISTICAL METHODS
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The results were analysed using the s ta t is t ica l  procedures l is ted  below.
Chapter 3i>5ection 4
The comparison of inh ib i t ion  of PIP in SF and serum was ca rr ied  out using the 
W ilcoxon signed rank tes t. A lthough the sample size in th is comparison (Fig 
3.7) is fa i r ly  small, this non-param etr ic  tes t is the most appropria te  fo r  
analysis.
Chapter 3, Section 3
The comparison of C4 levels in serum samples f ro m  RA patien ts  w ith  normal 
PIP and subnormal PIP was carr ied  out using the grouped t - te s t  (Students 
t - te s t) .  This tes t was also used to compare the percentage C4 consumed in 
the sera o f R A  pa t ien ts  w ith  normal and abnormal PIP and contro ls  (see Table 
3.2).
Grouped t- te s ts  were used fo r  comparing the means o f d i f fe re n t  groups, since 
non -param etr ic  tests have low power fo r  small sample sizes.
A lthough the t - te s t  is in fa c t  com para t ive ly  robust against non -no rm a lity ,  the 
data were checked fo r  approx im ate  no rm a lity  and equa lity  o f variance 
between the two groups compared.
To quote "... .whereas tests on popula tion means (ie. "S tudents" t - te s t  fo r  the 
mean of a norm al popula tion, and fo r  the d if fe rence  between the means o f 
two normal populations w ith  the same variance) are ra the r  insensitive to 
departures f ro m  n o rm a l i ty ,  tests on variances...." are very sensitive to such 
departures. Tests on means are robust; by comparison tests on variances can 
only be described as f r a i l " .  (Kendal & S tuart,  The Advanced Theory of 
S ta t is t ics , Vol 2, Ch 31, pp 483-484).
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The co rre la t ion  between C4 consumption and in h ib i to ry  a c t iv i ty  and between 
C4 consumption and PIP was carr ied  out using Spearman's rank co rre la t ion  
c o -e f f ic ie n t  (see Fig 3.8). This analysis was also used in comparing C4 
consumption w ith  inh ib i to ry  a c t iv i ty  and PIP in synovial f lu id .
The comparison between the mean C4 consumption in serum and SF was 
carr ied  out using the grouped t - te s t  (see Table 3.2).
Chapter 3, Section 7
The s ign if icance  o f the d if fe rence  in consumption o f C4 when complexes were 
fo rm ed in the presence o f R A  serum or IgM -RF was tested using the grouped 
t - te s t  (see Table 3.3)
Chapter 3, Section 8
S t a t i s t i c a l  a na lyses  w e re  c a r r ie d  o u t  using the  U n iv e r s i t y  o f  G lasgow  
Com puter Service. The so ftw are  was the S ta t is t ica l Package fo r  the Social 
Sciences (M cG raw -H il l ) .
Com puter entr ies:
(1) C l in ica l indices
Diagnosis, age, sex, disease duration , morning s t if fness  duration , pain 
score. Jo in t  pain, jo in t  tenderness, synovial hypertrophy, cum u la t ive  
index.
(2) Synovial f lu id
Volume, p ro te in , w h ite  ce ll count, CH5D, C3, C4, Fac B, C 1 - in h ib i to r ,  
PIP, in h ib i t ion  of PIP, RF la tex , IgM -RF, IgG -RF, IgA -R F .
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(3) Blood
H aem oglob in , ESR, p la te le ts
(4) Serum
CH50, C3, C4, FacB, PIP, in h ib itio n  o f PIP, RF la te x , IgM -R F , IgG -R F, 
IgA -R F .
STUDY A
PIP and in h ib ito ry  a c t iv ity  in sera and synovia l flu id s .
C o rre la tions  w ith  c lin ica la n d  labo ra to ry  indices o f disease a c t iv ity .
A ll pa tien ts  had blood and SF data ava ilab le .
STUDY B
Study o f PIP and in h ib itio n  o f PIP in RA pa tien ts  w ith  and w ith o u t e x tra - 
a r t ic u la r  fea tu res  o f disease.
In th is study m easurem ents were ca rrie d  out on blood only.
S ta tis t ic a l Methods
(a) N o n -pa ra m e tric  tests were used fo r a ll analyses.
(b) Com parison of param eters between d if fe re n t groups was ca rrie d  out
using the M ann-W hitney U tes t, s ign ificance  le ve l ^  0.05, two ta ile d .
(c) Com parison between d if fe re n t param eters was ca rrie d  out using the
2
Spearman Rank c o rre la tio n  c o -e ff ic ie n t expressed as r( yj r  ) w ith  
pos itive  or negative  d ire c tio n . S ign ificance  leve l was taken as ^  0.05, 
tw o  ta ile d .
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Because o f the large numbers o f tests used in the s ta t is t ic a l analyses of 
resu lts o f th is  c lin ic a l study, the B onfe rron i in e qu a lity  demands th a t a 
c o r re c t io n  be a p p lie d  to  the  s ig n if ic a n c e  va lues  o b ta in e d . (S nedecor & 
Cochran, 1980). 'T rue ' s ign ificance  the re fo re  can be found by co rre c tin g  the P 
value according to  the fo rm u la  0 .05/^ where n = the num ber o f tests applied. 
For exam ple, i f  10 co rre la tions  have been used P would have to  equal 5/10% 
or p = 0.005 fo r  s ign ificance  to  be reached. (For fu r th e r discussion o f the 
s ta t is t ic a l s ign ificance  o f the resu lts  obtained in th is  c lin ic a l study see 
C hapter 4, Section 7).
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C HAPTER THREE
RESULTS
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The chap te r is arranged in nine sections and a t the end o f each section  a 
sm all paragraph is used to  sum m arise the expe rim en ta l data .
I l l
SECTION 1
The estab lishm ent o f an assay to  measure com p lem ent-m ed ia ted  preven tion  o f 
imm une p re c ip ita tio n  (PIP) in human serum.
The assay to  measure PIP in serum is described in M a te ria ls  and Methods, 
section  (2 .2.1(a jl
K in e t ic s  and c o m p le m e n t re q u ire m e n ts  fo r  th e  p re v e n t io n  o f im m un e  
p re c ip ita tio n
In the absence o f serum app rox im a te ly  95% o f the com plexes had p re c ip ita te d  
by the tim e  the f i r s t  sample was taken at 15 m inutes (F ig  3.1(a)). In the 
presence o f norm al human serum (50|ji und ilu ted) over 80% o f the complexes 
rem ained in so lu tion  even a fte r  1 hour (F ig 3.1(a)). T re a tm en t o f serum w ith  
EDTA com p le te ly  abrogated its  a b ility  to  keep com plexes in so lu tion  (Fig 
3.1(a)). In C2 d e fic ie n t serum and C 1 -in h ib ito r d e fic ie n t serum, most o f the 
fo rm ed com plexes p re c ip ita te d  (F ig  3.1(a)). L ikew ise  the im portance  of the 
a lte rn a tiv e  pathw ay was illu s tra te d  by p a rtia l p re c ip ita tio n  in the M g-EG TA 
tre a te d  serum and in B depleted serum (F ig 3.1(a)). The lack o f requ irem ent 
of the te rm in a l com ponents was dem onstra ted by the  fa ilu re  o f complexes to 
p re c ip ita te  in C5 d e fic ie n t and C7 d e fic ie n t sera (F ig 3.1(a)).
F o rm a tion  of complexes in norm al serum
An expe rim en t was ca rried  out to establish the optim um  am ount o f serum 
which was used in the assay to  measure PIP. The op tim um  am ount o f serum 
would be th a t q u a n tity  which would hold the m axim um  am ount o f immune 
c o m p le xe s  s o lu b le . T h is  d i lu t io n  o f se rum  was e s ta b lis h e d  by t i t r a t io n .
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Figure 3.1(a)
K in e tics  o f imm une p re c ip ita tio n  in serum (# -------# ) and in b u ffe r (0--------- 0).
The v e rtic a l bars show the range (±2 s.d. o f the mean) a t each tim e  po in t fo r 
25 serum samples fro m  norm al ind iv idua ls.
-A), and C 1 -in h ib ito r(a) shows’ the a b il ity  o f C2 ()■— ■ ) ,  C5 (2V-—A ), C7 (▲— 
( y — sgr ) d e fic ie n t sera to  preven t imm une p re c ip ita tio n .
(b) shows the a b ility  o f B depleted serum (
( A  A  ) and M g -E G T A  tre a te d  serum (
p re c ip ita tio n .
), ED TA trea ted  serum 
) to  preven t imm une
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A row o f p la s tic  Eppendorf tubes was set up. To the f ir s t  tube was added 
20D|j1 o f norm al human serum . Doubling d ilu tions  were made of th is  serum 
in to  GVB^^ (1D0|j1) w hich had been added to  subsequent tubes. The d ilu tions  
of serum were th e re fo re  neat, 1/2 to  1/16. Immune com plexes were form ed in 
each tube by the add ition  o f 5|j1 ^^^I-BSA  (350  yg /m l) and subsequently 10|j1 
o f a n t i-B S A  a n tis e ru m  (d ilu te d  1/2). C o m p le xe s  w e re  thus fo rm e d  a t 
equivalence in each d ilu tio n  o f norm al serum.
C on tro l tubes were (1) TCA p rec ip ita b le  counts (th is  tube conta ined 5G|ji BSA 
(5m g /m l) and 60pl o f TC A  (20%) and 5^1 of ^^^I-B S A  (2) to ta l ra d io a c tiv ity , 
th is  tube conta ined 110|j1 GVB^^ and 5|j1 ^^^I-BSA .
A fte r  m ix ing , a ll the tubes were incubated fo r 1 hour a t 37°C. A 50|ul a liquo t 
o f the m ix tu re  was taken and trans fe rred  to  an Eppendorf tube conta in ing  
1 m l o f ice -co ld  PBS. The tubes were cen trifuged  (Beckman M icro fuge) fo r  5 
m inutes and 250jjl o f supernatant was taken fo r coun ting  in a y  coun ter.
The cpm in the supernatant d iv ided by cpm in the supernatant o f the to ta l 
ra d io a c tiv ity  c o n tro l tube, m u ltip lie d  by 100, gave the % immune complexes 
soluble, or %PIP. This was p lo tte d  on a graph against d ilu tions  o f norm al 
serum in the  assay tube (F ig  3.1(b)).
The d ilu tio n  o f serum was associated w ith  a rap id  decline  in its  a b ility  to  
prevent imm une p re c ip ita tio n . As a resu lt o f th is observation  i t  was decided 
to  use 50pl und ilu ted  serum (fin a l d ilu tio n  app rox im a te ly  1/2 in reac tion  
m ix tu re ) in ro u tine  assays.
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Figure 3.1(b)
Graph showing percent of Immune complexes remaining soluble (% PIP) in 
various dilutions of normal human serum (NHS).
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In 25 norm al sera the mean percent PIP at 15, 30 and 60 m inutes was 95.9 
(±s.d. 3.44), 95.6 (+3.89) end 92.1 (±4.55) re spec tive ly . By sub trac ting  2 
standard devia tions fro m  the mean the low er l im it  o f the norm al ranges (%
PIP) in my system a t the three  tim e  in te rva ls  stud ied was 89.0%, 87.8% and
83.0% re sp ec tive ly  (F ig  3.2). Thus, in my ro u tine  assay, in w hich a single 
incubation  tim e  o f 1 hour was used^and when % PIP was less than 83% i t  was 
reduced.
In the norm al sera studied the d is tr ib u tio n  o f % PIP o f d if fe re n t sera was 
sym m etrica l about the  mean at each of the tim es (15, 30 and 60 m inutes) and 
the  s ta n d a rd  d e v ia t io n s  r e f le c te d  th e  s m a ll s c a t te r  a b o u t the  m eans.
For ro u tin e  purposes assays on ind iv idua l samples were repeated i f  the resu lts 
p e r fo rm e d  on d u p lic a te  d e te rm in a t io n s  d i f fe re d  by 10% o r g re a te r .
The re p ro d u c ib ility  o f the assay was tested by repea ting  the assay on six
serum samples on tw o separate days. The va ria tio n  between assays on
ind iv idua l sera was between 1% and 10% the mean being 6%
Storage o f serum samples a t 4°C fo r 24 hours, -20°C  fo r 3 days and repeated 
fre ez ing  and thaw ing  o f samples (up to  f iv e  cycles) did not resu lt in a 
s ig n ific a n t loss o f serum PIP a c tiv ity ,
SUM M ARY
An assay to  measure PIP was established and its  dependency upon the 
com plem ent system  con firm ed . Its  re p ro d u c ib ility  was acceptab le  and was 
the re fo re  able to  be used on a rou tine  basis. The f i r s t  study was to  measure 
PIP in the sera o f pa tien ts  su ffe rin g  fro m  a v a rie ty  o f diseases. In some of 
these cond itions hum oral imm une mechanisms are considered to  play an
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im p o rta n t pa thogenetic  ro le  (5LE, GN, RA).
SECTION 2
M e a s u re m e n t o f p re v e n t io n  o f im m un e  p r e c ip i ta t io n  in p a t ie n ts ' sera  
The c lin ic a l de ta ils  o f the p a tie n t groups in th is  study are described in 
M a te ria ls  and Methods (2.1.2). B lood was co lle c ted  and serum prepared as 
d e s c r ib e d  (2 .1 .1 ) . C 3, C 4, F a c to r  B, to ta l  h a e m o ly t ic  c o m p le m e n t and 
a lte r n a t iv e  p a th w a y  h a e m o ly t ic  a c t i v i t y  w e re  m easured  as d e s c r ib e d  in  
section  (2.2.14(a)(b)).
R heum ato id  a r th r it is  and o ther a rth ropa th ies
T h ir ty -s ix  o f 75 sera (48%) fro m  patien ts  w ith  se ropositive  RA showed 
reduced PIP whereas sera fro m  pa tien ts  w ith  seronegative  R A, ankylosing 
spondy litis , p so ria tic  a r th r it is  and degenerative jo in t  disease showed norm al 
PIP (F ig  3 .2 ). E le ve n  o f th e  R A  sera  show ing  a re d uce d  PIP w ere  
hypocom plem entaem ic as judged by the APH50. O f these 1 1 ,5  had a reduced 
CH50 leve l, one o f whom had a low  C4 leve l. The haem o ly tic  com plem ent 
levels in the rem ain ing  sera w hich showed reduced PIP were e ithe r norm al or 
e levated (F ig  3.2).
The re la tionsh ip  between the capac ity  o f se ropositive  RA sera to prevent 
p re c ip ita tio n  o f complexes and the CFI50 and APH50 levels is shown in F ig 
3.3, A lthough the re  was a tendency fo r the low est levels o f PIP to  be 
associated w ith  reduced CH50 and APH 50 there  were many pa tien ts  who had 
low  PIP and norm al or e levated CH5Ü and APH5D.
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Figure 3.2
P reven tion  o f im m une p re c ip ita tio n  by sera fro m  p a tie n ts .
The h o rizon ta l line  shows the low er l im it  o f the norm al range (83%)
RA+ = seropositive  R A ,
R A - = seronegative  R A ,
AS = ankylosing spondy litis , 
psA = p so ria tic  a r th r it is .
DJD = degenera tive  jo in t  disease,
SLE = system ic lupus erythem atosus,
GN = g lo m eru loneph ritis .
(o = fo ca l GN; # = membranous GN; + -  acute post s tre p to co cca l GN).
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Figure 3.3
R ela tionsh ip  between % o f com plexes rem ain ing soluble and (a) classica l 
pathw ay (CPH50) and (b) a lte rn a tiv e  pathway (APH50) hae m o ly tic  a c t iv ity  in 
sera fro m  pa tie n ts  w ith  seropositive  rheum ato id  a r th r it is .  The h o rizon ta l and 
v e rtic a l lines show the lim its  o f the norm al ranges. (% IC  soluble 83%~100%; 
CPH50 150-250 u n its /m l; APH50 185-327 u n its /m l).
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Figure 3.4
R ela tionsh ip  between % o f com plexes rem ain ing  soluble and (a) c lassica l 
pathway (CPH50) and (b) a lte rn a tiv e  pathway (APH50) h ae m o ly tic  a c t iv ity  in 
sera fro m  pa tie n ts  w ith  SLE, The ho rizon ta l and v e rt ic a l lines show the 
lim its  o f the norm al ranges. (% I.C . soluble 83%-100%; CPH50 150-250 
u n its /m l; APH50 185-327 u n its /m l).
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System ic lupus erythem atosus(5LE)
Fourteen of 32 (43.4%) 5LE sera had reduced PIP (F ig  3.4). O f these 14 sera, 
8 had subnorm al CFI50 levels and 8 had reduced APFI50 leve ls. Low leve ls o f 
PIP tended to  be associated w ith  reduced CH50 and APH50 but again there  
were several pa tien ts  who displayed low levels o f PIP but had norm al CF150 
and APH50 (F ig  3.4)
G lom eru loneph ritis  (ON)
Four o f 17 sera (23.5%) had reduced PIP (F ig 3.2). One sample had been taken 
fro m  a p a t ie n t  w ith  a c u te  p o s t-s tre p to c o c c a l GN who was s e v e re ly  
hypocom plem entaem ic. None o f the rem ain ing th ree  samples were fro m  
h y p o c o m p le m e n ta e m ic  p a t ie n ts ;  2 p a t ie n ts  had fo c a l GN and one had 
membranous GN.
SUM M ARY
The most s tr ik in g  fin d ing  fro m  th is  study was the im p a irm en t o f PIP found in 
48% of pa tien ts  w ith  se ro -pos itive  R A. This proved even more in te res ting  
when i t  was noted th a t th is  im pa irm en t o f PIP in RA could not be a ttr ib u te d  
to  hypocom plem entaem ia; indeed the vast m a jo r ity  o f these RA sera had 
norm al or o fte n  e levated serum com plem ent leve ls. This suggested th a t the 
reduced PIP in RA p a tie n ts ' sera was due to  the presence of a serum 
in h ib ito r o f PIP.
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SECTION 3
The estab lishm ent o f an assay to measure the in h ib itio n  o f the prevention  o f 
immune com plex p re c ip ita tio n  ( in h ib ito ry  a c tiv ity )  in serum
The assay used to  measure the in h ib itio n  o f PIP was as described in M a te ria ls  
and Methods (2.2.1(b)).
D em onstra tion  o f in h ib ito ry  a c t iv ity  in RA serum
A series o f Eppendorf tubes was set up in a rack and placed on ice. To eaeh
tube 50|jI o f neat norm al human serum was added. A no the r row  o f tubes was
set up and to  these lOOpI o f RA serum, w ith  known m arked ly im pa ired PIP,
was added to  tube one, 10OpI o f GVB^^ was added to  the other tubes.
Doubling d ilu tions  were ca rried  out in these tubes, the RA serum being
und ilu ted  or doubly d ilu ted  to  1:32 in GVB^^ (pH 7.4). 50^1 o f each d ilu tio n
was added to  the tubes con ta in ing  50|j1 of und ilu ted  norm al serum. Immune
125complexes were fo rm ed  by adding I-B5A  5pl (350pg/m l) and then lOpl o f 
an ti-BS A  (d ilu ted  1:2) to  each tube.
C on tro l tubes included;
(1) T o ta l r a d io a c t iv i t y  in p u t,  5pl ^ ^ ^ I-B S A  and 100^1 o f G V B ^^
(2) TC A  p re c ip ita b le  counts, 50jjl o f BSA (5m g/m l), 60 pi o f 20% TC A and
1255(jl '^^ I-B S A
(3) R a d io a c t iv i t y  p re c ip i ta te d  by a n tib o d y  a lone  10Opl G V B ^^ , 5pl
^^^I-B S A  and 10|j 1 anti-BS A
(4) M axim um  possible PIP by serum alone, 50pl norm al serum , 50pl GVB^^,
^^^I-BS A  5pl and lO pl an ti-B S A .
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A fte r  m ix ing  and incubating  fo r 1 hour a t 37°C, a 50^1 a liquo t was removed 
fro m  each tube and added to 1ml ice cold PBS (pH 7.4) in another Eppendorf 
tube. Fo llow ing  c e n tr ifu g a tio n  in a m icro fuge  a 230jj1 a liq u o t was taken fo r 
counting  in a -y  coun ter. The per cent immune com plexes w hich rem ained 
soluble (% PIP) was ca lcu la ted  thus;
% PIP = cpm in serum supernatant - cpm in b u ffe r supernatant x 100 
T o ta l cpm /tube  - cpm in b u ffe r supernatant
The co n tro l tube con ta in ing  norm al serum alone plus b u ffe r a llowed fo r 93% 
PIP. A dd itio n  of increasing amounts o f the RA serum resu lted in a dose 
dependent decrease in % PIP. The % in h ib itio n  o f PIP was expressed as 100-n 
where n=% PIP. I t  can be seen th a t the in h ib ito ry  e ffe c t o f RA serum on th is 
process becomes less m arked as the RA serum is fu r th e r d ilu ted  (F ig 3.5).
The e ffe c t  o f h e a t- in a c tiv a tio n  of RA serum on the in h ib itio n  o f PIP 
3mls o f RA serum w hich displayed reduced PIP was heat in a c tiva te d  a t 56°C 
fo r 30 m inu tes. A row  o f tes t tubes was set up and lOOpl o f the heat 
in a c tiva te d  (H I) RA serum was added to  the f ir s t  tube. 100|j1 of GVB^^ was 
added to  the  rem a in ing  tubes. Doubling d ilu tions  o f (H I) RA serum were made 
ranging from  und ilu ted  to 1 ;32. The experim ent was ca rrie d  out exac tly  as 
described above (dem onstra tion  o f in h ib ito ry  a c t iv ity  in RA serum). The only 
d iffe re n ce  was th a t the RA serum in th is  experim en t was heat—inac tiva ted  
(56°C fo r 30 m inutes). The co n tro l tubes were s im ila r and the resu lts 
ca lcu la ted  in the same m anner, % in h ib ition  = IGG-n where n = % PIP.
It can be seen th a t the degree o f in h ib itio n  o f PIP became m ore pronounced 
fo llo w in g  h e a t- in a c tiv a tio n  of the RA serum (see F ig  3.5).
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Figure 3.3
E ffe c t o f RA serum on p reven tion  o f immune p re c ip ita tio n  by norm al serum.
Dose-response curves fo r  RA serum p rio r to  ( A — —A  ) and a fte r  ( #    # )
h e a t- in a c tiv a tio n . % In h ib itio n  on the y axis re fe rs  to  the degree of 
in h ib ito ry  a c t iv ity .
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Measurement of inhibition of PIP in sera
Because h e a t- in a c tiv a tio n  increased the amount o f in h ib itio n  o f PIP observed 
in the experim en t perfo rm ed  above (F ig 3.5) i t  was decided to  measure 
in h ib ito ry  a c t iv ity  in 40 sera (10 norm al, 10 seropositive  R A , 10 seronegative 
RA, 5 ankylosing spondylitis  and 5 pso ria tic  a r th r it is )  before  and a fte r  
h e a t- in a c tiv a tio n . The resu lts are summarised in Table 3.1. Fo llow ing  heat 
in a c tiv a tio n  a sm all degree o f in h ib ito ry  a c t iv ity  ( <  5%) was observed in 
norm al sera. On the basis o f th is find ing  i t  was decided th a t in h ib ito ry  
a c t iv ity  was present i f  i t  was present in excess o f 5%. The p ropo rtion  o f sera 
w hich inh ib ite d  PIP increased d ra m a tica lly  fo llo w in g  h e a t- in a c tiv a tio n  (Table 
3.1). Thus fo r  a il fu r th e r studies I decided to  use h e a t-in a c tiva te d  sera 
exc lus ive ly .
A ll assays were perfo rm ed in dup lica te . Assays were repeated i f  the resu lts  
d iffe re d  by m ore than ±5% o f the mean o f the dup lica te  de te rm ina tions.
The assay was ca rrie d  out on 10 serum samples on two separate days. The 
va ria tio n  between assays on ind iv idua l sera was ±5% mean 7%.
SUM M ARY
A reproducabie assay to  measure in h ib itio n  o f PIP was established. This assay 
was used to  measure in h ib itio n  o f PIP in p a tien ts ' sera.
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Table 3.1
E ffe c t o f h e a t- in a c tiv a tio n  o f serum on 
measurem ent o f in h ib ito ry  a c t iv ity .
% Inh ib ition o f PIP *
Group Number 
in group Fresh Serum
H eat
Inac tiva ted
C on tro l 10 0 1.3 ± 0.57
RA seropositive 10 *19.9 ± 8.1 59.2 ± 8.1
RA seronegative 10 0 3.7 ± 2.1
Ankylosing spondylit is 5 2.3 ± 1.2 13.6 ± 1.2
P so ria tic  a r th r it is 5 0 0
*  % in h ib itio n  o f PIP recorded as mean ± standard e rro r o f mean
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SECTION 4
M easurem ent o f in h ib itio n  o f PIP (in h ib ito ry  a c t iv ity )  in sera o f pa tien ts  
su ffe rin g  fro m  rheum atic  disease.
Inh ib itio n  o f PIP was measured as described in M a te ria ls  and Methods 
(2.2.1(b)). C lin ic a l aspects o f pa tie n t groups were as described in M a te ria ls  
and Methods (2.1.3).
P revalence of in h ib ito ry  a c t iv ity  in d if fe re n t diseases
In h ib ito ry  a c t iv ity  did not exceed 5% in 25 sera fro m  norm al ind iv idua ls. 
N in e ty -tw o  o f the 130 sera (71%) fro m  pa tien ts  w ith  seropositive  RA were 
in h ib ito ry , the mean leve l being 33.2% (± standard e rro r o f mean 2.7%). In 
con tras t only 6 o f 25 (24%) fro m  pa tien ts  w ith  seronegative RA were 
in h ib ito ry , but the leve l o f in h ib ito ry  a c t iv ity  was low  (mean 13.3 ± 1.0%). Six 
o f 7 sera (85.7%) fro m  pa tien ts  w ith  ankylosing spondy litis  were in h ib ito ry  
(mean 13.1 ± 2.1%) whereas none of 5 sera fro m  pa tien ts  w ith  pso ria tic  
a r th r it is  were in h ib ito ry  (F ig  3.6).
Inh ib itio n  o f PIP in synovial f lu id
Synovial f lu id  was obta ined fro m  13 patien ts and prepared fo r assay as 
described in chap te r (2.1.1). The m ethod of measuring in h ib itio n  o f PIP in SF 
was id e n tic a l to  th a t described fo r  serum samples above. SF was used instead 
o f tes t serum (eg RA serum). As w ith  pa tie n ts ' serum samples the SF was 
h e a t- in a c tiv a te d  at 56°C fo r 30 m inutes p rio r to  being tested in the assay.
Synovial f lu id  inh ib ite d  PIP. The mean leve l o f in h ib ito ry  a c t iv ity  in synovial 
f lu id  (58 ± 6.8%) did not d if fe r  s ig n ific a n tly  fro m  th a t in paired serum 
samples (53 + 11.2%) F ig  3.7. (W ilcoxon signed rank tes t).
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Figure 3.6
Leve l o f in h ib ito ry  a c t iv ity  (% Inh ib itio n ) in h e a t- in a c tiv a te d  sera fro m  
p a tien ts  w ith  se ropositive  RA (RA Pos), seronegative R A (R A  Neg) p so ria tic  
a r th r it is  (PSA) and ankylosing spondy litis  (AS).
co
rG
x:c
Serum
Figure 3.7
In h ib ito ry  a c t iv ity  in paired serum and synovial f lu id  (SF) samples. The
ho rizon ta l bars represent the mean ( --------------) and the standard e rro r o f the
mean (-------- ).
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SUM M ARY
In h ib ito ry  a c t iv ity  has been dem onstra ted in RA serum and to  a lesser ex ten t 
in sera fro m  pa tien ts  w ith  seronegative a r th r it is .  I t  was the re fo re  decided to 
undertake studies which would help to  c la r ify  its  mode o f ac tion  as these 
m igh t shed lig h t on the nature  o f the in h ib ito ry  m olecu le  in whole serum and 
perhaps ind ica te  a m ethod fo r  the  iso la tion  o f the in h ib ito ry  a c t iv ity  from  RA 
serum.
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SECTION 3
Studies on the mechanism o f ac tion  o f an in h ib ito r o f PIP in serum and 
synovia l f lu id  (SF)
C4 and C4 consum ption were measured in serum and SF as described in 
M a te ria ls  and Methods (2.2.15 and 2.2.16).
C4 levels and C4 consum ption in serum and synovia l f lu id
C4 levels were measured in sera and synovial f lu id s  before  and a fte r  the 
add ition  o f an tigen-an tibody com plexes (Table 3.2). The C4 levels in serum 
samples fro m  RA pa tien ts  w ith  norm al PIP (mean 317, 309 u n its /m l ± SE 
18,152), were s ig n if ic a n tly  h igher than the levels in those w ith  subnormal PIP 
(212,566 ± 15,572; P <  0.001). (Grouped t- te s t) .
F o llow ing  the fo rm a tio n  of an tigen-an tibody com plexes in the serum C4 
consum ption occurred. The percentage of C4 consumed in the sera from  RA 
pa tien ts  w ith  abnorm al PIP (39 + 5.0%) was s ig n if ic a n tly  low er (P <. 0.001) 
than in the sera fro m  pa tien ts  w ith  norm al PIP (68 + 2.3%) and co n tro l sera 
(64 ± 3.1%). (Grouped t- te s t) .
There was an inverse co rre la tio n  between C4 consum ption and in h ib ito ry  
a c t iv ity  and a d ire c t co rre la tio n  between C4 consum ption and PIP in RA sera 
(F ig  3 .8 ). (S p e a rm a n 's  R ank c o r re la t io n ) .  (P <  0 .0 1 . in  b o th  cases).
C4 consum ption in synovia l f lu id  (39 ± 4.0%) was low er than th a t in norm al 
serum (64 ± 3.1%; P <  0.001) (Grouped t- te s t)  and was a lm ost id e n tica l w ith  
C4 consum ption in RA serum w ith  reduced PIP (Table 3.2).
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C o rre la tio n  between (a) C4 consum ption and sérum in h ib ito ry  a c tiv ity  
(% Inh ib itio n ) r = -0.72; P 0.01
(b) C4 consum ption and PIP (% IC soluble) r = 0.67; P < 0.01 
(Spearman's rank c o rre la tio n )
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In order to  exclude the poss ib ility  th a t the p ropo rtion  o f C4 consumed was 
re la ted  to  the concen tra tion  of C4 availab le  a t the onset o f the experim en t, 
C4 consum ption was measured in serum samples (und ilu ted  and d ilu ted  1/2, 
1/4, 1/8) fro m  norm al con tro ls  and RA pa tien ts . The p ropo rtion  o f C4 
consumed in the d ilu ted  samples was s im ila r to th a t in the und ilu ted  samples 
in norm al sera and in h ib ito ry  and n o n -in h ib ito ry  sera fro m  pa tien ts  w ith  RA.
K in e tics  o f in h ib itio n  o f PIP (see M a te ria ls  and Methods (2.2.6).
When RA serum or synovia l f lu id  was added to  norm al serum p rio r to  the 
add ition  o f antigen and antibody (tim es 0) the in h ib ito ry  e ffe c t was m axim a l. 
When added a fte r  antigen and antibody the in h ib ito ry  e ffe c t was less m arked. 
The m agnitude o f the e ffe c t d im in ished as the tim e  a fte r  the add ition  o f 
antigen and antibody increased (F ig  3.9)
S en s itiv ity  o f in h ib ito ry  a c t iv ity  to  tryps in , SBTI and PM5F 
(See M a te ria ls  and Methods 2.2.4 and 2.2.5)
Incubation  w ith  tryps in  destroyed over 90% o f the in h ib ito ry  a c t iv ity .  T rypsin  
+ SBTI and SBTI alone had no e ffe c t .  Exposure to  PMSF did not reduce the 
in h ib ito ry  a c t iv ity .
SUM M ARY
C4 levels and C4 consum ption was measured in serum and SF and the 
re la tionsh ip  to  in h ib ito ry  a c t iv ity  noted. The in h ib ito r o f PIP was sensitive to  
tryps in  but not to  PMSF. K in e tic  studies showed th a t in h ib itio n  o f PIP was 
m a x im a l w hen R A  se rum  o r SF was added p r io r  to  im m un e  co m p le x  
fo rm a tio n .
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Figure 3.9
K in e tic s  o f in h ib ito ry  a c t iv ity  o f RA serum . In h ib ito ry  RA serum (unbroken 
line ) was added to  norm al serum a t t im e  0, or 5, 15, 30 and 60 m inutes a fte r  
the add ition  o f antigen and antibody. The in h ib ito ry  e ffe c t  was m axim al a t 
tim e  0. Synovial f lu id  gave a s im ila r re su lt.
N orm a l c o n tro l w ith o u t add ition  o f R A  serum (broken line ).
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SECTION 6
The is o la t io n  and p u r i f ic a t io n  o f in h ib i to r y  a c t i v i t y  fro m  R A s e ru m . 
The methods used in th is  section  are described in M a te ria ls  and Methods 
(2.2.2)
IgG Sepharose chrom atography o f RA serum 
Reagents
Veronal b u ffe red  saline (VBS pH 7.5, 0.15M)
EDTA (20 m m ol/1, pH 7.5)
Dextrose so lu tion  5% W/V
Veronal b u ffe re d  saline conta in ing  400 mmol/1 N aC l pH 7.5
Veronal bu ffe red  saline conta in ing  guanidine hydroch lo ride  2 mol/1 pH
7.5
IgG  Sepharose , p re p a re d  as p re v io u s ly  d e s c r ib e d  (see 2 .2 .1 0 ). 
RA serum. This had been tested previously to co n firm  th a t i t  was able 
to  in h ib it PIP.
M ethod
This procedure was ca rrie d  out in a w a lk in  4°C cold room . RA serum (15mls) 
was d ilu ted  in an equal volum e o f the EDTA (20 mm ol/1 pH 7.5) and applied 
to a colum n (1cm x 40cm) o f IgG Sepharose. This IgG Sepharose colum n had 
previously been e qu ilib ra ted  w ith  VBS d ilu ted  1:1 w ith  dextrose so lu tion  
(e q u ilib ra ting  b u ffe r).
The s ta r t in g  m a te r ia l was s low ly  passed through the co lum n (ra te  5m l/hour) 
using a pump. Fo llow ing  app lica tion  o f the sample the  colum n was washed 
ex tens ive ly  w ith  e q u ilib ra tin g  b u ffe r (5 colum n volum es) u n til no fu r th e r 
p ro te in  was de tected  in the e luate . 3m l fra c tio n s  were co lle c ted  using an 
a u tom a tic  fra c t io n  c o lle c to r.
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The bound m a te r ia l was e lu ted  in tw o  stages. F irs tly  w ith  VBS con ta in ing  400 
mmol/1 N aÇ l (3 colum n volumes) and secondly w ith  VBS con ta in ing  guanidine 
hydroch lo ride  (2 mol/1) (3 colum n volumes). A lte rn a te  fra c tio n s  were screened 
fo r p ro te in  co ncen tra tion  (OD^gg), in h ib ito ry  a c t iv ity  (% in h ib itio n  o f PIP) and 
rheum ato id  fa c to r  by Rose-W aaler t i t ra t io n  and radioim m unoassay (F ig  3.13a). 
P rio r to  screening,each fra c t io n  including  the RA serum s ta rtin g  m a te ria l was 
dialysed ex tens ive ly  against VBS pH 7.5 0 .15M at 4°C. 50|j 1 samples o f each 
fra c t io n  were taken and measured fo r in h ib itio n  o f PIP (in h ib ito ry  a c tiv ity )  
using the assay p reviously described.
Three p ro te in  pools were made, pool (a) represented the exclusion peak, pool
(b) com prised the p ro te in  peak e lu ted  w ith  0.4M NaC l and pool (c) the p ro te in  
peak e lu ted  w ith  2M guanidine hydroch lo ride  (see F ig 3.10). These p ro te in  
pools were fu r th e r d ia lysed against VBS 0.15M pH 7.5.
The pools were tested fo r  in h ib ito ry  a c t iv ity  and i t  was found th a t pool (a)
was n o n - in h ib ito r y ,  poo l (b) was s l ig h t ly  in h ib i to r y  and poo l (c ) w h ich  
conta ined rheum ato id  fa c to r  a c t iv ity ,  was e x trem e ly  in h ib ito ry . (F ig  3.11). 
There fo re  in h ib ito ry  a c t iv ity  bound to  IgG Sepharose and the m a jo r ity  o f i t  
was e lu ted  w ith  guanidine hydroch lo ride .
M ix ing  E xperim ents
This expe rim en t was ca rried  out to see i f  the in h ib ito ry  a c t iv ity  o f the 
s ta rtin g  m a te r ia l could be re co n s titu te d  by m ix ing  tog e the r pools (a), (b) or
(c) in various com binations. The volumes o f the various pools w hich were 
tested fo r  in h ib ito ry  a c t iv ity  (in the assay to  measure in h ib itio n  o f PIP) and 
the various com bina tions used are de ta iled  in the  legend to  F igure  3.12. The 
in h ib ito ry  a c t iv ity  o f the s ta rtin g  m a te ria l could be re co n s titu te d  fu lly  by
m ix ing  the exclusion peak pool (a) w ith  pool (c) or pools (b) and (c), but not
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Figure 3.10
C hrom atography o f R A  serum (13 mis) 
on 5epharose-IqG colum n (1.0 x 40 cms)
P ro te in  co nce n tra tio n  (OD 28D ).
and
Pool a represents the exclusion peak; ^
pool b consists o f p ro te in  e lu ted  w ith  NaC1 (400 m m ol.l^  ) 
pool c is the p ro te in  e lu ted  w ith  guanidine-HC1 (2m o l.l ).
The arrows 1 and 2, represent the points o f app lica tio n  o f the NaC1 and 
guan id ine -H C I re sp ec tive ly .
The scale o f the abscissa represents the num ber o f the ind iv idua l colum n 
fra c tio n s .
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Figure 3.11
T itra t io n  of the in h ib ito ry  a c t iv ity  In pools
a C A - A  ) b (# ----- • )  c ( A --A  ) (See F ig . 3 .10)
and the R A  serum w hich was the s ta rtin g  m a te ria l (sm o -o  ).
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Figure 3.12
R e co n s titu tio n  o f in h ib ito ry  a c t iv ity  o f R A  serum.
The in h ib ito ry  a c tiv it ie s  o f 25 o f RA serum s ta rtin g  m a te ria l (sm ^  );
100 pi o f pool a (exclusion peak) 25 pi o f pool b and 25 p i o f pool c are 
shown above.
C om binations o f the various p ro te in  pools 100 pi pool a + 25 pi pool b; 
100 p i pool a + 25 p i pool c;
25 p i pool b + 25 pi pool c, and 100 p i pool a + 25 p i pool b + 25 p i pool c 
were also tested fo r  in h ib ito ry  a c t iv ity .
When pool c or pools b and c toge the r were added to  the exclusion peak 
(pool a), in h ib itio n  o f PIP was restored .
(P ro te in  pools as in F igure  3.10)
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w ith  pool (b) alone (F ig  3.12).
Gel f i l t r a t io n  chrom atography on Sephacryl S3DD 
Reagents
A ce ta te  b u ffe r 100 mmol/1 pH 3.5 
Tris base 1 mol/1
Sephacryl 5300 colum n (1.6 x 90cm)
M ethod
The in h ib ito ry  pool (c) fro m  the IgG-Sepharose colum n was concen tra ted  by 
vacuum d ia lys is  and then dia lysed against ace ta te  b u ffe r. One m l o f the 
concen tra ted  pool (GD^gg -  15.1) was applied to  the  Sephacryl S300 colum n 
which had been e qu ilib ra ted  w ith  the  same b u ffe r.
The colum n was e lu ted  a t a f lo w  ra te  o f 16m ls/hour and 1.5ml fra c tion s  were 
co lle c ted  in to  tubes con ta in ing  20jjl o f tr is  (1 mol/1), to  restore  the pH o f the 
fra c tio n s  to  n e u tra lity  (pH 6.5-7.5).
A lte rn a tiv e  fra c tio n s  were screened fo r  to ta l p ro te in  (OD^gg), in h ib ito ry  
a c t iv ity  (% in h ib itio n  o f PIP) and rheum ato id  fa c to r  by radio-im m unoassay. 
Two p ro te in  peaks were obta ined; the f ir s t ,  which was e lu ted  synchronously 
w ith  IgM (e lu tion  volum e 112.5 m is) conta ined IgM -R F and the  m a jo r ity  o f the 
in h ib i to r y  a c t i v i t y .  The second peak w h ich  c o n ta in e d  s m a ll a m oun ts  o f 
in h ib ito ry  a c t iv ity  was e lu ted  w ith  the same b u ffe r volum e (135 m is) as IgG. 
(F ig  3.13(b)).
These tw o  p ro te in  peaks were pooled separa te ly, concen tra ted  by vacuum 
dia lysis and analysed by SDS-PAGE (see M a te ria ls  and Methods (2.2.12). The 
gel e le c tro p h o re tic  pa tte rns  are shown in (Fig 3.14). The f i r s t  in h ib ito ry  pool
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Figure 3.13(a)
P u r if ic a tio n  o f in h ib ito ry  a c t iv ity
IgG Sepharose ch rom a tog raphy . 15 mis o f RA serum were applied to  a 
(1.0 X 40 cm ) co lum n w hich was e lu ted  as described in the te x t.  
P ro te in   ); in h ib ito ry  a c t iv ity  (% ---------);
R heum ato id  ra c to r by radio-im m unoassay (u n its /m l, A -— -A  ) and 
haem og lu tina tion  (Rose-W aaler te s t; RW + /-).
The arrow s, 1 and 2 represen t the po in ts o f app lica tio n  o f N a C l and 
guan id ine -H C l re sp ec tive ly .
The scale o f the abscissa represents the number o f the ind iv idua l colum n 
fra c tio n s .
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Figure 3.13(b)
Sephacryl 5300 ch rom a tog raphy . 1ml o f pool c was applied to  a 1.6 x 
90cm) co lum n w hich  had been e qu ilib ra ted  a t pH 3.5 as described in 
the te x t.  Symbols as in F igu re  3.13(a). The e lu tion  volum e shown on 
the abscissa. Two m a jo r p ro te in  peaks were e lu ted , represen ting  IgM 
and IgG rheum ato id  fa c to r  re sp ec tive ly .
(Pool c was a guanidine e lu ting  peak, see Figs 3.10 and 3.13(a))
IgM IgG
; ;
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ill
Ig M Io '’
IgG 160,000
j/l chain 72,500 
^  chain 54,000
Light Chain 
25,000
Figure 3.14
5D5-PAGE analysis (5% gels) o f p ro te in  pools fro m  Sephacryl S300 columns 
(F ig .3.13(b)). E le c tro p h o re tic  analysis o f the f ir s t  pool is shown on the le f t  
(non-reduced and reduced), and the analysis o f the second pool is shown on 
the r ig h t. The es tim a ted  m o lecu la r w eights o f the bands are shown. The band 
above the lig h t chain o f IgM has not been id e n tif ie d .
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conta ined IgM, and the second IgG. F (ab ')^ fragm ents o f the IgG pool bound 
to  FA and inh ib ited  the binding o f IgM -R F, Thus pools 1 and 2 were IgM and 
IgG -RF re sp ec tive ly .
SUM M ARY
In h ib ito ry  a c t iv ity  was iso la ted  fro m  RA serum and shown to  be a p rope rty  o f 
IgM -R F. A lthough IgM -R F accounted fo r  the m a jo rity  o f in h ib ito ry  a c tiv ity  in 
RA serum sm all amounts o f in h ib ito ry  a c tiv ity  were found associated w ith  
IgG -R F.
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SECTION 7
The fo llo w in g  section  describes studies in which the e ffe c ts  o f p u rifie d  IgM 
rheum ato id  fa c to r  and RA sera on PIP were com pared. These studies were 
undertaken in an a tte m p t to  dem onstra te  th a t the in h ib ito ry  a c t iv ity  present 
in RA sera could be explained on the basis o f th e ir  con ten t o f rheum ato id  
fa c to r.
Studies eva lua ting  the ro le  o f rheum ato id  fa c to r on the in h ib ition  o f PIP 
The expe rim en ta l methods used in the section can be found in M a te ria ls  and 
Methods (2.2.6, 2.2.15, 2.2.16).
Com parison o f the e ffe c ts  o f p u rifie d  IgM -RF w ith  whole RA serum on PIP 
P u rifie d  IgM -R Fs and the RA sera fro m  which they were prepared were 
su itab ly  d ilu ted  so th a t they conta ined id e n tica l concen tra tions o f IgM -R F. 
When tested  fo r  th e ir  a b ility  to in h ib it PIP, p u r if ie d  IgM -R F  was more potent 
than the same am ount o f IgM -R F conta ined in RA serum (F ig  3.15). N orm al 
IgM did not in h ib it PIP.
E ffe c t o f IqG -RF on PIP
N orm al m onom eric IgG did not in h ib it PIP. IgG -RF ( Im g /m l)  exh ib ited  a 
m oderate capac ity  (35.5% ± 2.5 SEM) to in h ib it PIP, as did the same
concen tra tion  o f F (ab ' ) 2  fragm ents  (26.7% ± 5.2 SEM).
K in e tics  o f in h ib ito ry  ac tion  (see 2.2.6).
When RA serum or IgM -R F (both conta in ing  5D00u R F /m l) were added to
norm al serum p rio r to  the add ition  of antigen and antibody (tim e  0) the 
in h ib ito ry  e ffe c t  was m ax im a l. When added a fte r  antigen and antibody the
Inh ib ito ry  e ffe c t  was less m arked. The m agnitude o f the e ffe c t dim inished
w ith  increasing tim e  a fte r  the add ition  of antigen and antibody (F ig  3.16)
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The e ffe c t  o f p u r if ie d  IgM -R F  and whole RA serum on PIP*
P u rif ie d  IgM -R Fs ( o ----- o )  and the h e a t- in a c tiv a te d  R A  sera ( #------ • )  from
w hich they were prepared were d ilu ted  so th a t they conta ined  Iden tica l
q ua n titie s  o f IgM -R F . The leve l o f in h ib itio n  produced by each is shown.
Each p o in t represents the mean and standard e rro r o f the mean o f three
p repara tions.
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Figure 3*16
K in e tics  o f p re c ip ita tio n  o f an tiqen-an tibody com plexes in the presence o f 
serum and IgM -R F
The e ffe c t o f adding h e a t- in a c tiv a te d  (H I) RA serum ( #-----# ) or IgM -R F
( o o ) a t d if fe re n t tim es a fte r  the m ix ing  o f antigen and antibody a t
equ iva lence. The ho rizon ta l line  ( - - - —) shows the low er l im it  o f the norm al 
range. Each p o in t represents the mean + SEM o f 3 experim ents.
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IgM-RF produced more inhibition than RA serum.
K in e tics  o f p re c ip ita tio n  o f an tiqen-an tibody com plexes in the absence o f 
serum.
When RF or h e a t-in a c tiva te d  RA serum (both a t 5000u/m i) v/ere present 
during the fo rm a tio n  o f complexes a t equivalence, the ra te  o f p re c ip ita tio n  
was increased (F ig  3.17).
C4 consum ption by complexes fo rm ed in the presence of RA serum and 
IgM -R F (see 2.2.15, 2.2.16).
Fo llow ing  the fo rm a tio n  o f an tiqen-an tibody com plexes in norm al serum, C4 
consum ption occurred (Table 3.3). Consumption o f C4 was reduced when 
complexes were fo rm ed  in the  presence o f RA serum, but not in the presence 
o f IgM -R F.
The re la tionsh ip  between IqM -R F and in h ib ito ry  a c t iv ity  (%)
The sera o f one hundred and f i f t y  seven pa tien ts  w ith  rheum ato id  a r th r it is  
were tested fo r  in h ib ito ry  a c t iv ity .  I t  can be seen (F ig  3.18) th a t the leve l o f 
in h ib ito ry  a c t iv ity  (% in h ib itio n  o f PIP) showed a poor co rre la tio n  w ith  serum 
levels o f IgM -R F . Many pa tien ts  w ith  very high levels o f IgM -R F  in th e ir  sera 
have low  leve ls o f in h ib ito ry  a c t iv ity  and vice versa.
SUM M ARY
P u rifie d  IgM -R F was found to  behave somewhat d if fe re n t ly  fro m  RA serum 
conta in ing  the same am ount o f IgM -R F in re la tio n  to  expression o f in h ib itio n  
o f PIP. This d iffe re n ce  was noted in k in e tic  studies and in C4 consum ption 
studies. P u rifie d  IgM -R F was more in h ib ito ry  than the same am ount of 
IgM -R F present in RA serum. IgM -R F and in h ib ito ry  a c t iv ity  were only poorly 
co rre la ted  when measured in a large group of p a tie n t sera.
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Figure 3.17
K in e tic s  o f p re c ip ita tio n  o f an tiqen-an tibody com plexes in the presence o f 
norm al serum , h e a t- in a c tiv a te d  R A  serum and p u r if ie d  IqM -R F
A n tigen -an tibody  com plexes were fo rm ed  a t equivalence in the presence of 
IgM -R F ( o o );
h e a t- in a c tiv a te d  R A  serum ( •  # );
norm al serum ( D - O  ) and
b u ffe r  alone ( X — K )•
The ra te  o f p re c ip ita tio n  of com plexes is shown. Each p o in t represents the 
mean (+5EM) o f 3 experim ents.
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Table 3.3
The e ffe c t o f IgM -R F and RA serum on the  consum ption of 
C4 by immune com plexes
U n its  C4^ 
pre I.C .
U n its  C4 
post I.C .
U n its  o f C4 
consumed
% C4
C o n s u m p tio n
NHS
NHS+IgM -RF
NHS+(HI)NHS
NHS+(HI)RA5
24160+2445 
24000+2788 
36053+1499 
30577+ 510
5660+141 
5120+152 
8830+537 
14709+252
18500+2340 
18880+2646 
28348+ 837 
15867+ 740
76.1+2.11
78.2±1,88
76.2+1.64
51.6+1.62
FlI = Heat in a c tiva te d  
NHS = N orm al human serum 
RF = R heum atoid fa c to r  
(HI)RAS= (H I) R heum atoid a r th r it is  serum 
*  = R e s u lts  re p re s e n t m ean + SEM o f th re e  e x p e r im e n ts
The am ount o f 0 4  consumed by immune com plexes was measured by com paring 
the q u a n tity  o f C4 in the reac tion  m ix tu re  before  and a fte r  incubation  (1 hour 
a t 37°C) w ith  imm une complexes form ed at equiva lence. 0 4  consum ption is 
expressed as a percentage of the s ta rtin g  value. Immune complexes consumed 
0 4  in com parable amounts in the presence o f NHS, NHS + RF, NHS + (HI) NHS. 
0 4  consum ption was reduced (51.6% + 1.62) in the presence o f (H I) RA serum.
THE RELATIONSHIP BETWEEN IgMRF and INHIBITORY ACTIVITY (%)
INHIDtTION{%)
100-1
40
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Figure 3.18
The relationship between IgM-RF and inhibitory activity (%)
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SECTION 8
The re la tionsh ip  between in h ib itio n  o f PIP and c lin ic a l aspects o f disease 
The p a tie n t groups studied in th is  section are de ta iled  in M a te ria ls  and 
Methods (2.1.4(a)(b)). PIP and PIP in h ib ito r levels were measured in serum and 
SF as prev ious ly  described. S ta tis t ic a l methods used are de ta iled  in M a te ria ls  
and Methods (2.3).
STUDY A
PIP and in h ib itio n  o f PIP in sera and synovial flu ids
P atien ts  in group A-1 com prised 15 patien ts  w ith  seropositive  R A , group A -II 
com prised 8 pa tien ts  w ith  RA who were seronegative fo r  IgM -R F and group 
A - I l l  com prised 6 pa tien ts  w ith  m iscellaneous a rth r it id e s . PIP (%) in group A-1 
sera was reduced m arked ly in 60% (9/15) o f pa tien ts , whereas only m inor 
reductions were observed in 2 o f 7 pa tien ts  in group A - I l (F ig 3.19). L ikew ise  
in h ib ito ry  a c t iv ity  was m arked ly e levated in group A -I pa tien ts  w ith  87% 
(13/15) having increased in h ib ito ry  a c t iv ity .  O f the 8 pa tien ts  in group A-11 
only one had a s ig n ific a n t leve l o f in h ib ito ry  a c t iv ity  in her serum and one 
p a tie n t in group A - l l I  w ith  p so ria tic  a r th r it is  had a m a rg in a lly  e levated leve l 
o f serum in h ib ito ry  a c t iv ity  a t 12% (Fig 3.19). PIP was reduced in the 
synovial flu id s  fro m  a ll 3 groups. The mean leve l o f IC which rem ained 
soluble in 5F of pa tien ts  in group A -I was s ig n if ic a n tly  low er (p <0 .01  ) than 
the mean leve l in group A -III.  The mean leve l in group A-11 did not d if fe r  
fro m  the mean of e ith e r group A-1 or group A - lI I  (F ig  3.20). Levels of 
in h ib ito ry  a c t iv ity  in SF fro m  group A -I were raised in a ll but one p a tie n t. 
The mean leve l (48% ± 7% SEM) was s ig n ific a n tly  h igher than the mean leve l 
o f in h ib ito ry  a c t iv ity  in group A - I l and A -III (20% ± 7% SEM p <  0.02) and 
12% + 6% SEM p <  0.01) resp ec tive ly . In h ib ito ry  a c t iv ity  was also seen in SF 
o f 6 o f 8 pa tien ts  in group A -II and 2 o f 6 pa tien ts  in group A-111, however, 
there  was no s ig n ific a n t d iffe re n ce  between the mean levels o f in h ib ito ry
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Figure 3.19
Study A : Serum (PIP) % (0) and in h ib itio n  o f PIP (%) (I) ( in h ib ito ry  a c t iv ity )  on 
y axis; in seropositive  RA (group A -I), seronegative RA (group A - I I )  and 
m iscellaneous a rth r it id e s  (group A -III) .
The h o rizo n ta l line  in each group represent the mean.
The short h o rizo n ta l lines above and below each mean represents 
the standard e rro r o f the mean (SEM)
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F igu re  3.20
Study A ; Synovial f lu id  PIP(%)(o) and in h ib itio n  o f PIP (% )(•) ( in h ib ito ry  
a c t iv ity )  on y axis; in seropositive  RA (Group A -I), seronegative  RA 
(Group A -II) and m iscellaneous a rth r it id e s  (Group A -III) .
The h o rizo n ta l lin e  in each group represents the mean. The short 
h o rizo n ta l lines above and below each mean represents the standard 
e rro r o f the mean (SEM).
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a c tiv ity  in the tw o  groups (F ig .3.20).
C o rre la tions  w ith  c lin ic a l indices of disease a c tiv ity
In group A -I the leve l o f PIP in the serum did not co rre la te  w ith  any o f the 
c lin ic a l or la b o ra to ry  param eters o f system ic disease a c t iv ity  which were 
exam ined. F u rthe rm ore  the re  was no co rre la tio n  between serum PIP and any 
of the indices o f loca l disease a c t iv ity  w ith in  the asp ira ted  jo in ts . The serum 
levels o f in h ib ito ry  a c t iv ity  o f group A -I pa tien ts  did not co rre la te  w ith  any 
o f the c lin ic a l or la b o ra to ry  indices o f disease a c t iv ity .
The leve l o f synovial f lu id  PIP in group A -I pa tien ts  showed a negative 
co rre la tio n  w ith  jo in t hypertrophy (r= -0.52, p <  0.05), and the leve l of 
in h ib ito ry  a c t iv ity  in SF co rre la ted  w ith  jo in t tenderness (r= 0.54, p <  0.04). In 
group A -II, the re  were no co rre la tion s  between SF, PIP or in h ib ito ry  a c tiv ity  
and the c lin ic a l param eters o f disease a c t iv ity .  In group A -II I  however 
p a tie n ts ' SF PIP showed a negative co rre la tio n  w ith  jo in t hypertrophy (r= 
-0.88, p < 0 .02 ). No o the r co rre la tions  were observed.
C o rre la tions  w ith  labo ra to ry  indices o f disease a c t iv ity
The only s ig n ific a n t co rre la tions  observed were in group A -I. The serum leve l 
of PIP co rre la ted  d ire c t ly  w ith  CH50 (r= 0.72, p <  0.002), and in d ire c tly  w ith  
the leve l o f IgM -R F in serum (r= -0.64, p<0 .01) and the leve l o f in h ib ito ry  
a c t iv ity  in serum (r= -0 .77, p <  0.002). The leve ls o f serum PIP and in h ib ito ry  
a c t iv ity  in any of the th ree  groups did not co rre la te  w ith  the levels in SF. (%) 
in h ib itio n  o f PIP did not co rre la te  w ith  IgM -R F levels.
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Study B
P atien ts  w ith  RA were d iv ided in to  3 groups. Group B -I com prised patien ts  
w ith  pure ly a r t ic u la r  R A. Group B -II com prised pa tien ts  w ith  RA and 
nodules and Group B - I I I  com prised pa tien ts  w ith  RA and vascu litis  (see 
M a te ria ls  and Methods (2.1.4(b)).
PIP and in h ib itio n  o f PIP ( in h ib ito ry  a c t iv ity )  in RA sera
Reduced PIP occurred in 7 o f 20 (35%) o f sera in group B -I, 15 o f 18 (82%) of 
group B -II and 18 o f 20 (90%) o f group B -III (F ig  3.21). L ikew ise  in h ib ito ry  
a c t iv ity  was m arked ly  e levated in group B -III pa tien ts  w ith  100% (20/20) 
having increased leve ls o f in h ib ito ry  a c t iv ity .  In add ition  a ll the pa tien ts  in 
group B -II had increased levels o f in h ib ito ry  a c t iv ity  w h ich  was also present in
15 of 20 (75%) of pa tien ts  in group B -I (F ig 3.22).
The mean leve l o f PIP in group B -III sera was s ig n if ic a n tly  low er than the 
mean leve l in group B-11 (p < 0 .0 5 ) and group B-1 pa tien ts  (p <0 .0001 ). The 
m ean le v e l in  g ro up  B - I I  was a lso  s ig n if ic a n t ly  lo w e r than  g roup  B-1 
(p < 0 .005). The mean leve l o f in h ib ito ry  a c t iv ity  in sera from  group B -IlI
(74% ± 5 SLM) was s ig n if ic a n tly  h igher than the mean leve l o f in h ib ito ry
a c t iv ity  in group B -II (60% ± 6 5LM ; p < 0 .0 5 ) and group B -I (38 ± 6 SEM; 
p <  0.0005). A s ig n ific a n t d iffe re n ce  was also observed between in h ib ito ry  
levels in groups B -I and B -II (p <  0.05).
In group B -I the leve ls o f PIP in the serum co rre la te d  inverse ly w ith  the 
IgM -R F (r= -0.58 p < 0 .0 1 ) and the in h ib ito ry  a c t iv ity  (r= -0.74,P <0.001). In 
the same group serum leve ls o f C3 and B showed a pos itive  co rre la tio n  w ith  
the levels o f in h ib ito ry  a c t iv ity  in the serum (r= 0.46, and r= 0.61 re spec tive ly  
(p < 0 .0 0 2  in both cases).
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F igure  3.21
Study B : Serum PIP ( % IC soluble) in RA w ith o u t nodules 
(Group B -I), w ith  nodules (Group B -II), and w ith  
va scu litis  (Group B -III)
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F igu re  3.22
Study B ; Serum in h ib ito ry  a c t iv ity  (% in h ib itio n  o f PIP) in RA 
w ith o u t nodules (Group B -I), w ith  nodules (Group B -II), 
and w ith  vascu litis  (Group B -III)
135
The only s ig n ific a n t co rre la tio n  in group B -II was an inverse re la tio n  between 
PIP levels and the IgM -R F concen tra tion  (r= -0.60, p<0 .01).
In group B -III the leve ls o f PIP co rre la ted  w ith  C4 leve ls (r= 0.73, p<0.002) 
(F ig  3.23) and inverse ly w ith  IgG-RF concen tra tions (r= -0 .63, p <0.005) (F ig 
3.24) and levels o f in h ib ito ry  a c t iv ity  (r= -0.80, p <  0.001). No co rre la tio n  was 
found between the in h ib ito ry  a c t iv ity  levels and the concen tra tions o f the 
IgM, IgG and IgA  RFs.
SUM M ARY
No co rre la tion s  were noted fo r  in h ib ito ry  a c t iv ity  and the rheum ato id  fa c to r  
isotypes IgM -R F , IgG -RF and IgA -R F . A lthough i t  was shown th a t p u rifie d  
IgM -R F does in h ib it PIP in v it ro  (see Results, Section 6) o the r fac to rs  present 
in whole serum appear also to  be im p o rta n t in m odu la ting  th is process, (see 
Results, Section 7 and Discussion, Section 7). I t  was th e re fo re  decided to 
a tte m p t the iso la tion  o f in h ib ito ry  a c tiv ity  by d if fe re n t p rocedu res ,from  RA 
serum. N orm al serum was used also as the s ta rtin g  m a te r ia l as i t  displayed a 
sm all bu t s ig n if ic a n t am ount o f in h ib ito ry  a c t iv ity  (see Results, Section 3).
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Study B : C o rre la tio n  o f serum PIP w ith  IgG -RF 
leve ls in Group B -III
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SECTION 9
Isolation of inh ib i to ry  a c t iv i ty  by sucrose gradient u l t ra c e n tr i fu g a t io n  and IgG 
Sepharose chromatography f ro m  normal serum and R A  serum.
Sucrose density gradient f ra c t io n a t io n  of normal serum and RA serum. 
The method used was tha t  described in de ta il in M a te r ia l and Methods (2.2.3).
The leve l of in h ib i to ry  a c t iv i ty  in the various frac t ions  is shown in Fig 3.25. 
In this experim ent ne ither of the s ta r t ing  sera (SM) (normal serum or RA 
serum) displayed inh ib i to ry  a c t iv i ty .  Flowever high levels o f inh ib i to ry  a c t iv i ty  
were found in frac t ions  2 and 3 o f both normal and RA serum. The peak 
inh ib i to ry  f ra c t io n  (No. 2) in both sera co-inc ided w ith  the IgM peak. A 
s im ila r  p ro te in  concen tra t ion  p ro f i le  across the frac t ions  and in the s ta r t ing  
sera was seen in normal serum and RA serum. Rose-Waaler p o s i t iv i ty  and 
IgM -RF a c t iv i ty  was most abundant in frac t ions  2 and 3 o f RA serum and in 
the RA serum s ta r t ing  m a te r ia l.  The frac t ions  f ro m  the normal serum did not 
conta in  IgM -RF.
Sucrose density gradient f ra c t io n a t io n  o f normal and rheum ato id  serum - the 
e f fe c t  of h e a t- in a c t iv t io n  (FII)
RA and normal sera were h e a t- in a c t iva te d  at 56°C fo r  30 minutes p r io r  to 
sucrose  d e n s i ty  g ra d ie n t  u l t r a c e n t r i f u g a t i o n .  The g ra d ie n t  p ro f i le s  f o r  
inh ib i to ry  a c t iv i t y  and IgM and IgG are shown in Fig 3.26. There was marked 
loss o f  inh ib i to ry  a c t iv i ty  in frac t ions  2 and 3 of norm al serum while  the 
inh ib i to ry  p ro f i le  in RA serum was essentia lly unchanged and indeed appears 
to be s l ig h t ly  more pronounced w ith  increases in frac t ions  1 and 3. It is worth  
noting tha t  inh ib i to ry  a c t iv i t y  could only be detected  in the RA serum 
fo l low ing  h ea t- inac t iva t ion .  The pro te in  concentra t ions and the rheum ato id  
fa c to r  p ro f i les  were both unchanged in the h ea t- inac t iva ted  frac t ions  o f  RA
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F igure  3.23
Sucrose density g rad ient u lt ra c e n tr i fu g a t io n  
o f normal serum (NHS) and rheum ato id  serum (RA).
Inh ib ito ry  a c t iv i ty  ( inh ib it ion  of PIP) is 
measured on the y axis (% inh ib it ion ).
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Figure 3.26
Sucrose density g rad ient u l t ra c e n tr i fu g a t io n  of 
h ea t- in a c t iva te d  (HI) serum.
SM “ s ta r t ing  m a te r ia l
NHS - N o rm a l human serum
RA - Rheumato id  a r th r i t is  serum
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serum.
The t i t r a t io n  o f in h ib i to ry  a c t iv i t y  in f ra c t io n  2 f rom  both normal serum and 
RA serum is shown in F ig  3.27. The s ta r t ing  p ro te in  concentra t ion  was 
adjusted so tha t  both were comparable. The nature o f the curves suggest tha t 
in h ib i to ry  a c t iv i t y  in normal and RA f ra c t io n  2 is found in s im i la r  quantit ies .
R econs t i tu t ion  of PIP
In these experim ents the peak inh ib i to ry  f ra c t io n  f ro m  the sucrose density 
gradients o f  normal and RA serum was mixed w ith  f ra c t ion s  1 , 3 , 4 ,  5 and 6 
and the leve l o f inh ib i to ry  a c t iv i t y  measured.
The method was as fo l lows:
The peak in h ib i to ry  f ra c t io n  f ro m  normal and RA serum was f ra c t io n  2. A 
row  o f 6 p las tic  Eppendorf tubes were set up on ice and 50jjl of f ra c t io n  2 
f rom  norm al serum was added. B u f fe r  (50pl PBS) was added to tube 1, and 
50jjl f rac t ions  of 1, 3, 4, 5 and 6 were added to  tubes 2, 3, 4, 5 and 6 
respec t ive ly .  The procedure was repeated w ith  the g rad ien t frac t ions  o f  the 
RA serum.
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Norm al Serum
Tube No Sucrose F ra c t ion  No. (50|j1)
2 + b u ffe r  (PBS 50|j1) 
2 + 1 
2 + 3 
2 + 4 
2 + 5 
2 + 6
RA Serum
Sucrose F rac t ion  No. (5Djjl) 
2 + b u f fe r  (PBS 50^1) 
2 + 1 
2 + 3 
2 + 4 
2 + 5 
2 + 6
A ll  tubes then rece ived 9pl normal serum, then 5|j1 anti-BSA antiserum 
(d ilu ted 1/3 in PBS) and 5pl  ^^^1-BSA at (100|jg/ml).
The contro ls  were (1) normal serum alone (9yl normal serum, IOOjjI PBS, 5pl
anti-BSA and 5pl ^^^I-BSA), (2) to ta l  ra d io a c t iv i ty  input (114|j 1 PBS and 5^1 
125 I-BSA), (3) ra d io a c t iv i ty  p rec ip i ta ted  by antibody in the absence o f serum
125
(PBS 109|j1, anti-BSA 5|j1, 5[j1 I-BSA). The to ta l  volume In each tube was 
119|^il.
A f te r  m ix ing , a ll tubes were incubated at 37°C fo r  1 hour. Fo llow ing this a 
50pl a liquo t was taken and trans fe rred  to  an Fppendorf tube conta in ing 1ml 
ice cold PBS. The tubes were cen tr i fuged  (Beckman M icro fuge) fo r  5 minutes 
and a 250jjl supernatant sample was taken from  each fo r  counting in the "y 
c o u n te r .  The p e rc e n t  in h ib i t o r y  a c t i v i t y  was c a lc u la te d  as d e sc r ibe d  
previously. (See section 2.2.1(b)).
It  can be seen (Fig 3.28) tha t when fra c t io n  2 was m ixed w ith  f ra c t io n  5 
inh ib i t ion  o f PIP did not occur.
%
IN H IB IT IO N
100 1
5 0 -
NHS
RA SERUM
28 4
RECIPROCAL DILUTION
Figure 3.27
T it ra t io n  of sucrose g rad ient f ra c t io n  number 2 
f ro m  rheum ato id  and normal serum fo r  inh ib i to ry  
a c t iv i ty  (% inh ib it ion ).
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Figure 3.28
R e cons t itu t ion  o f PIP
N = normal sérum
R = rheum ato id  serum
(HI) = h e a t- in a c t iva te d
(%) in h ib i t io n  o f PIP was measured in sucrose g rad ien t f ra c t ion s  f ro m  normal 
serum (NHS) and RA serum (RA). The numbers under each bar denote the 
sucrose g rad ien t f ra c t io n  numbers, showing which f ra c t io n s  were mixed in each 
sample.
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This reversal phenomenon was seen w ith  both normal and RA sera. This 
antagonistic  e f fe c t  of f ra c t io n  5 was abolished i f  f ra c t io n  5 was subjected to 
h e a t- in a c t iv a t io n .  When inh ib i to ry  f ra c t io n  2 from  norm al serum was mixed 
w ith  f ra c t io n  5 f rom  RA serum the recons t itu t ion  of PIP was much less. 
However, the antagonist to inh ib i to ry  a c t iv i ty  appeared to be more potent in 
f ra c t io n  5 from  normal serum when acting against the inh ib i to ry  a c t iv i ty  in 
RA f ra c t io n  2.
IgG Sepharose chromatography of inh ib i to ry  m a te r ia l  isolated f rom  sucrose 
density g rad ien ts , (see M ater ia ls  and Methods (2.2.3).
S m a ll (2 m l)  co lu m ns  c o n ta in in g  IgG Sepharose w e re  p re p a re d  and the  
inh ib i to ry  frac t ions  f rom  normal and rheum ato id  sucrose gradients ( f ra c t io n  2) 
were applied and washed through w ith  s ta r t ing  b u f fe r  (phosphate buffe red 
saline 0.15M; pH 7.4). The volume of the s ta r t ing  m a te r ia l  was 1.5mls and the 
pro te in  concen tra t ion  as measured by OD^gg was 350pg/ml fo r  normal 
f ra c t io n  2 and 890 jjg /m l fo r  RA fra c t io n  2. These s ta r t ing  m ater ia ls  were 
dialysed against the s ta r t in g  b u f fe r  (PBS, pH 7,4) p r io r  to  app lica tion  to the 
column. A f te r  app lica tion  the column was washed through w ith  5 column 
volumes (10ml) s ta r t ing  b u f fe r  to ensure a ll unbound pro te in  was washed 
through. The bound pro te in  was e luted in two steps:
1. Ü.4M NaCl (5 column volumes, 10mls)
2. 2M guanidine hydroch loride (5 column volumes, 10mis)
1ml frac t ion s  were co l lec ted . A l l  f rac t ions  were ex tens ive ly  dialysed against 
PBS pH 7.4 and were then screened ind iv idua lly  fo r  in h ib i to ry  a c t iv i ty  (%) and 
rheum ato id  fa c to r  (Rose-Waaler t i t ra t io n )  (Fig 3.29(a)(b)). The vast m a jo r i ty  
of inh ib i to ry  a c t iv i t y  bound to IgG Sepharose both in normal and rheum ato id  
serum and was e luted by 2M guanidine hydroch loride or 0.4M N aC I (Fig
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Figure 3.29(a)
R e p re s e n ta t iv e  c h ro m a to g ra m  IgG Sepharose c h ro m a to g ra p h y  o f sucrose  
g rad ien t f ra c t io n  number 2 f ro m  RA serum.
1 = Q.4M NaCl e lu tion
2 = 2M guanidine e lu tion
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Figure 3.29(b)
R e p re s e n ta t iv e  c h ro m a to g ra m  IgG Sepharose c h ro m a to g ra p h y  o f sucrose  
g rad ien t f ra c t io n  number 2 f ro m  normal serum.
(OD 280----- ) 1 = Ü.4M NaCl e lu tion
2 = 2M guanidine e lu tion  
% Inh ib it ion  o f PIP ( inh ib i to ry  a c t i v i t y ) -----------
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3.29(a)(b)). In the rheum ato id  column IgM -RF was found in the pro te in  peak 
eluted w ith  2M guanidine hydroch loride. In the normal serum column most of 
the in h ib i to ry  a c t iv i t y  was e luted w ith  0.4M sa lt (Fig 3.29(b)) but in the RA 
serum column most o f the inh ib i to ry  a c t iv i ty  resided in the 2M guanidine 
eluted peak.
Pro te in  analysis (see M a ter ia ls  and Methods (2.2.12)
The p ro te in  fra c t ion s  e luted f rom  the IgG Sepharose columns described above 
were tested ind iv idua lly  fo r in h ib i to ry  a c t iv i ty .  For RA f ra c t io n  2 th is 
inh ib i to ry  a c t iv i t y  was found in the frac t ions  e luted w ith  0.4M NaCl and to a 
much g rea te r  ex ten t in the frac t ions  e luted w ith  2M guanidine hydroch loride. 
These in h ib i to ry  f rac t ion s  were pooled separately so tha t  tw o  inh ib i to ry  pools 
were made, v iz . a 0.4M NaCl e luted in h ib i to ry  pool and a 2M guanidine eluted 
inh ib i to ry  pool. L ikew ise  tw o  inh ib i to ry  p ro te in  pools (0.4M NaCl e luted and 
2M guanidine eluted) were made fo r  the normal serum f ra c t io n  2 IgG 
Sepharose column.
The fou r p ro te in  pools were concentra ted by f reeze -d ry ing  and subsequently 
were recons t i tu ted  in a small volume o f PBS pFl 7.4 p r io r  to being analysed 
by SD5-PAGE, The method fo r  SDS-PAGE analysis is described in M ater ia ls  
and Methods, Section (2.2.12). The concentra ted p ro te in  pools were analysed 
by SDS-PAGE under reducing and non-reducing condit ions. The tube gels were 
stained w ith  Coomassie blue and a m o lecu lar we ight standard was run under 
s im i la r  condit ions. The gel p ic tures o f the p ro te in  pools showing the greatest 
amount of in h ib i to ry  a c t iv i t y ,  RA serum and normal serum, are shown in Figs 
3.30 and 3.31. The pro te in  eluted w ith  0.4M NaCl f rom  IgG Sepharose 
chromatography o f normal serum f ra c t io n  2 contained most of the inh ib i to ry  
a c t iv i ty .  I t  can be seen th a t  there are several high MW bands and a band at 
a p p ro x im a te ly  60 kD , w h ic h  was no t re d uce d  w i t h  5 - m e rc a p to e th a n o l .
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The intensely inh ib i to ry  pro te in  pool e luted w ith  2M guanidine hydrochloride 
from  IgG Sepharose chromatography of RA serum f ra c t io n  2 contained large 
amounts of IgM -RF as tested by Rose-Waaler and ELISA. The gel p ic ture  
shown in F ig 3.31 demonstrates the pro te in  cons t i tu t ion  of this pool. In the 
non-reduced gel there  are tw o  bands, high and low MW. The high MW band 
represents IgM -RF and reduces to heavy and l ig h t  chains of IgM respective ly . 
The lower MW band (approx 60 kD) was not reduced under these conditions.
SUM M ARY
Inh ib ito ry  a c t iv i ty  has been shown to be present in norm al serum as w e ll as 
RA serum. The expression of in h ib i to ry  a c t iv i ty  appears to be contro lled  by 
o th e r  (as y e t  unkn ow n) se rum  fa c to r s  w h ic h  a n ta g o n is e  the  in h ib i t o r y  
molecule. P u r i f ic a t io n  o f the inh ib i to r  of PIP f rom  normal and RA serum 
(using sucrose gradient separation and subsequent a f f in i t y  chromatography) has 
re v e a le d  the  p resence  o f  a 60kD  m o le c u le  in a d d i t io n  to  Ig M -R F  on 
SDS-PAGE.
2 3 4
I
Figure 3.30
SDS-PAGE. Inh ib ito ry  p ro te in  pools from  IgG Sepharose chrom atography of 
sucrose g rad ien t f ra c t io n  2. Gels 1 and 2 are from  normal serum (reduced and 
non-reduced respective ly ). Gels 3 and 4 are f ro m  rheum ato id  serum 
(non-reduced and reduced respective ly ).
m*
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Figure 3.31
S D S -P A G E . IgG Sepharose c h ro m a to g ra p h y  o f  suc rose  g ra d ie n t  i n h ib i t o r y  
f ra c t io n  2 from  RA serum. 2M guanidine hydroch loride e luted 
inh ib i to ry  pool.
1 = non reduced
2 = a f te r  reduction  w ith  5-mercaptoethanol.
The pro te in  band at MW rv /  60,000 Daltons is c lea r ly  seen.
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CHAPTER FOUR
DISCUSSION
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In this Chapter I w i l l  discuss my c l in ica l and experim en ta l work the results of 
which have been presented in the preceding Chapter (3). Each Results Section 
w i l l  be d iscussed  s e p a ra te ly  and w i l l  f o l lo w  the  same sequence as in 
Chapter 3.
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SECTION 1
The e s ta b l is h m e n t  o f  an assay to  m easure  the  c o m p le m e n t -m e d ia te d  
prevention  of immune p re c ip i ta t io n  (PIP) in human serum.
The estab lishment of an assay to measure prevention o f immune p rec ip i ta t ion  
has been described. The method was based on the assay described by 
S ch i f fe r l i  and colleagues (1980). The immune complexes used were form ed at 
equivalence. The equivalence point had previously been determ ined by a 
standard q u a n t i ta t ive  p re c ip i ta t io n  curve as described in (2.2.1) and Fig 2.1. 
This was con f irm ed  when complexes which were fo rm ed in b u f fe r  alone were 
shown to qu ick ly  p re c ip i ta te ,  a lmost com p le te ly  by 15 minutes. In contrast 
complexes fo rm ed in normal serum remained soluble; over 80% of complexes 
were re ta ined in so lu tion  at 1 hour (Fig 3.1). As expected seria l d i lu t ion  of 
normal serum was accompanied by a rapid decline in the capac ity  of serum to 
re ta in  complexes in so lution. The findings tha t  serum t re a ted  w ith  EOT A and 
serum which had been h e a t- ina c t iva ted  (56°C fo r 30 m inutes) were unable to 
prevent immune p re c ip i ta t io n  support the v iew tha t  PIP depends upon the 
complem ent system.
The im portance of the classical pathway in PIP was shown by the observations 
tha t in serum d e f ic ie n t  in C2 and C l - in h ib i to r  most of the complexes 
p rec ip i ta te d .  The p re c ip i ta t io n  o f complexes in C2 d e f ic ie n t  serum was slow 
and incom plete  and was s im i la r  to  tha t seen in C 1 - in h ib i to r  d e f ic ien t  serum. 
The C l - in h ib i t o r  d e f ic ie n t  serum was depleted o f C4 and C2, leaving C l  
in tac t .  I t  has been shown tha t  pu r if ied  C l  slows immune p re c ip i ta t io n  
(S ch if fe r l i ,  e t  al, 1982 ; Naama e t al, 1984 ) so i t  is probable tha t  in tac t  C l  
in these sera was responsible fo r  this e f fe c t .  In Mg EGTA trea ted  serum, 
which prevents classica l pathway a c t iva t ion  but allows a l te rna t ive  pathway
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f u n c t io n ,  th e re  was a c o n s id e ra b le  im p a i r m e n t  o f  P IP w i t h  m a rke d  
p re c ip i ta t io n  o f complexes. However p re c ip i ta t ion  was not complete  and the 
degree o f  p re c ip i ta t io n  leve lled out a f te r  30 m inutes incubation. This fa i lu re  
of com plete  p re c ip i ta t io n  may be due to so lubil isa tion  of the p rec ip i ta ted  
immune complexes by the  a lte rna t ive  pathway.
In C 1 - in h ib i to r  d e f ic ie n t  serum C4 and C2 ac t iva t io n  occurs and the re fo re  
patients w ith  C1 - in h ib i to r  de fic iency  o ften  have reduced levels of C4. C4 
defic iency is s trong ly  associated w ith  an "SLE l ike  syndrome" suggesting tha t  
C4 is im p o r ta n t  in immune complex processing. In the se tt ing  of PIP absence 
of C4 would prevent the fo rm a tion  of a C3 cleaving enzyme, (th is is also the 
case fo r  C2). C 1 - in h ib i to r  d e f ic ien t  patients although o ften  having reduced C4 
levels do not appear to  be as prone to the "SLE l ik e "  il lness which is seen in 
C4 d e f ic ien t  patien ts  although an increased incidence o f  immune complex like 
diseases is seen in C 1 - in h ib i to r  de f ic ien t  patien ts . Therefore  i t  fo l lows tha t  
what C4 there is in C 1 - inh ib ito r  de fic iency i t  is obviously enough to fo rm  a 
C3 cleaving enzyme. In C ' l - in h ib i to r  de fic iency  com plem ent a c t iva t ion  occurs 
spontaneously in the f lu id  phase; the presence o f C 1 - in h ib i to r  allows fo r  the 
complem ent a c t iva t io n  to occur on the immune com plex the re fo re  a llow ing 
PIP to proceed norm a lly .
P a r t ia l p re c ip i ta t io n  in the Mg EGTA serum and B-deple ted serum showed the 
im portance of the a l te rna t ive  pathway in the PIP process. In Mg EGTA and B 
depleted serum fu l l  p re c ip i ta t io n  of the complexes was not observed and the 
complexes did not p re c ip i ta te  fu l ly  even a f te r  1 hour o f incubation. The 
in i t ia l  fas t aggregation o f complexes seen in the presence of Mg EGTA 
(S ch if fe r l i  e t  al, 1982) was not seen in my experim ents but this may have 
been missed because my f i r s t  sample was taken at 15 m inutes a f te r  m ix ing  
whereas the in i t ia l  fas t aggregation described by the above workers tended to
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occur p r io r  to  th a t  t im e . In B -d e p le te d  serum (deprived of a lte rna t ive  
pathway function) p re c ip i ta t io n  is delayed, but s low ly  over an hour the 
immune p re c ip i ta te  was seen to fo rm  (Fig 3.1).
These results are in agreement w ith  those o f  (S c h if fe r l i  e t  al, 1980) who 
showed tha t  the ear ly  events in PIP are m ediated by the classical pathway 
and the la te r  events by the a lte rna t ive  pathway.
A f te r  establishing an assay fo r  the measurement o f  PIP in serum, a normal 
range was established using 25 normal sera. In these sera PIP was never below 
83%. Sera in which PIP was less than 83% were considered to show reduced 
PIP a c t iv i t y .  The re p ro d u c ib i l i ty  of the assay was acceptab le  w ith  a day to  
day va r ia t ion  o f  between 1% - 10%. The a b i l i ty  o f the serum to w ithstand 
repeated freeze thaw ing  showed tha t  PIP was not l ik e ly  to be a d i f f i c u l t  
phenomenon to measure and allowed me to be con f iden t in assaying routine  
c l in ica l samples fo r  PIP where delays in transport  are sometimes inev itab le . 
Q u a l i t y  c o n t r o ls  w e re  in c lu d e d  in  e ve ry  run  o f  se rum  sam p les  w h ic h  
strengthened the v a l id i ty  of the assay.
SECTION 2
M e a s u re m e n t  o f  p re v e n t io n  o f  im m u n e  p r e c ip i t a t i o n  in  p a t ie n ts '  se ra .
PIP was m ea su red  in an u n s e le c te d  g roup  o f  p a t ie n ts '  sera us ing  the  
previously described assay. The patien ts  were grouped only according to 
disease. The unexpected f ind ing  of reduced PIP in nearly  50% of pa tien ts  w ith  
RA ce r ta in ly  warran ted  closer sc ru t iny . Several pa tien ts  w ith  SLE and GN 
also had reduced PIP levels. The most obvious reason fo r  this im pa irm en t o f  a
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com plem ent dependent func t ion  was hypocomplem entaem ia, a fea tu re  which is 
no t  u n c o m m o n  in  p a t ie n ts  w i t h  these  c o n d i t io n s .  H o w e v e r ,  when those  
hypocom plem entaem ic sera were excluded there s t i l l  remained 25 RA sera, 3 
GN sera and 5 SLE sera which showed reduced PIP. The only idea which
would s a t is fa c to r i ly  explain these findings would be the presence o f inh ib i to ry
fac to rs  in these pa t ien ts ' se ra ,w h ich  were in some way in te r fe r in g  w ith  this 
com plem ent mediated func t ion . I t  is possible th a t  the in h ib i to ry  fa c to r  could 
be the same in the three diseases studied (RA, SLE, GN) but on the other
hand more than one fa c to r  could be involved. The fa c t  th a t  only seropositive
RA patien ts  seemed to  have reduced PIP argued th a t  IgM -RF may be the 
responsible fa c to r  at least in RA, but high levels o f IgM -RF are not 
frequen t ly  found in SLE and are rare in GN. 1 did not measure IgM -RF in my 
SLE or GN patien ts . A l l  these diseases may be associated w ith  c ircu la t in g  
immune complexes (Theofilopoulos &  Dixon, 1980) but the presence of immune 
complexes causing com plem ent consumption and thereby reducing PIP would 
be re f le c te d  in reduced com plem ent levels but these sera o f  course o ften  had 
normal or even e levated com plem ent levels (F ig 3.3 a and b). There was a 
co rre la t ion  between serum PIP, CH50 and APH50 in patien ts  w ith  RA and 
SLE (Fig 3.3 and 3.4). This implies th a t  levels o f CH5G and APH5Ü regulate  
PIP, and th is  may occur through the C3 leve l common to both these 
pathways.
H y p o c o m p le m e n ta e m ic  sera ( re d u ce d  C H 50) a lw a ys  had re duced  PIP in 
pa tien ts  w i th  RA although there  were a few  patien ts  w ith  reduced APH50 
who had normal levels of PIP, thus dem onstra ting  tha t  the a lte rna t ive  
pathway, in contras t to  the classical pathway, was not essential fo r  normal 
PIP. In pa tien ts  w i th  SLE (Fig 3.4) CH50 was more c losely re la ted  to  the 
level o f  PIP observed than the APH50 in these patien ts . C om plem ent studies 
were not perfo rm ed  on my normal contro ls  and the re fo re  I cannot com m ent
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on the relationship of PIP with haemolytic complement in normal sera.
Studies using the model of com plem ent mediated so lub il isa tion  o f p re fo rm ed 
prec ip i ta tes  have shown reduced so lubil isa tion  in the m a jo r i ty  o f SLE sera 
(Baatrup e t al, 1983, 1984; Aguado e t al, 1981; Sakurai et al 1982; S ch i f fe r l i  
et al, 1981). In these studies low levels o f com plem ent components were 
genera lly  associated w ith  the reduced so lub il isa tion  seen in SLE sera. However 
the studies o f  Baatrup and colleagues (1984), pointed to the existence of 
in h ib i to ry  fac to rs  in SLE sera which could in part be responsible fo r  the low 
levels o f  so lub il isa tion  seen. Using an inh ib it ion  o f  so lub il isa tion  assay he 
sugges ted  th a t  in c o m p le te ly  s o lu b i l is e d  im m un e  c o m p le x e s  may be the  
inh ib i to ry  fac to rs  in SLE sera (Baatrup et al, 1984). Measurement o f immune 
complex levels in RA sera could a llow  one to  assess the re la t ionsh ip  between 
c ircu la t in g  immune complexes and levels o f PIP in h ib i to ry  a c t iv i t y  and 
IgM -RF but to  date such studies have not been perfo rm ed.
B a les tr ie r i  and colleagues (1983) studying PIP in SLE sera noted tha t  5 out of 
9 sera of pa tien ts  w ith  ac tive  SLE had reduced PIP compared w ith  only 1 
f rom  44 patien ts  w i th  inac tive  disease. He however, re la ted  this im pa irm en t 
o f PIP to low C4 levels. He did suggest, although based on very small 
numbers o f abnormal SLE sera, tha t  o ther fac to rs  besides reduced C4 may be 
responsible fo r  the im pa irm en t o f PIP seen in these sera. He mainta ined tha t 
rheum ato id  fa c to r  may be im po rtan t ,  although no evidence was presented to 
show tha t these SLE sera conta ined rheum ato id  fa c to r  (B a les tr ie r i ,  Pagani & 
Tincani, 1983).
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SECTION 3
E s ta b l is h m e n t  o f  an assay to  m easure  in h ib i t o r y  a c t i v i t y  in  se rum  
The presence o f  an in h ib i to r  o f PIP in RA serum was demonstrated by the 
f ind ing  o f a dose dependent reduction  o f  PIP level when RA serum was added 
to normal serum (Fig 3.5). In this experim ent the assay to  measure PIP was 
perfo rm ed (as deta iled  in Results, Section 3) in which R A  serum was added to 
normal serum and immune complexes were fo rm ed in th is  m ix tu re .  In the tube 
conta in ing norm al serum and undilu ted RA serum there  was a to ta l  abrogation 
o f normal serum PIP. This e f fe c t  became less marked as the RA serum was 
d ilu ted out. The only explanation fo r  this f ind ing  was tha t  the RA serum 
contained an in h ib i to r  o f PIP. This inh ib i to ry  phenomenon was found to a 
vary ing degree in o the r RA sera tested in this way. Inh ib ito ry  a c t iv i t y  was 
expressed as the  percent reduction  of PIP of normal serum when RA serum 
was added.
In order to  op tim ise  the condit ions under which in h ib i to ry  a c t iv i t y  in RA sera 
could be measured the PIP assay was m od if ied  to  make i t  more sensitive to 
small amounts o f  in h ib i to ry  a c t iv i ty .  The basic concept behind the assay to 
measure inh ib i t ion  of PIP was to  be able to dem onstra te  tha t the sample 
under tes t could reduce the amount of PIP due to the normal serum in the 
test tube. I f  there was too much normal serum in the tube, and the re fo re  
very high levels o f PIP (eg 100%), then small amounts o f in h ib i to ry  a c t iv i ty  in 
the tes t sample would not be detected. PIP in normal serum is dose dependent 
(Fig 3.1(b)) and the re fo re  small amounts o f inh ib i to ry  a c t iv i t y  in the test 
sample are more l ik e ly  to  be detected  i f  i t  is opera tive  on the steep part of 
the curve (Fig 3.1(b)). This was achieved by (1) reducing the load of immune 
complexes in the assay (2) by t i t r a t in g  the normal serum to  give between 70% 
- 80% PIP. Therefore  the immune complex load was reduced from  1.75 pg
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BSA fo r  the PIP assay to 0.5|jg BSA fo r the inh ib i t ion  of PIP assay. Immune 
complexes were s t i l l  prepared at equivalence. There fo re  using th is immune 
complex load the normal serum was t i t ra te d  to f ind  tha t  d i lu t ion  which gave 
70% - 80% PIP and th is  was used in the assay to  measure inh ib i t ion  o f PIP. 
These manoeuvres meant tha t i t  was much easier to  dem onstra te  in h ib i to ry  
a c t iv i t y  than i t  would have been w ith  a higher immune complex load and less 
d ilu te  serum.
The in h ib i to ry  e f fe c t  became more pronounced fo l lo w in g  h e a t- in a c t iv a t io n  of 
the RA serum showing tha t  the fa c to r  was heat stable (56"C fo r  30 minutes). 
H e a t- in a c t iva t io n  only destroys C l ,  C2 and fa c to r  B o f  the components which 
are involved in PIP. Therefore  one is in e f fe c t  adding among others C4 and 
C3. There fo re  one would expect th a t  PIP m igh t be increased in sera w ith  high 
levels o f C3 and C4. However, PIP in RA sera has been shown to co rre la te  
poorly w ith  C3 and C4 levels (Naama et al, 1983). There fo re  fo r  PIP to occur 
i t  appears to  be re la ted  to  com plem ent ac t iva t io n  and the  generation o f C3 
convertase and th is  would only be supplied by the normal serum in the test 
tube. There fo re  one would expect to  see increased in h ib i to ry  a c t iv i t y  in 
h ea t- inac t iva te d  serum.
Another possible reason why hea t- in a c t iva t io n  "re leased" more in h ib i to ry  
a c t iv i t y  could be th a t  the expression of the in h ib i to r  is modulated by some 
unknown antagonist. This question, in te res t ing ly ,  w i l l  be raised again based on 
the results recorded in Section 9 of Chapter 3.
When establishing my normal range fo r  inh ib i t ion  o f  PIP a small amount of 
inh ib i t ion  o f PIP was observed in normal serum a f te r  h e a t- in a c t iva t io n .  This 
can only be explained by the presence o f inh ib i to ry  m a te r ia l  in normal serum 
being added to the  system. I t  is w o rth  bearing in m ind tha t  the amount of
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in h ib i to ry  a c t iv i ty  generated from  normal serum ^  5% may be a t t r ib u te d  to 
the inherent e rro r  in any b io log ica l assay (up to 10%). However the f inding of 
in h ib i to ry  a c t iv i t y  in sucrose gradient f ra c t io n  2 of normal serum (see 
Chapter 3, Section 9 and Chapter 4, Section 9) provides f i rm  evidence o f  a 
normal serum fa c to r  which inh ib its  PIP.
SECTION 4
Measurement o f inh ib i t ion  of PIP in pa tien ts ' sera
Inh ib it ion  o f PIP a c t iv i t y  ( inh ib i to ry  a c t iv i ty )  was measured in both serum and 
synovial f lu id  (SE) of patien ts  w ith  a va r ie ty  o f rheum atic  diseases. In 25 
normal ind iv iduals in h ib i to ry  a c t iv i t y  did not exceed 5% as noted in the 
previous study (see Section 3 of this chapter). Sera f ro m  patien ts  w ith  
seronegat ive  a r t h r i t i s  ( s e ro n e g a t iv e  R A , a n k y lo s in g  s p o n d y l i t is ,  p s o r ia t ic  
a r th r i t is )  conta ined l i t t l e  or no inh ib i to ry  a c t iv i ty .  I t  is quite  c lear (F ig 3.6) 
tha t the highest levels of in h ib i to ry  a c t iv i ty  are found in seropositive RA 
sera.
The synovial f lu id  was obtained f rom  13 patients w ith  sero-pos it ive  RA. A l l  
SFs measured showed evidence of inh ib i to ry  a c t iv i t y  ranging from  26% to 
93%. Inh ib ito ry  a c t iv i t y  in SF may be due to fac to rs  o the r than those which 
are present in RA sera. For instance, chondro it in  sulphate binds to C lq  and 
inh ib its  its  a c t iv i t y  (S ilvestr i e t al, 1981). As ca r t i la ge  degradation occurs in 
RA chondro it in  sulphate must be released in to  the synovial f lu id .  However, 
subsequent studies showed tha t  the inh ib i to ry  fa c to r  binds to IgG and not to 
C lq  (Chapter 3, Section 6). F u rthe r evidence tha t  in h ib i t ion  o f  PIP was not 
due to a p e cu l ia r i ty  o f SF was obtained from  the experim ents described in
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C h a p te r  3, S e c t io n  8, w h ic h  showed th a t  SF f o r  some p a t ie n ts  w i t h  
seroposit ive RA (1 sample), seronegative RA (2 samples) and miscellaneous 
a r th r i t id es  (3 samples) were non - inh ib ito ry  (see F ig  3.20).
There was no re la t ionsh ip  between the level o f in h ib i to ry  a c t iv i ty  in serum 
and SF, although the mean levels were comparable. Scru tiny o f F ig 3.7 shows 
th a t  m any  se rum  sam p les  d is p la y e d  less in h ib i t o r y  a c t i v i t y  than  t h e i r  
corresponding SF sample but also tha t  there were some serum samples which 
had greate r amounts of in h ib i to ry  a c t iv i ty  than th e ir  corresponding SF sample. 
It  does suggest tha t  serum and SF behave independently as regards the 
expression o f in h ib i to ry  a c t iv i ty  and tha t loca l fac to rs  in the jo in t  are 
probably im p o r ta n t  in the f in a l expression of inh ib i to ry  a c t iv i t y  in this 
env ironm ent. I f  only one type of molecule is responsible fo r  inh ib i to ry  a c t iv i ty  
i t  does suggest th a t  loca l production  in the jo in t  is occurr ing  or tha t other 
fac to rs  in the rheum ato id  jo in t  eg immune complexes may be modulating the 
f in a l expression o f  the in h ib i to ry  a c t iv i ty  found in SF.
U s ing  the  m o d e l o f  c o m p le m e n t  m e d ia te d  s o lu b i l i s a t io n  o f  p re fo rm e d  
p rec ip i ta tes  Dayer and colleagues (1983) examined R A serum and SF fo r  
so lub il isa tion  a c t iv i t y .  He found immune complex so lub il isa tion  capac ity  to be 
reduced in RA SFs and re la ted  this to low levels o f SF a lte rna t ive  pathway 
haem o ly t ic  com plem ent. However, these workers suggested tha t  o ther fac to rs  
in SF (eg a n t ig lo b u l in s  or im m u n o c o n g lu t in in )  m ig h t  in f lu e n c e  the  
so lub il isa tion  process. Their experim ents also showed tha t  fac to rs  present in 
SF could in te r fe re  w i th  the capac ity  of fresh normal serum to solubilise 
immune complexes. A ro le  fo r  IgM -RF in this process was suggested (Dayer et 
al, 1983). A lthough the so lub il isa tion  of a p re fo rm ed  p re c ip i ta te  is d is t in c t  
f rom  PIP some s im i la r i t ie s  do exist (S ch if fe r l i  e t al, 1982). PIP is absolutely 
dependent on the classica l pathway while  so lub il isa tion  depends on an in tac t
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a lte rna t ive  pathway. However, so lub il isa tion  works in e f f ic ie n t ly  in the absence 
of an in tac t  c lassical pathway. Therefore  the in h ib i to ry  substances in SF (to 
so lub il isa tion  and PIP) may be the same and act through the common features 
of both processes. In o ther words, i f  an inh ib i to ry  substance was acting via 
classical pathway functions th is  would be apparent as an im pa irm en t o f PIP 
(as described above), and so lub il isa tion  would be in e f f ic ie n t  because o f lack of 
classical pathway co n tr ibu t io n  to the process.
SECTION 5
Studies on the mechanism o f ac tion  o f an in h ib i to r  of PIP in serum and 
synovial f lu id  (SF)
Studies on the k ine tics  o f inh ib i t ion  of PIP showed tha t  fo r  m axim al e f fe c t  
i n h ib i t o r y  a c t i v i t y  m u s t be p re s e n t  a t  the  t im e  o f  f o r m a t io n  o f  the  
antigen-antibody complex (Fig 3.9) and tha t  the e f fe c t  diminishes w ith  t im e  
a f te r  the onset of the fo rm a tion  of the immune complex. When this study was 
perfo rm ed using in h ib i to ry  synovial f lu id  a s im i la r  p a t te rn  was seen, a f ind ing  
which supports the v iew tha t  the nature of the in h ib i to ry  molecule(s) is the 
same in serum and SF. This pa tte rn  of k ine tic  behaviour (Fig 3.9) where the 
m ax im a l in h ib i to ry  e f fe c t  was seen a t the onset o f the reaction  suggests a 
d ire c t  e f fe c t  o f the in h ib i to ry  molecule(s) on the antigen-an tibody complex at 
the t im e  oF its fo rm a t io n  or on the com plem ent system ra the r than an e f fe c t  
on the complexes conta in ing  bound complem ent components. This tends to 
exclude a ro le  fo r  imm unocong iu tin ins in inh ib i t ion  o f PIP. I f  immuno- 
conglutin ins were responsible fo r  inh ib i t ion  o f PIP then one would expect 
them to work even when the complex has been rendered soluble which c lea r ly  
was not the case.
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Inh ib ito ry  a c t iv i t y  could be achieved by a number o f mechanisms up to the 
im po rta n t  step o f C3 ac t iva t io n  and binding to  the complex. The in h ib i to r  
could prevent C1 binding to  antibody, prevent C1 a c t iva t io n  or could prevent 
C1 ac t iva t in g  C4 or C2. An inh ib i to r  could also act by inh ib i t ing  the binding 
of C4b to the immune complex, or the binding o f  C2 to C4b. I t  could bind to 
the C3 convertase (C42) and reduce its  a c t iv i ty  by b locking its  a c t ive  s ite . An 
inh ib i to r  could also ac t by preven ting  C3 being c leaved by C3 convertase and 
it  could also ac t  by preventing  C3b binding to the complex e ithe r by binding 
to C3b i ts e l f ,  or binding to the complex. An in h ib i to r  of PIP could also act 
by a c t iva t in g  the com plem ent system d ire c t ly  and causing inappropria te  
c o m p le m e n t  a c t i v a t io n  in the  f lu id  phase. In a p p r o p r ia te  c o m p le m e n t  
ac t iva t io n  would occur when the serum contained c ircu la t in g  antigen-antibody 
complexes which were s t i l l  capable of causing com plem ent ac t iva t ion ,  and 
s u f f ic ie n t  in concen tra t ion  to a c t iva te  the m a jo r i ty  o f  the C4 and C3, and 
thus such sera  w o u ld  p ro b a b ly  be h y p o c o m p le m e n ta e m ic .  In o rd e r  to  
d isc r im ina te  amongst these possib il it ies C4 consumption fo l low ing  the addit ion 
of complexes to  sera and synovial f lu ids was examined. The f ind ing  th a t  sera 
and synovial f lu id  from  RA patients w ith  subnormal PIP showed reduced C4 
consumption (Table 3.2) favours one o f the f i r s t  th ree  explanations advanced 
above as w e ll  as the mechanism of inh ib it ion  of C4 cleavage by C l ,  ie .  C1 
binding and/or ac t iva t io n  is reduced. The f in a l explanation would require  
excessive C4 consumption fo r  va lida tion . I f  any of the o ther explanations was 
co rre c t  C4 consumption would be normal. The negative co rre la t ion  between 
C4 consumption and the degree o f inh ib it ion  o f  PIP and the d ire c t  co rre la t ion  
b e tw e e n  C4 c o n s u m p t io n  and the  degree  o f  P IP (F ig  3.8) s u p p o r t  the  
conclusion th a t  the fa c to r  in RA sera which inh ib its  PIP acts by inh ib i t ion  of 
com plem ent a c t iva t io n .
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Two more recen t reports  have produced evidence to  support th is mechanism. 
Measuring the uptake o f rad io labelled C1q by both aggregated IgG and 
B S A /an t i-B S A  complexes in the presence or absence o f rheum ato id  fa c to r ,  
O 'Sullivan and her colleagues were able to show th a t  p re incubation of 
complexes w ith  rheum ato id  fac to rs  lead^ to  inh ib i t ion  o f rad io- labe lled  C1q 
uptake (O ’Sullivan et ai, 1987), They also reported  a s ig n if ican t  negative 
co rre la t ion  between the inh ib i t ion  of C lq  uptake and the binding o f IgM -RF. 
I t  should be noted th a t  the rheum ato id  fac to rs  described in th is repor t  were 
no more than crude preparations and i t  is of course possible tha t  these 
preparations conta ined o ther constituen ts .
In th e ir  paper exam ining the mechanism of inh ib i t ion  of PIP in RA sera, 
N iven and Whaley (1986) described a cons t i tuen t o f RA sera and synovial 
f lu ids wh ich  reduced the binding o f  C1q to immune complexes. They were, 
however, unable to  f ind  any co rre la t ion  between reduc t ion  in binding o f C lq  
and inh ib i t ion  o f PIP in the SF samples tested wh ich  m igh t suggest th a t  the 
inh ib i t ion  o f PIP in SF may occur by mechanisms o ther than the prevention of 
a c t iva t io n  o f  the classical pathway. The fa c to r  wh ich  they described could 
bind to IgG Sepharose, reduce immune complex binding to  C lq ,  and inh ib i t  
PIP, suggesting th a t  i t  was opera ting  via binding to  the immune complex 
ra the r than to C lq .  As regards the poss ib il i ty  th a t  RF i t s e l f  may be involved 
these workers s ta ted  th a t  pu r if ied  IgM -RF and F(ab ')^ IgG -R F did not reduce 
the binding of immune complexes to C lq .  The data on th is point however, 
were not shown in th is paper (N iven &. Whaley, 1986).
Thus fa r  the nature o f the inh ib i to ry  fa c to r  has not been ascerta ined. 
However, the tryps in  se ns it iv i ty  o f the a c t iv i ty  suggests th a t  i t  is a pro te in , 
while  i ts  resistance to PMSF and 5BTI argue th a t  i t  is no t an enzyme of the 
serine protease class. The observation tha t inh ib i t ion  o f  PIP occurs almost
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exc lus ively in patien ts  w ith  seropositive RA suggests th a t  i t  may be RF, or 
some re la ted  serum cons t ituen t.
Regarding the poss ib il i ty  tha t  the inh ib i to ry  a c t iv i t y  may be RF, i t  is of 
in te res t th a t  under cond it ions o f high antibody density RF has been shown to 
inh ib i t  com p lem ent-m ed ia ted  lysis o f  antibody coated sheep ery th rocy tes  
(Schmid, R o i t t  &  Rocha, 1970). Recent studies by Ng, Peters & W alport (1988) 
have examined the ro le played by RF in immune complex ac t iva t ion  of 
com plem ent. Monoclonal RF-IgG complexes f ix  C3 and C4 poorly . However, 
p re form ed R F- lgG  complexes did a c t iva te  com plem ent but because o f  l im ite d  
f ix a t io n  o f  C3 and C4 the complexes did not bind to CR1. These workers 
argued th a t  poor f ix a t io n  o f opsonic C3 and C4 to RF conta in ing  complexes 
would resu lt  in im paired transport  o f the complexes to  the cells of the 
re t icu lo -en d o th e lia l system fo r  safe disposal. I t  was postu la ted tha t  a s im i la r 
fa i lu re  o f  c learance o f RF conta in ing complexes m igh t be operative in the 
rheum ato id  jo in t  (Ng e t al, 1988). The role of RF in the process o f inh ib i t ion  
of PIP in RA w i l l  be discussed la te r  in this chapter in the l igh t  of my own 
findings.
SECTION 6
Isolation of in h ib i to ry  a c t iv i t y  from  R A  serum by IgG Sepharose and Sephacryl 
S30D chrom atography
In patien ts  w ith  seroposit ive  RA the impaired a b i l i ty  o f serum to prevent 
immune p re c ip i ta t io n  is due to  the presence o f  an in h ib i to r  o f this process 
(see Chapter 3, Section 3). In the previous section I have shown tha t sera and 
synovial f lu id  f ro m  RA patien ts  w ith  subnormal PIP showed reduced C4 
consumption. This reduction  in C4 consumption co rre la ted  w ith  the degree of 
inh ib i t ion  o f  PIP (see Chapter 3, Section 5). The most l ike ly  explanation was 
tha t  C l  binding and/or ac t iva t io n  was reduced. Studies on the k ine tics  of
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inh ib i t ion  o f  PIP showed th a t  fo r  m axim um  in h ib i to ry  e f fe c t  the in h ib i to ry  
substance had to  be present at the t im e  o f fo rm a tion  o f  the an t igen-an tibody 
complex (see Chapter 3, Section 5).
In order to  iso late th is  inh ib i to ry  a c t iv i t y  1 f i rs t  assessed its  a b i l i ty  to  bind to 
and be e luted f rom  an IgG Sepharose column which is in e f fe c t  imm obil ised 
bound antibody. In i t ia l  studies showed tha t inh ib i to ry  a c t iv i t y  could bind to 
and be e luted f ro m  an IgG Sepharose column. Most o f the inh ib i to ry  a c t iv i ty  
could be e lu ted w ith  guanidine hydroch loride and m ix ing  o f a ll the e luted 
pro te in  pools (a, b and c) could fu l ly  recons t i tu te  the in h ib i to ry  a c t iv i t y  of 
the s ta r t ing  RA serum. This shows tha t  all the in h ib i to ry  a c t iv i t y  could be 
eluted f ro m  the column under the conditions described. Pool (c) (guanidine 
e luted pool) displayed more inh ib i to ry  a c t iv i ty  than the RA serum s ta r t ing  
m a te r ia l  i t s e l f .  The exclusion peak (pool a) was devoid of in h ib i to ry  a c t iv i ty .  
However when pool (c) and pool (a) were m ixed toge ther the inh ib i to ry  
a c t iv i t y  o f the m ix tu re  was less than tha t  o f pool (c) alone. This suggested 
tha t pool (a) conta ined fac to rs  which were antagonising the Inh ib ito ry  e f fe c t  
o f pool (c). When the RA serum s ta r t ing  m a te r ia l and the m a te r ia l e luted 
w ith  guanidine hydrochloride from  the IgG Sepharose column (pool c) were 
t i t r a te d  by doubling d i lu t ion  fo r  inh ib i to ry  a c t iv i ty ,  i t  was noted tha t  RA 
serum and pool (c) exh ib ited  s im i la r  dose response patte rns .
Using sera from  7 ind iv idua l seroposit ive RA patien ts , in h ib i to ry  a c t iv i t y  was 
eluted f ro m  IgG Sepharose under the conditions described. On subsequent gel 
f i l t r a t io n  (Sephacryl S300) chromatography, the m a jo r i ty  o f in h ib i to ry  a c t iv i ty  
was e lu ted as a single peak which on SDS-PAGE was shown to conta in  19S 
IgM,
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On the basis of the fo l low ing  observations i t  was concluded tha t  the inh ib i to ry  
a c t iv i t y  in R A  sera was due to  IgM -RF.
(1) S ign if ican t levels o f  in h ib i to ry  a c t iv i ty  are only found in the sera of 
patien ts  who are seroposit ive  fo r  IgM -RF.
(2) The fa c to r  responsible fo r  the inh ib i to ry  a c t iv i t y  binds to IgG-Sepharose.
(3) I n h ib i t o r y  a c t i v i t y  c o -c h ro m a to g ra p h s  w i t h  Ig M -R F  th ro u g h o u t  the  
p u r i f ic a t io n  procedure.
B a les tr ie r i  and his colleagues described an inh ib i to ry  e f fe c t  o f  IgM -RF on PIP 
and immune complex so lub il isa tion  (B a les tr ie r i et al, 1984). In contras t to  my 
own approach these workers made the assumption tha t  IgM -RF was the 
m o le c u le  re s p o n s ib le  f o r  th is  in h ib i t o r y  a c t i v i t y  b e fo re  d e s c r ib in g  i ts  
inh ib i to ry  e f fe c t .  A sounder s c ie n t i f ic  approach, was to iso late the inh ib i to ry  
a c t iv i ty  f ro m  RA serum as i t  makes no p r io r assumptions as to the nature of 
the func t iona l a c t iv i t y  which is being sought. More im p o r ta n t ly  i t  enables one 
to  de tec t o ther substances which m igh t be im p o r ta n t  in inh ib i t ion  o f PIP. For 
example the sm all bu t d e f in i te  amount of a c t iv i ty  e lu ted w ith  0.4M sa lt (Fig 
3.13(a)) and s im i la r ly  the small amount of a c t iv i ty  which could possibly be 
a t t r ib u te d  to  IgG-RF (Fig 3.13(b)).
Thus i t  would appear th a t  IgM -R F and to a lesser e x ten t IgG-RF could 
account fo r  the m a jo r i ty  of the inh ib i to ry  a c t iv i t y  found in RA serum. The 
5% phosphate gels shown in F ig 3.14 a ttes t to the p u r i ty  o f the IgM and 
IgG-RF. I t  can be seen, however, tha t  a p ro te in  band above the l ig h t  chain of 
IgM was noted in some but not a ll  of the preparations. The nature of th is 
band has not been id e n t i f ie d .
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SECTION 7
Studies eva luating the ro le o f IgM -RF on the inh ib i t ion  o f PIP o f  immune 
complexes.
P ur if ied  IgM -RF and the whole RA serum from  which  i t  had been prepared (as 
described in Chapter 3, Section 6) were compared fo r  th e ir  capac ity  to inh ib i t  
PIP. The p u r i ty  o f the IgM -R F was confirm ed by SDS-PAGE and did not 
conta in  any con tam ina ting  p ro te in  bands. An ELISA was used to measure the 
q uan ti ty  of IgM -R F in each p repara tion. To ensure u n i fo rm ity  the samples 
were d ilu ted  so tha t  they contained equal amounts o f IgM -RF. P ur if ied  
IgM -RF was a more po ten t inh ib i to r  o f PIP than the same amount o f  IgM -RF 
in whole RA serum. To ensure tha t  th is e f fe c t  was not jus t a fea tu re  o f IgM 
i tse lf ,  pu r if ied  IgM was also tested but did not in h ib i t  PIP. This shows tha t  i t  
was the rheum ato id  fa c to r  a c t iv i t y  of the IgM -RF which was responsible fo r  
the observed inh ib i t ion  of PIP.
There are tw o  reasons why pu r if ied  IgM -RF m igh t be a more potent inh ib i to r  
of PIP than IgM -RF found in RA serum. F irs t ly  the IgM -R F may have been 
a l te r e d  by the  p u r i f i c a t i o n  process o r se c o n d ly ,  o th e r  f a c to r s  may be 
opera tive  in reduc ing the inh ib i to ry  a c t iv i ty  o f IgM -RF in whole RA serum.
The nature o f the m odula t ing  in fluences on IgM -RF on the inh ib it ion  o f PIP 
reac tion  which m igh t be present in the whole RA serum are unknown at 
present. Inh ib it ion  o f PIP increases w ith  Increasing quan ti t ies  of IgM -RF in a 
dose dependent fashion as expected (Fig 3.15) but the d if fe rence  between the 
inh ib i to ry  properties of the pur if ied  IgM -RF and the IgM -RF conta ined in 
whole RA serum remains much the same except at levels o f IgM -RF o f 1250 
u n i ts /m l and less. Whole serum contains C lq  and o ther F e y  binding proteins
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and an in h ib i to ry  molecule may exist in serum bound to such prote ins. Thus 
inh ib i t ion  o f PIP in whole serum may be modulated by the degree of binding 
o f an inh ib i to ry  m olecule  to  such F c ^b in d in g  prote ins.
As the RA serum was hea t- in a c t iva te d  p r io r to the measurment o f inh ib i t ion
of PIP these m odula t ing  in fluences in whole serum must be hea t*  lab ile .
P ur if ied  IgG-RF was shown to  be m oderate ly  in h ib i to ry  and th is  was re la ted  
to i ts  F(ab')g fragm ents. IgG-RF or another RF class may be responsible fo r
m odula t ing  the in h ib i to ry  e f fe c t  o f IgM -RF on PIP. This could be brought
about by co m pe t it ion  between IgM -RF and IgG-RF fo r  the availab le binding 
sites on the immune complex. P r io r depletion o f  serum o f  the other RF 
classes by im m uno -adso rp t ion  would enable th is hypothesis to be tested.
The in h ib i to ry  e f fe c t  of RA serum or IgM -RF on PIP was m ax im a l i f  these 
reagents were added p r io r  to  the add it ion  o f antigen and antibody (Fig 3.16).
This con f irm s  the results shown in Fig 3.9 where in h ib i to ry  RA serum was
added to  normal serum, the k in e t ic  p ro f i le  of both these experim ents being 
s im ila r .  Again i t  was noted tha t pu r if ied  IgM -RF was a more po ten t inh ib i to r  
o f PIP at a ll t im es than the same amount o f IgM -RF in whole RA serum.
In this section the e ffe c ts  o f IgM -RF on the k ine tics  o f p re c ip i ta t io n  of
antigen-an tibody complexes in the absence of serum were studied. Pur if ied  
IgM -R F, or IgM -RF in hea t- inac t iva ted  RA serum was able to increase the 
ra te  o f  p re c ip i ta t io n  o f  immune complexes (Fig 3.17). Again i t  w i l l  be noted 
tha t p u r if ied  IgM -RF was more poten t in this respect than IgM -RF contained 
in whole serum. These findings of an increased ra te  o f p re c ip i ta t io n  of 
complexes in the presence o f IgM -RF would be consistent w ith  the mechanism 
of IgM -RF mediated inh ib i t ion  of PIP suggested above ie. tha t  IgM -RF inh ib its  
PIP by ac ting  on the complexes p r io r  to them being rendered soluble by
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complement activation.
There are tw o  o ther reports  o f inh ib it ion  of PIP by IgM -R F. Using monoclonal 
and po lyc lonal rheum ato id  fac to rs  B a les tr ie r i  and his colleagues studied the 
e ffe c ts  o f  these RF's on the PIP reac tion  (termed ICPIC assay in his paper) 
(B a les tr ie r i e t al, 1984). Their assay was s im ila r  to  tha t  described in this 
thesis. Fiowever the p u r i ty  of B a les tr ie r i 's  RFs can be questioned as the ir  
preparations were not apparently  analysed by SD5-PAGE although the authors 
stated tha t  IgA -R F  and IgG-RF contam inated th e ir  IgM -R F preparations. 
N o tw iths tand ing  th is  an in h ib i to ry  e f fe c t  o f IgM -RF on PIP was described 
which was dose dependent and (although only two doses were used) s im i la r  to 
tha t described in my own experim ents.
B a les tr ie r i  and colleagues were able to  show tha t  inh ib i t ion  of PIP by RF was 
most marked when the RF was added at the t im e  of immune complex 
fo rm a tion  which is in agreement w ith  my results. They were also able to 
demonstrate th is in h ib i to ry  e f fe c t  of RF on PIP using a human immune 
complex system (tetanus toxo id  and an t i- te tanus  toxo id  antibodies) which was 
not used in my experim ents. The ir RF's did not display any anticom p lem enta ry  
a c t iv i t y  wh ich  is again in keeping w ith  my own results (see Table 3.3). (The 
amount o f C4 in normal serum and in normal serum + IgM -RF was the same 
in these experim ents on C4 consumption thus showing tha t  IgM -RF had no 
an t icom p lem enta ry  a c t iv i t y  by itse lf .) .
In 1985 M i le t ic  &. Rodic published th e ir  paper on the k ine tics  of rheum ato id  
fa c to r  in f luence  on PIP (M i le t ic  & Rodic, 1985), In th e ir  system ovalbumin 
anti-ova lbum in  immune complexes were used. They made measurements of the 
e x te n t  o f  the  l a t t i c e  f o r m a t io n  o f  im m u n e  c o m p le x e s  us ing  a lase r 
n e p h e lo m e t r ic  te c h n iq u e .  These w o rk e rs  assessed th e  p u r i t y  o f  t h e i r
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monoclonal rheum ato id  fa c to r  p reparation by using double d if fus ion  and 
im m uno-e lec trophores is  against an ti-w ho le  human serum and a n t i - l ig h t  chain 
antisera but not by SD5-PAGE. Measurement of RF concentra tions in the ir  
preparations was determ ined using a com m erc ia l q u a n t i ta t ive  nephelom etric  
method and this was approx im ate ly  quan tif ied  in a rb i t ra ry  units and compared 
to a la tex  agg lu t ina t ion  t i t r e .
In the ir  k in e t ic  experim ents RF in the absence o f com plem ent caused a dose 
dependent enhancement o f  immune complex la t t ic e  fo rm a tion  as measured by 
the ir  laser nephe lom etr ic  method. This is in keeping w ith  my findings o f  an 
increased ra te  o f p re c ip i ta t io n  o f complexes in the presence o f RF (see Fig 
3.17).
They also showed th a t  complem ent was able to in h ib i t  th is RF dependent 
enhancement o f  p re c ip i ta t io n  and also tha t RF induced a dose dependent 
in h ib i t i o n  o f  P IP . In t h e i r  e x p e r im e n ts  RF was ab le  to  in h ib i t  these  
complem ent e f fe c ts  in the phase o f p re c ip i ta te  fo rm a t io n .  This f ind ing  is in 
keeping w ith  my own dem onstra tion  of IgM -RF exert ing  its most potent 
inh ib i to ry  e f fe c t  on PIP when the RF was present at the begining o f  the 
reac tion  ie. a t the t im e  o f immune complex fo rm a tion .  M i le t ic  and Rodic also 
postu lated the reverse phenomenon and showed tha t  a c t iva t io n  of the classical 
pathway o f com plem ent, inh ib ited  RF e ffec ts  on p re c ip i ta t io n .  This reac tion  
had previously been demonstra ted in agg lu t ina tion  experim ents in which 
com plem ent a c t iva t io n  could inh ib i t  the in te rac t ion  between RF or C1q and 
IgG coated la tex  part ic les  (Hallgren, 1979).
I have shown previously (see Chapter 3, Sections 3 and 5) tha t  whole RA 
serum not only inh ib its  PIP but also inh ib its  the consumption o f C4 by 
c o m p le x e s .  The in ve rse  c o r r e la t io n  b e tw e e n  in h ib i t i o n  o f  P IP and C4
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consumption suggested th a t  the mechanism o f  inh ib i t ion  o f  PIP was due to 
inh ib i t ion  o f the binding or a c t iva t io n  o f C l  by the complexes. However in 
this set o f experim ents, examining the e f fe c t  of IgM -RF and RA serum 
conta in ing the same amount of IgM -R F on the consumption o f  C4 by immune 
complexes, a c lear d if fe rence  was noted (see Table 3.3). In the presence of 
pu r if ied  IgM -RF immune complexes were able to  a c t iva te  the complem ent 
system norm a lly  and thus C4 was consumed in the reac tion . However, when 
IgM -RF was present in the same quan ti ty  in h e a t- in a c t iv a te d  RA serum C4 
consumption was reduced. Thus in whole RA serum the inh ib i t ion  of C4 
consumption observed cannot be explained by the presence o f IgM -RF. The 
e v id en ce  p o in ts  to  the  p resence  o f  o th e r  f a c to r s  w h ic h  in f lu e n c e  the  
in te rac t ion  o f complexes w ith  the complem ent system. This conclusion is 
re in fo rced  by the observation tha t  serum levels of IgM -R F  (as measured by 
ELISA) showed only a low degree of co rre la t ion  w ith  the leve l o f  inh ib i to ry  
a c t iv i t y  (%) (F ig 3.18).
SECTION 8
The re la t ionsh ip  between inh ib i t ion  of PIP ( in h ib ito ry  a c t iv i ty )  and c l in ica l 
aspects of disease.
In this study PIP and inh ib i t ion  o f PIP was measured in serum and SF of 
p a t ie n ts  w i t h  r h e u m a t ic  d isease . The p a t ie n ts  in th is  s tu d y  w e re  w e l l  
characterised c l in ic a l ly  and I a ttem p ted  to re la te  PIP and inh ib i t ion  of PIP to 
the deta iled  c l in ica l aspects o f  the ir  disease. The results o f c l in ica l studies 
deta iled  ea r l ie r  in this thesis (see Chapter 3, Sections 2, 3 and 4) were main ly  
concerned w ith  studying PIP and inh ib it ion  o f PIP in the sera o f unselected 
patients a ttend ing  rou tine  o u t-p a t ie n t  c lin ics.
The study was d iv ided in to  tw o  parts, A and B.
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In Study A, PIP and inh ib i t ion  of PIP was measured in the sera and SF of 
three groups o f pa tien ts  w ith  a r th r i t is .
In Group A -I  60% of the p a t ie n ts ’ sera displayed im pa ired  PIP and conversely 
87% of sera in this group showed increased in h ib i to ry  a c t iv i t y .  These patien ts  
a ll had seropositive RA. Patien ts  in Groups A - I I  and A - I I I  su ffe red from  
seronegative a r th r i t is  and serum PIP and inh ib i t ion  o f PIP was in general 
normal in these tw o  groups. These findings are in keeping w ith  those
described previously in this thesis where s ig n if ican t reduction  in PIP and
e levation  o f  inh ib i t ion  o f  PIP were v ir tu a l ly  confined to seropositive RA 
patients (see Chapter 3, Sections 2, 3 and 4).
A l l  SF's tested showed reduced PIP, the greatest amount o f im pa irm en t of
PIP being found in the seropositive RA group. PIP in h ib i to ry  a c t iv i ty  was
almost invariab ly  present in SF. No patients were found who had normal
levels o f PIP, a l l showed marked reduction  in PIP levels, the highest levels 
being o f 20% or less. This may be a fea tu re  o f a ll SF as no normal SF's were 
available fo r  tes t ing  and thus no normal range was established. I t  may be tha t 
the im p a irm en t of PIP in SF is an a r te fa c t  and may be due to  the d i f fe re n t  
physical ch a rac te r is t ics  of SF compared to serum eg. v iscosity . The most 
l ike ly  reason is tha t  low com plem ent levels were found in the SF of these 
patien ts . A lthough SF PIP levels were low and SF com plem ent levels were low 
there was no s ign if ican t re la t ionsh ip  between the ind iv idua l SF PIP and SF 
C3, C4, F ac to r  B or CFI50 levels in the patients studied. Fiowever in contrast 
inh ib i t ion  of PIP was not abnormal in a ll SF's tested (Fig 3.20). There have 
been no studies to date by o ther authors exam ining PIP in SF w ith  which to 
compare my own resu lts . In general term s the greatest amount o f  inh ib i t ion
of PIP in SF was found in the seropositive RA group although e levated levels
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were seen in some patien ts  w ith  seronegative a r th r i t is .  The only s ign if ican t 
co rre la t ion  between serum PIP and serum inh ib i t ion  o f PIP was found in group 
A -I ,  those patien ts  w ith  seroposit ive RA (r= -0.77 p < 0.002).
In te res t ing ly  there  was no apparent co rre la t ion  between serum levels o f PIP
or inh ib i t ion  o f PIP w ith  any o f the c l in ica l param eters of systemic disease 
measured or w i th  any o f the labora to ry  indices o f system ic disease a c t iv i ty .  
Indeed there was also a lack of co rre la t ion  between serum PIP and serum 
inh ib i t ion  o f  PIP w ith  any o f  the c l in ica l or labora to ry  tests of loca l disease 
a c t iv i ty  in the in f lam m ed knee jo in ts  examined. This suggests tha t  PIP and 
inh ib i t ion  o f PIP may re f le c t  aspects of the underly ing rheum ato id  process 
ra the r than day to  day va r ia t ion  o f c l in ica l  disease. I t  would be in teres ting  to 
see i f  so called disease m od ify ing  drugs eg gold or pen ic il lam ine  would a lte r  
these measurements (PIP and inh ib i t ion  of PIP) and whether norm a lisa tion  of 
these param eters m ir ro red  im provem ent in c l in ica l disease. One m igh t expect 
tha t  th is  would occur as disease m od ify ing  drugs are known to reduce the
concentra tions o f RF found in RA (W right & Amos, 1980).
I t  is im p o r ta n t  at th is  po in t to  voice a caveat in the in te rp re ta t ion  o f results 
r e ly in g  so h e a v i ly  on c o r r e la t io n  c o - e f f i c i e n t s  w h ic h  o f te n  o c c u r  in 
c l in ic a l / la b o ra to ry  studies such as the one discussed here. Based on the 
concept of a tte m p t in g  to  assess the im portance of a new measurement and 
param eter (in my case PIP and inh ib i t ion  o f PIP) in c l in ica l disease one o ften  
carries out extensive co rre la t ions  of this new param eter w ith  more standard 
c l in ica l and labora to ry  assessments. The s ign if icance  o f these values are o ften  
quoted and f ro m  th a t  value the im portance o f  the co rre la te  is judged. The 
inherent f la w  in th is  kind o f study is tha t i f  many co rre la t ions are ca rr ied  out 
some o f these w i l l  occur by chance and tha t  the s ign if icance of the values 
obtained should be co rrec ted  fo r  the number o f tests applied (see S ta t is t ica l
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Methods, Chapter 2).
In th is  study no co rrec t ions  fo r  the numbers o f tests applied were ca rr ied  out 
and a re la t iv e ly  large number o f  co rre la t ions were done. For the purposes of 
this discussion I have the re fo re  t r ie d  to concen tra te  on those corre la t ions 
which were s t i l l  s ign if ican t a f te r  I had at a la te r  stage applied co rrec t ing  
fac to rs . For example in this study there were no s ig n if ican t corre la t ions 
observed in the level o f SF PIP or inh ib it ion  o f PIP and the c l in ica l and 
labora to ry  param eters measured.
Moving on to  the second pa r t  o f this c l in ica l study which is probably the 
most im p o r ta n t ,  I examined the  re la t ionsh ip  between PIP and inh ib i t ion  o f PIP 
in seroposit ive  RA sera from  patients w ith  and w ith o u t  e x tra -a r t ic u la r  
fea tures o f  th e ir  disease. The hypothesis is advanced in the in troduc t ion  
(C h a p te r  1) t h a t  f a i lu r e  o f  im m un e  c o m p le x  c le a ra n c e  m e ch an ism s  v ia  
impaired PIP m igh t be responsible fo r  the e x tra -a r t ic u la r  m anifesta t ions of 
RA which are thought to be mediated by immune complexes. This concept can 
be d i r e c t l y  addressed  in the  c l i n i c a l  s tud ie s  p re s e n te d  in  th is  s e c t io n .
The hypothesis was supported by the f ind ing  tha t  82% of pa tien ts  w ith  nodular 
RA and 90% of patien ts  displaying the e x tra -a r t ic u la r  fea tures of RA had 
impaired PIP and conversely in h ib i to ry  a c t iv i ty  was found in a ll pa tien ts  w ith  
e x tra -a r t ic u la r  RA. The f igu re  of 35% of sera w ith  reduced PIP, found in 
purely a r t ic u la r  RA , is lower than the 47% of RA sera w ith  impaired PIP 
previously recorded in th is  thesis (see Chapter 3, Section 2). Fiowever, the 
number o f patien ts  in th is study w a s  lower, and in the previous study (see 
Chapter 3, Section 2) the RA patients were unselected fo r  the presence of 
nodules or e x t ra -a r t ic u la r  fea tures. 75% of patien ts  w ith  uncom plica ted RA 
displayed in h ib i to ry  a c t iv i t y  which is in keeping w ith  th a t  previously recorded
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(see Chapter 3, Section 4). Not unexpectedly the mean level of PIP was
lowest in those patien ts  w ith  vascu lit is  or nodules and this was re f le c te d  in
the highest levels o f  inh ib i to ry  a c t iv i t y  being also found in these tw o  groups.
T he re  was no h ig h ly  s ig n i f i c a n t  c o r r e la t io n  b e tw e e n  le v e ls  o f  PIP and 
in h ib i t i o n  o f  P IP , and Ig M -R F .  A l th o u g h  the  q uo ted  r va lues  do g ive  
s ign if ican t P values these became less so when the co rre c t io n  fo r  the number 
o f  te s ts  used was a p p l ie d  (see above).  The on ly  s t r o n g ly  s ig n i f i c a n t  
corre la t ions were between levels o f PIP and levels of PIP inh ib i to ry  a c t iv i ty  
(negative ly  corre la ted ).  This is not unexpected as i t  is probable tha t  reduced 
PIP in RA serum is due to the presence o f inh ib i to ry  a c t iv i t y  in the serum 
(see Chapter 3, Section 3).
In the patien ts  w i th  vascu lit is , PIP co rre la ted  s trongly w ith  in h ib i to ry  a c t iv i ty  
(negative co rre la t ion )  and w ith  levels o f C4. It is d i f f i c u l t  to explain why th is  
association w ith  C4 was confined to patients w ith  RA and vasculit is  but not
found in the other tw o  groups (B-I and B-11). I t  may be tha t  C4 plays an
im po rtan t ro le in R A  w ith  vasculit is . Fiowever, C4 levels were not reduced in 
RA patients w ith  vascu lit is . C4 levels were comparable in groups B-I, B-II and 
B -II I  (F igure 3.23). Plasma C4 consists o f the products o f  tw o  separate genes 
C4A and C4B (O 'N e il l ,  Yang & Dupont, 1978) each o f which binds cova len tly  
to surfaces but C4A binds more e f f ic ie n t ly  to amino groups whereas C4B 
binds more e f f ic ie n t ly  to  hydroxy l groups (Law, Dodds &  P o r te r ,  1984). C4A 
has been shown to be more e f fe c t iv e  in PIP (S ch if fe r l i  et al, 1986) than C4B 
and thus i t  would be o f in teres t to measure the re la t ive  serum concentrations 
o f C4A and C4B in these three groups of RA patien ts  (Groups B-I, B -I I  & 
B-III). In group B-I, those patien ts  w ith  purely a r t ic u la r  RA, serum inh ib i to ry  
a c t iv i ty  was found to  co rre la te  w ith  serum C3 and fa c to r  B levels r= 0.46 and 
r= 0.61 respec t ive ly  (p <  0.002 In both cases). I am unable to explain this
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association and indeed when co rrec ted  fo r  the number of tests applied this 
association became much less s ign if ican t.
The most s tr ik in g  fea tu re  of this study was the lack o f co rre la t ion  between 
inh ib i t ion  of PIP and any o f the rheum ato id  fa c to r  classes (IgM, IgG and IgA) 
although i t  was noted tha t  in the vascu l i t ic  group PIP was inversely re la ted  to 
IgG-RF concen tra t ion . This may ind icate  tha t IgG-RF is po te n t ia l ly  more 
im po rtan t  in the development o f the vascu l i t ic  fea tu res o f RA as has 
previously been reported  (Scott e t al, 1981). This lack o f  association o f  PIP 
inh ib i to ry  a c t iv i t y  w i th  serum levels of IgM -RF was demonstra ted ea r l ie r  in 
this thesis (see Chapter 3, Section 7). In a large number o f RA patients (157 
sera) there was no clear re la t ionsh ip  between IgM -RF levels and % PIP 
inh ib i to ry  a c t iv i t y .  This argues s trong ly  against IgM -RF having a m ajor ro le to 
play in PIP in h ib i to ry  a c t iv i t y  in R A  serum. Thus in th is  study, although 
inh ib it ion  o f PIP is s trong ly  associated w ith  RA com p lica ted  by vasculit is  
which supports the hypothesis proposed in the in troduc t ion  (see Chapter 1), 
the evidence suggests th a t  in whole serum the various RF classes have at 
most only a l im i te d  ro le  to play in the expression of in h ib i t ion  of PIP in RA 
sera.
SECTION 9
P u r i f ic a t io n  o f  in h ib i to ry  a c t iv i t y  by Sucrose gradient u l t ra c e n tr i fu g a t io n  and 
IgG Sepharose a f f in i t y  chrom atography.
I have shown previously (Chapter 3, Section 6) tha t  the m a jo r i ty  o f inh ib i to ry  
a c t iv i t y  in RA serum resides w ith  IgM -RF. The results in th is study in general 
support th is  concept. Inh ib ito ry  a c t iv i ty  in RA serum was found in the higher 
M.W. frac t ion s  on the sucrose grad ien t along w ith  IgM, and these frac t ions
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were s trongly RF pos it ive . This RF positive f ra c t io n  bound to  IgG Sepharose 
and the in h ib i to ry  a c t iv i t y  could be eluted w ith  2M guanidine hydrochloride 
(see also Chapter 3, Section 6). The presence o f h e a t- lab i le  antagonists to the 
inh ib i to ry  m olecule  opera tive  in the whole RA serum is supported by the 
f in d in g  o f  g r e a te r  e xp ress io n  o f  in h ib i t o r y  a c t i v i t y  in the  w h o le  h ea t 
inac tiva ted  RA serum as has been noted before (see Chapter 3, Section 3 and 
Table 3.1).
An im p o r ta n t  f ind ing  in this study was tha t  s im i la r  t re a tm e n t  of normal 
serum (sucrose grad ient f ra c t io n a t io n  and IgG Sepharose chromatography) 
revealed the presence o f  an inh ib i to ry  molecule in normal serum. This 
molecule  appeared to  have a s im i la r  sed im enta tion  c o e f f ic ie n t  to  tha t  found 
in RA serum (see F igure 3.27), F raction  2 f ro m  the grad ient contained 
m a te r ia l  which inh ib ited  PIP. This inh ib i to ry  a c t iv i t y  in f ra c t io n  2 was 
com p le te ly  abrogated by the addit ion of f ra c t io n  5. This must mean tha t  
f ra c t io n  5 conta ined an antagonist to  the inh ib i to ry  a c t iv i t y  found in f ra c t io n  
2 and tha t  under normal c ircum stances in h ib i to ry  a c t iv i t y  in normal serum is 
suppressed by th is  antagonist. This a b i l i ty  o f f ra c t io n  5 to antagonise the 
inh ib i to ry  a c t iv i t y  in f ra c t io n  2 was s im ila r  in both normal and RA serum. 
The m ix ing  experim ents (described in Chapter 3, Section 9) were ca re fu l ly  
adjusted fo r  f in a l  volume of reagents and the re fo re  the e f fe c t  was not one of 
d i lu t ion . The mechanism whereby f ra c t io n  5 was able to antagonise the 
inh ib i to ry  a c t iv i t y  o f f ra c t io n  2 is so fa r  unexplained.
The e f fe c t  o f h e a t - in a c t iv a t io n  (FlI) on the f in a l expression o f inh ib i to ry  
a c t iv i ty  in both sera is in te res t ing  and may provide some clues to this 
problem. Inh ib ito ry  a c t iv i t y  in normal serum was h e a t- la b i le  whereas in RA 
serum i t  was heat—stable (Fig 3.26). The antagonists to  inh ib i to ry  a c t iv i ty  
were both h e a t -  lab ile  and addit ion of (FlI) f ra c t io n  5 did not abrogate
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in h ib i to ry  a c t iv i t y  (Fig 3.28). This was fu r th e r  supported by the f ind ing  of 
increased in h ib i to ry  a c t iv i t y  expression in h e a t -  inac t iva ted  RA sera. If ,  
however, one considers in h ib i to ry  a c t iv i ty  in normal and RA sera to be due to 
the presence of the same fa c to r  one must postu la te  th a t  in RA sera 
(sero-positive  fo r  IgM - RF) the fa c to r  responsible fo r  in h ib i to ry  a c t iv i t y  is in 
some way p ro tec ted  f rom  h ea t- in a c t iva t io n  by the presence o f the IgM -RF. It 
may be however, th a t  there  is a h ea t- lab i le  fa c to r  which is present in normal 
serum and rheum ato id  serum and a heat-stable  fa c to r  which is only present in 
rheum ato id  serum. This h e a t -s ta b le  fa c to r  would o f  course be IgM -RF.
The results of la te r  studies in this chapter lend some support to  this concept. 
Inh ib ito ry  a c t iv i t y  ( from  f ra c t io n  2) o f  normal and R A  serum bound to IgG 
Sepharose but the e lu tion  p ro f i le  was, however, d i f fe re n t .  RA inh ib i to ry  
a c t i v i t y ,  as e x p e c te d ,  was a lm o s t  e n t i r e l y  c o n f in e d  to  the  g u a n id in e  
hydroch loride  e luted pool where i t  was found w ith  IgM -R F. In normal serum, 
however, the m a jo r i ty  o f  in h ib i to ry  m a te r ia l was found in the f ra c t io n  eluted 
w ith  Ü.4M NaC l wh ich  did not conta in  IgM-RF.
The concept th a t  IgM -R F is responsible fo r  the inh ib iton  o f PIP found in RA 
serum is somewhat re fu ted  by the dem onstra tion o f  an apparently  s im i la r  
inh ib i to ry  a c t iv i t y  in normal serum which is quite  c lea r ly  devoid o f  IgM -RF 
a c t iv i t y  as measured by Rose-Waaler t i t r a t io n  and ELISA. This does not mean 
tha t IgM -RE is not responsible fo r  inh ib it ion  o f PIP in R A  serum, as I and 
others (B a les tr ie r i  et al, 1984) have shown tha t  p u r if ied  IgM -RF does indeed 
inh ib i t  PIP (see Chapter 3, Section 7) but i t  does cast doubt on the cen tra l 
ro le o f  IgM -RF in th is  process. However, both the IgM -R F preparations used 
in this study and those used by o ther workers (B a les tr ie r i e t al, 1984) may not 
have been pure enough, and o ther molecules may have been present which had 
gone undetected by our ana ly t ica l methods. Indeed i t  has been reported
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(Ahmed & Whaley, 1988) tha t  a 60kD plasma g lycopro te in , te rm ed gp60, can 
a c c o u n t  fo r  the  in h ib i t i o n  o f  PIP in n o rm a l se rum  and R A  se ru m .
Recently , O 'Sull ivan, Amos & W ill iam s (1986) have reported  th e ir  f indings on 
rheum ato id  fa c to r  and its in f luence on c o m p lem en t-m e d ia te d  inh ib it ion  of 
immune p re c ip i ta t io n .  In agreement w ith  my own f ind ings and those of 
B a le s t r i e r i  e t  a l ,  (1984), th e y  show ed th a t  is o la te d  m o n o c lo n a l  Ig M -R F  
d is p la y e d  a d o s e -d e p e n d e n t  in h ib i t o r y  a c t i v i t y .  F io w e ve r ,  w i t h  p o ly c o n a l 
IgM -RF this in h ib i to ry  a c t iv i t y  was less marked and was not observed in the 
whole RA serum. I t  was also shown th a t  heat-aggregated IgG could in h ib i t  the 
binding o f RF. This study supports the results of my own experiments in 
which IgM -R F  in serum was less potent than pu r if ied  IgM -R F (see Chapter 3, 
Section 7). I have not carr ied  out measurements on immune complex levels in 
my own serum samples and am the re fo re  unable to  com m ent on the role of 
immune complexes in RA serum as being a m ajor in f luence on the inh ib it ion  
o f PIP. F u rthe r evidence against IgM -RF having a ce n tra l ro le in inh ib it ion  of 
PIP in RA serum has also come from  this study by O 'Sull ivan and her 
colleagues. She found a poor co rre la t ion  between inh ib i t ion  o f PIP and IgM -RF 
as measured by ELISA in a large group o f patien ts , thus con f irm ing  my own 
findings (see Chapter 3, Section 7, F ig 3.18).
In v iew of the above, the dem onstra tion  of another p ro te in  band in addit ion to 
IgM -RF (Fig 3.31) in the pu r if ied  inh ib i to ry  f ra c t io n  f ro m  RA serum eluted 
from  IgG Sepharose is o f considerable in te res t.  I have been unable to separate 
th is approx im a te ly  60 kD pro te in  f ro m  IgM -RF and as such cannot s tate  tha t 
this p ro te in  is responsible fo r  the inh ib it ion  o f PIP in R A  serum. SD5-PAGE 
analysis (Fig 3.30) showed tha t  a pro te in  o f s im i la r  size could also be 
d e m o n s t ra te d  in th e  p u r i f ie d  in h ib i t o r y  f r a c t i o n  f r o m  IgG Sepharose 
chromatographed normal serum and i t  is the re fo re  tem pting  to  suggest tha t
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these pro te ins may play a ro le in the inh ib it ion  o f PIP in' RA and normal 
serum.
In support o f  this notion Ahmed & Whaley (1988) have reported  the iso lation 
and p u r i f ic a t io n  f rom  normal serum o f  an in h ib i to r  o f PIP which was a 60kD 
molecu lar w e igh t g lycopro te in  (termed gp60). This p ro te in  was found in
normal serum and, in g reate r quan tit ies , in RA serum. The serum levels of
gp60 co rre la ted  very s trong ly  w i th  the a b i l i ty  o f  tha t  serum to  in h ib i t  PIP. 
Gp60 appears to  be a normal plasma pro te in  which inh ib its  PIP by dose 
dependent inh ib i t ion  o f C lq  binding to IgG, thus preven ting  com plem ent 
ac tiva t ion .  I t  appears to  bind to  the Fc piece o f IgG and so inh ib i t  the binding 
of C lq  to the IgG molecule.
The p u r i f ic a t io n  method used by Ahmed and Whaley (1988) to  isolate the ir  
gp60 m o le c u le  was in some re s p e c ts  s im i la r  (IgG  Sepharose a f f i n i t y  
chromatography) to tha t  used by me to isolate a 60kD molecule. The s trength 
of the ir  p u r i f ic a t io n  scheme was tha t  they a ttem p ted  th e ir  iso lation from  
normal serum which could be obtained in re la t iv e ly  large quantit ies . This of 
course avoided the con tam ina ting  and sometimes confusing in fluence of 
rheum ato id  fac to rs  which were encountered in my p u r i f ic a t io n  procedures 
perform ed on RA serum. Fiowever, my approach was ju s t i f ie d  on the grounds 
tha t the inh ib i to r  o f  PIP was f i r s t  demonstrated in seroposit ive  RA sera and 
only at a la te r  stage was I able to demonstrate the presence of an inh ib i to r  in 
normal serum. A fu r th e r  c r i t ic is m  of my studies is tha t  my SDS-PAGE
analysis was probably in s u f f ic ie n t ly  sensitive to de te c t  o ther contam ina ting  
prote ins. I f  o ther gel techniques and stain ing procedures were used eg
Laem m li system w ith  s i lve r staining, my own 'p u r i f ie d ’ preparations could 
possibly have been shown to conta in  o ther prote ins including the 60kD 
molecule described above. Indeed this c r i t ic is m  could be leve lled a t o ther
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w o rk e rs  in  th is  f ie ld  c o n c e rn in g  Ig M -R F  and i t s  a c t io n s  on PIP and 
so lub il isa tion  (Naylo r et al, 1979; B a les tr ie r i  e t al, 1984 &  O 'Sullivan e t al, 
1986). None o f these workers ' IgM -R F preparations were shown to be pure by 
the same s tr ingen t standards as those adopted by Ahmed and Whaley (Ahmed 
&C. Whaley, 1988) and thus a ll could have contained vary ing  amounts o f gp60 
which could explain th e ir  findings.
The results of Ahmed & Whaley rem ain  to  be con f irm ed  but i t  does appear 
tha t  the ir  gp60 molecule  is an im p o r ta n t  con tr ibu t ion  to our understanding of 
the mechanism of inh ib i t ion  o f PIP by RA serum. C e r ta in ly  the presence of 
th is molecule  explains the re la t iv e ly  weak co rre la t ion  between serum levels of 
IgM -RF and inh ib i t ion  o f PIP.
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C O N C LU D IN G  DISCUSSION
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The studies described in this thesis concern the spec if ic  in te rac t io n  between 
c o m p le m e n t  and im m u n e  c o m p le x e s  a t  the  t im e  o f  t h e i r  f o r m a t io n .  
C o m p le m e n t ,  r e a c t in g  w i t h  an im m u n e  c o m p le x  im m e d ia te ly  a f t e r  the  
fo rm a tion  o f an immune complex prevents the fo rm a t io n  o f insoluble, and 
the re fo re  p o te n t ia l ly  tissue-damaging aggregates which may be deposited in 
vessel w a l ls  or re m a in  lo c a l is e d  in  t issues . Th is  c o m p le m e n t -m e d ia te d  
prevention o f immune p re c ip i ta t io n  reaction  (PIP) allows fo r  the fo rm a tion  of 
complement-processed soluble complexes. In Chapter 1 I have outlined the 
complex physio log ica l mechanisms whereby c ircu la t in g  immune complexes 
reac t w ith  com plem ent and are transported to  ce lls o f the f ixed  macrophage 
system, some via com plem ent receptors , fo r  safe disposal. A m ajor role fo r  
com plem ent in th is  process appears to be opsonisation o f immune complexes. 
The com plem ent reacted  immune complexes are coated w ith  C3b in the PIP 
and so lub il isa tion  reac tion  and can subsequently be taken up by cells bearing 
CR1. Complexes rendered sm all and soluble by the PIP process bind poorly to 
e ry th ro cy te  CR1 in contras t to  solubilised complexes which bind w e ll.  This is 
probably re la ted  to the fa c t  th a t  because the number o f  CR1 on e ry th rocy tes  
is low, la rger amounts o f C3b would be required fo r  s table m u lt ip o in t  binding 
to  occur (A rnaout e t al, 1981).
To summarise, antigen-an tibody complexes can be fo rm ed e ithe r in the 
in travascu la r or ex travascu la r com partm ents. Com plem ent is ac t iva ted  a t the 
t im e  o f immune complex fo rm a tion  and the complex is coated w ith  C3b. 
Under normal c ircumstances a large number o f  C3b molecules are bound to 
the  c o m p le x  f o l lo w in g  a c t i v a t io n  o f  the  c la s s ic a l  and s u b s e q u e n t ly  the  
a lte rna t ive  pathway (the C3b feedback loop). Immune p re c ip i ta t io n  and the 
fo rm a tion  of large la t t ices  is prevented (S ch if fe r l i  et al, 1980). The next 
im p o rta n t  step is the reac tion  of opsonised complexes w ith  CR1 on the 
surfaces o f  various cells. The binding of opsonised complexes to CR1 (main ly
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on red blood cells) prevents the immune complex reac ting  w ith  nearby 
s truc tures  (eg vascuiar endothe lium) and i t  also allows fo r  the carriage of 
complexes to the f ixed  macrophage system. I f  fo rm ed  in the extravascu lar 
space the immune complexes are removed by the lym phatics  and are trapped 
in the reg ional lymph nodes (Pepys, 1976).
E ry th rocy tes  w ith  bound immune complexes then transpo rt  the complexes to 
the cells o f the f ixed  macrophage system. The complexes are trans fe rred  to 
macrophages by as ye t unknown mechanisms but probably the high density of 
Fc receptors  and CR1 receptors  on the macrophages enable a stronger binding 
fo r  the complex to the macrophage than to the e ry th rocy te  w ith  its re la t iv e ly  
low concen tra t ion  o f CR1. D efec ts  a t any level o f  th is  physiologica l immune 
complex c learance process, summarised above, could lead to  Immune complex 
disease. I have studied the ear l ie r  stages o f this process namely, p revention of 
im m un e  p r e c ip i t a t i o n  by c o m p le m e n t  a t  the  t im e  o f  im m un e  c o m p le x  
fo rm a tion .
This physiologica l system fo r  handling immune complexes can fa i l  fo r  several 
reasons, eg a genetic  or acquired de f ic iency  of com plem ent, a fa i lu re  o f the 
various classes of antibody to f ix  com plem ent, a de f ic iency  o f CR1, or a 
d e p le t io n  o r o th e r  o c c u p a t io n  o f  C R 1 . An im p a i r m e n t  o f  the  f ix e d  
macrophage system i ts e l f  e ithe r  because of disease or because o f func t iona l 
overload can also resu lt in de fec t ive  immune complex c learance. Under 
normal c ircum stances because o f  the speed o f a c t iva t io n  o f the classical 
pathway to prevent the fo rm a tion  o f p re c ip i ta t in g  complexes ( in i t ia l ly  by the 
binding o f m acrom o lecu la r C1 fo l low ed by covalent binding o f  C3b and f in a l ly  
re c ru itm e n t  o f  the a lte rna t ive  pathway) immune complexes probably very 
ra re ly  are able to fo rm  large insoluble aggregates which w i l l  be easily 
deposited in tissues and cause disease. I f  formed in the blood immune
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complexes w i l l  c ircu la te  possibly bound to e ry th ro cy te  CR1 (C ornaco ff  et al, 
1983) and be removed from  the c ircu la t ion  by the cells of the f ixed  
m a c ro p h a g e  s y s te m . Thus t h e i r  te n d e n c y  to  be d e p o s ite d  in the  
m ic ro c irc u la t io n  and produce disease is reduced. When fo rm ed  in the tissues 
the ir  small size a llows them to d iffuse away fro m  the s ite  o f fo rm a tion  and 
thus - the estab lishment o f a focus o f pers is tent in f la m m a tio n  is prevented.
When PIP fa i ls  a large la t t ic e  is bu i l t  up w ith  the fo rm a tion  o f insoluble 
immune aggregates. This can be compensated fo r  by the a lte rna t ive  pathway 
mediated so lub il isa tion  process (see Chapter 1). Cova lent binding of C3b to 
the antigen and antibody reduces the various forces (Fc-Fc in terac tions, 
antigen-an tibody bonds) holding the la t t ic e  toge the r (M il le r  & Nussenzweig, 
1975; Takata et al, 1984 & F u j i ta  et al, 1981). A lthough so lub il isa tion  can 
deal w ith  app rox im ate ly  ten t im es less immune complexes than PIP and 
g e n e ra te s  a g r e a te r  lo c a l  i n f la m m a to r y  r e a c t io n  ( S c h i f f e r l i ,  S te ig e r  &. 
Paccaud, 1986) i t  is nevertheless a potent back up system i f  PIP fa i ls  fo r  any 
reason. It (so lubil isa tion) is, o f course, the only system so fa r  described which 
l im its  immune complex size and allows fo r  opsonisation in the s itua tion  where 
immune complexes fo r  w hatever reason are unable to f ix  C l  and in i t ia te  
classical pathway a c t iva t io n .  Thus IgA immune complexes which are unable to 
a c t iva te  the c lassical pathway and are somewhat in e f fe c t iv e  in f ix in g  C3 have 
been shown to bind poorly  to  e ry th rocy tes , and subsequently are not cleared 
by the l iv e r  (Waxman et al, 1986).
A wide range o f e ry th ro cy te  CR1 numbers is found in normal individuals 
(Wilson e t al, 1982; Walport et al, 1985; Holme et al, 1986). The number of 
C R Is  on normal e ry th rocy tes  has been reported  to  be con tro lled  by two 
autosomal co-dom inan t alle les (Wilson et al, 1982) based on the f ind ing  tha t 
e ry th rocy te  CR1 numbers were d is tr ibu ted  t r im o d a l ly .  This same group of
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workers have also shown tha t a re s t r ic t io n  fragm en t length  polymorphism of 
the CR1 gene co rre la tes  w ith  e ry th rocy te  CR1 numbers (Wilson et al, 1986). 
O ther studies have suggested th a t  the inheritance o f e ry th rocy te  CR1 in 
normal ind iv iduals was polygenic (W alport e t al, 1985; Ross et al, 1985; Holme 
et al, 1986) based on the dem onstra tion o f a continuous d is tr ibu t ion  curve fo r  
e ry th rocy te  C R I .  As mentioned above fa i lu re  o f the physio log ica l handling o f 
c ircu la t in g  immune complexes can occur when there  is an im pa irm en t of the 
binding o f com plem ent reacted  complexes w ith  the com plem ent recep to r.  
Reduced numbers o f CR1 are found on the e ry th rocy tes  o f  patients w ith  SLE. 
In i t ia l ly  thought to  be an inher ited  de fec t (Wilson e t al, 1982) i t  has now been 
shown qu ite  c lea r ly  tha t the reduction of CR1 on e ry th rocy tes  in SLE is due 
to  the  d isease p rocess  (W a lp o r t  e t  a l,  1985; H o lm e  e t  a l ,  1986). In 
experim ents using blood transfusions, transfusing e ry th rocy tes  in to  patients 
w ith  SLE and low numbers of CR1 on the ir  e ry th rocy tes  resulted in the rapid 
loss o f CR1 from  the transfused e ry th rocy tes  (W alport, Ng & Lachmann, 
1985).
In the case o f  rheum ato id  a r th r i t is  reduced levels o f  CR1 are found on RA 
e ry thocytes , the reduction  being much less however than tha t  found in SLE 
(lida, Mornaghi &. Nussenzweig 1982; Tay lor et al, 1983; Yoshida et ai, 1985 & 
Ross e t  a l,  1985). T here  is also e v id en ce  s u g g e s t in g  a d e fe c t  in  the  
mononuclear phagocyte system (MRS) in RA; th is  im pa irm en t of MRS func t ion  
has been suggested by the dem onstra tion o f defects  in the clearance o f 
rad io- labe lled  IgG a n t i -R h  (D)-sensitised autologous e ry th rocy tes  (Gordon et 
al, 1981; F ie lds e t al, 1983 &  Malaise et al, 1985). A more recent study has 
examined MRS fun c t ion  in RA using k ine tic  analysis to a llow eva luation of 
both com p lem ent-m ed ia ted  and Fc-m edia ted c learance processes. This study 
o f nine RA patien ts  revealed a spec if ic  com p lem ent-m ed ia ted  clearance 
dysfunction  which was associated w ith  norm al Fc recep to r func t ion  and
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normal com plem ent levels (K im b e r ly ,  Meryhew & Runquist, 1987). Therefore  i t  
appears tha t  com p lem ent-m ed ia ted  immune complex clearance defects  can 
occur in RA independent o f serum com plem ent levels and Fc recepto r 
func t ion .
1 w i l l  now t r y  and place in to  perspective my own results in the l ig h t  o f the 
above. The hypothesis fo rm u la ted  at the outset o f my w ork  was re la ted  only 
to  the early  stages o f  this in t r ic a te  physiological system fo r  immune complex 
handling in the human and addressed the problem of fa i lu re  to  make immune 
complexes small and soluble by PIP. The question was asked whether a 
fa i lu re  o f  PIP was present in any o f  the rheum atic  diseases in which immune 
complexes had in some way been im p lica ted  in pathogenesis. I f  th is  was the 
case what was the mechanism involved and what was the c l in ic a l re levance, i f  
any, o f  th is  fa i lu re  o f PIP? I mainta ined tha t  a fa i lu re  o f  PIP was a possible 
mechanism which  m igh t a llow  the fo rm a t io n  of large insoluble complexes in 
the c irc u la t io n  w ith  subsequent deposition in tissues thus p e rm it t in g  immune 
complex mediated m an ifes ta t ions  o f  the disease. A fa i lu re  o f PIP would of 
course not only make the complexes insoluble but because o f  the reduction  of 
the amount o f C3b on the surface of the complex such a complex would 
c lea r ly  be unable to bind to CR1 e f fe c t iv e ly  whether there were normal 
numbers o f  CR1 or not. I have shown tha t  fa i lu re  o f PIP was due to the 
presence o f  an in h ib i to r  (Chapter 3, Sections 2 and 3). I f  the in h ib i to r  bound 
to the Fc piece o f the complex, the Fc piece would not then be able to bind 
to an Fc recep to r on the surface o f  a phagocytic  ce ll.  Therefore  i t  can be 
seen th a t  a fa i lu re  o f PIP w ith  reduced opsonisation and possible Fc blockage 
could resu lt  in a very serious de fec t in the defence sequence o f  immune 
complex handling. Thus defects  early  on in th is sequence would be expected 
to lead to  a much more serious problem than se lective  defects lower down 
the defence cascade.
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My results  in general support th is  concept. A fa i lu re  o f  PIP was found in RA 
sera and th is  was shown to be re la ted to the presence o f  an inh ib i to r  (see 
Chapter 3, Sections 2 and 3). Fa ilu re  o f PIP and increased in h ib i to ry  a c t iv i ty  
was found in only a p roport ion  o f RA sera (47%) but was s t r ik in g ly  associated 
w ith  the presence o f the e x tra -a r t ic u la r  fea tures of R A  (see Chapter 3, 
Section 8). High levels of PIP inh ib i to ry  a c t iv i t y  were also found in the SF of 
RA patien ts . Both these findings support the concept o f  a fa i lu re  of PIP in 
RA . The presence and leve l o f  in h ib i to ry  a c t iv i t y  was most c losely re la ted to 
s i tu a t io n s  in  R A  w h e re  im m u n e  c o m p le x  le v e ls  w e re  h igh  (eg SF and 
vascu l i t ic  disease). Fu rthe r  work on this aspect requires to be perform ed 
re la t ing  the in h ib i to ry  a c t iv i t y  to  levels o f immune complexes in serum and 
SF. I t  would be In te res ting  to  know whether the leve l of inh ib i to ry  a c t iv i ty  
was re la ted  to the c irc u la t in g  immune complex load or to any spec if ic  type of 
immune com plex.
The c l in ic a l studies ca rr ied  out by me were l im ite d .  A number of fu r the r  
investigations are necessary to  examine the re la t ionsh ip  between inh ib i t ion  of 
PIP, PIP and disease a c t iv i t y .  These would require  more long te rm  studies, eg
1. A one or tw o  year prospective study in RA patien ts  exam ining the changes 
in PIP and in h ib i t i o n  o f  PIP in r e la t io n  to  c l i n i c a l  d isease a c t i v i t y .
2. A fu r th e r  prospective study comparing the changes in PIP and inh ib it ion  of 
PIP w ith  the c l in ic a l and labora to ry  parameters o f  disease a c t iv i t y  in a group 
of R A  patien ts  undergoing second-line drug therapy w ith  gold, pen ic i l lam ine  
or ch loroquine.
181
3. F u r t h e r  e x a m in a t io n  o f  the  v a s c u l i t i c  R A  p a t ie n ts ,  n o t in g  w h e th e r  
im pa irm en t o f PIP or inh ib i t ion  of PIP is re la ted  to  the t im e  of onset of 
vascu lit is  and whether t re a tm e n t  of the vascu lit is  by c y to to x ic  drugs or 
c o r t i c o s te r o id s  w i l l  a l t e r  PIP and in h ib i t i o n  o f  P IP  in these p a t ie n ts .
In add it ion  to  studying the c l in ic a l re levance of inh ib i t ion  o f PIP in RA, much 
of the work in th is  d isserta t ion  was concerned w ith  try in g  to establish the 
nature o f  the molecule(s) responsible fo r  inh ib i t ion  o f PIP in R A  sera. I 
approached th is  problem by a tte m p t in g  to isolate and p u r i fy  the molecule 
responsible fo r  inh ib i t ion  o f PIP from  RA sera. In i t ia l  resu lts  pointed s trong ly  
to IgM -RF being the responsible p ro te in  and indeed I and others found tha t 
pu r if ied  IgM -R F was able to  in h ib i t  PIP (B a les tr ie r i e t al, 1984; O 'Sull ivan et 
al, 1986) (see Chapter 3, Section 6). However, when I compared pur if ied  
IgM -RF and IgM -R F in whole RA serum to  see i f  a l l  the in h ib i to ry  a c t iv i t y  in 
RA serum could be a t t r ib u te d  to the  IgM -RF ce rta in  d iscrepancies emerged 
which argued against IgM -RF being solely responsible fo r  inh ib i t ion  o f PIP in 
RA serum (see Chapter 3, Section 7).
The deve lopm ent o f ELISA techniques fo r  sensitive and spec if ic  measurement 
of RE classes was a m a jo r fa c to r  in a llow ing me to dissect the re la tionsh ip  
between the various RE classes (IgM, IgG and IgA) and in h ib i t ion  o f PIP. I was 
able to show quite  c lea r ly  tha t  IgM -RF could not by i ts e l f  be com p le te ly  
responsible fo r  the in h ib i t ion  o f PIP in RA sera (see Chapter 3, Section 7; F ig  
3.18 and Chapter 3, Section 9). This f ind ing  has been con f irm ed  by o ther 
workers (O 'Sull ivan et al, 1986).
In order to  t r y  and resolve these problems I undertook fu r th e r  studies on 
p u r i f i c a t i o n  o f  i n h ib i t o r y  a c t i v i t y  using sucrose  d e n s i ty  g ra d ie n t  
u l t r a c e n t r i f u g a t i o n  and subsequen t a f f i n i t y  c h ro m a to g ra p h y .  The re s u l ts
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showed tha t  in h ib i to ry  a c t iv i t y  could be demonstra ted in normal serum as w e ll 
as RA serum. Norm al serum was devoid of IgM -RF as measured by ELISA and 
R o se -W a a le r  t i t r a t i o n  (see C h a p te r  3, S e c t io n  9). M y f in a l  p u r i f i c a t i o n  
revealed a 6QkD molecule which could conceivab ly be im p lica ted  as the 
m olecule  responsible fo r  in h ib i to ry  a c t iv i ty .
In re trospec t the confusing in fluence of RF could have been removed i f  I had 
used norm al serum in my p u r i f ic a t io n  procedure in i t ia l ly  once i t  became c lear 
tha t IgM -RF could not account fo r  a ll o f the in h ib i to ry  a c t iv i t y  in RA serum. 
R e c e n t  w o rk  by A h m e d  and W ha ley  (1988), has d e m o n s t ra te d  a 60kD  
g lycopro te in  (gp60) which has been shown to in h ib i t  PIP. I t  is probable tha t  
the 60kD m olecule  which I detected is the same as th a t  described by Ahmed 
and Whaley.
Much work is s t i l l  needed to unravel the complex re la t ionsh ip  o f a pu ta t ive  
60kD in h ib i to r  of PIP and IgM -RF and the other classes o f RF both in serum 
and in SF. As regards the mechanism of action o f an in h ib i to r  I was able to 
show, using C4 consumption studies tha t  an inh ib i to r  o f  PIP in RA serum and 
SF probably acted by preventing  complem ent a c t iva t io n  (see Chapter 3, 
Sections 5 and 7). This work has recently  been extended and three reports  
have c o n f i r m e d  my f in d in g s ,  n a m e ly  t h a t  an i n h ib i t o r  o f  PIP a c ts  by 
preventing  com plem ent a c t iva t io n  by inh ib i t ing  the b inding o f C lq  to antibody 
(Niven & Whaley, 1986; Ahmed & Whaley, 1988; O 'Sull ivan et al, 1987). 
O 'Sull ivan and colleagues showed this e f fe c t  w i th  p u r if ied  monoclonal and 
polyc lona l IgM -RF (O 'Sull ivan et al, 1987).
Gp60 is present in normal serum (Ahmed and Whaley, 1988). C e rta in  questions 
are at once raised eg , what ro le  does i t  serve in normal physiologica l con tro l 
of immune complex processing in man? Does i t  occur in o the r species? Where
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is i t  synthesised? D iscovering its  ce ll of o r ig in  w i l l  a l low  fo r  in v i t ro  ce ll 
cu ltu re  studies to  be set up to  establish its  b iosyn the t ic  patte rns and to assess 
the fac to rs  which regu la te  its p roduction.
As outlined at the beginning o f  this closing discussion, i t  is c lear tha t  the 
processing o f  p o te n t ia l ly  ph log is t ic  immune complexes is an in t r ic a te  and 
c o m p l ic a te d  p he nom enon  in w h ic h  c o m p le m e n t  m e d ia te d  p re v e n t io n  o f  
immune p re c ip i ta t io n  is only one aspect. My results  support the hypothesis 
tha t fa i lu re  o f PIP in RA due to the presence o f serum inh ib ito rs  may a llow 
fo r  the fo rm a tion  and deposition o f po te n t ia l ly  damaging immune complexes 
and th is may co n tr ibu te  to  some o f the patholog ica l fea tu res  o f RA. However, 
in v i t ro  studies cannot be taken in iso la tion especia lly in what appears to  be a 
very com p lica ted  in v ivo phenomenon. I t  is tem pting  to suggest tha t  the 
c l in ica l co rre la t ions  between disease and inh ib i t ion  of PIP are causally
re la ted . In th is  d isserta t ion  I have only examined one aspect o f  human
immune complex processing namely prevention o f immune p re c ip i ta t ion  and 
have not investiga ted the ro le  played in this process by, fo r  example, the 
com plem ent rece p to r  (CR1), o the r immune complex systems especia lly human 
immune complexes, and genetic  in f luences.
Whether a raised leve l o f an inh ib i to r  of PIP in R A  and possibly o ther
diseases is o f pathogenetic  im portance or is jus t a consequence o f tha t
disease remains to  be ascerta ined. I t  has been shown tha t  the H L A -D R 4  gene 
is most s trong ly  associated w ith  the presence o f e x tra -a r t ic u la r  R A  and 
F e lty 's  syndrome (Westedt et al, 1986). Both o f these subgroups o f RA are 
associated w ith  c irc u la t in g  immune complexes (Zubler e t al, 1976; Hurd e t al, 
1979). I have shown th a t  inh ib i t ion  o f PIP is most s trong ly  associated w ith  
vascu l i t ic  RA (see Chapter 3, Section 8). C are fu l im m unogenetic  studies are 
required to  de lineate  the re la t ionsh ip  between the presence and level of the
184
inh ib i to r  o f  PIP and H L A -D R 4  or an extended hapiotype conta in ing DR4 and 
com plem ent a lle les. This would be an im po rtan t  aspect to  study as the genes 
fo r  C2 and C4 are found on the short arm of chromosome number six w ith in  
the region of the m a jo r h is to co m p a t ib i l i ty  complex.
C4A null a lle les have been shown to be associated w ith  SLE in humans 
(F ie lder et al, 1983; Howard et al, 1986). I t  is C4A ra the r than C4B which is 
im po rtan t  in the com plem ent mediated PIP reac tion  (S ch if fe r l i  et al, 1986). 
However, somewhat paradox ica l ly , F e lty 's  syndrome has re ce n t ly  been shown 
to be associated w ith  C4B nulls ra th e r  than C4A nulls (Thomson e t al, 1987), 
so i t  would seem tha t  at least in this subgroup of RA patien ts  tha t  p a r t ia l 
de f ic iency  o f C4A is not con tr ibu t in g  to disease pathogenesis through a 
mechanism invo lv ing  PIP as measured by the assay described in th is thesis. I 
have not s tudied PIP in F e lty 's  syndrome as such and i t  may be th a t  the type 
of immune complex found in F e lty 's  syndrome is d i f fe re n t  to tha t  in RA 
vasculit is  w ith o u t  F e lty 's  syndrome. Fu rthe r studies are required on this point 
looking fo r  C4A or C4B nulls in a group o f RA vascu lit is  patien ts  w ithou t 
F e lty 's  syndrome.
I t  is w o rth  remembering, however, tha t  C4A d e f ic ien t  heterozygotes w i l l  
a lmost c e r ta in ly  have enough C4A in the ir  serum to  enable the PIP reaction  
to proceed as i t  has been shown tha t  a very small amount (approx im ate ly  1% 
of normal levels) o f  pu r if ied  C4 is a ll th a t  is requ ired  to normalise PIP in 
human C4 de f ic ien t  serum (S ch if fe r l i  et al, 1985). This argues against C4 
a llo type  de f ic iency , by causing im pa ired PIP, as being an im po rta n t  fa c to r  in 
th e  in c re a s e d  s u s c e p t ib i l i t y  to  im m u n e  c o m p le x  d isease n o te d  in these  
com plem ent d e f ic ien t  patien ts . The C4 null genes may only be a m arke r fo r  a 
disease suscep t ib i l i ty  gene. In v iew o f  the fa c t  th a t  the genes fo r  C4 and C2 
are found w ith in  the m ajor h is to co m p a tib i l i ty  complex, the association of
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defic ienc ies  o f C2 and C4 w ith  immune complex diseases may be explained by 
the genetic  linkage o f these abnorm alit ies w ith  aberrant immune response 
genes which are responsible fo r  the auto-im m une disorders. Indeed null a lleles 
are found in extended haplotypes which are known to  be associated w ith  
a u to - im m un ity  (Welch e t al, 1985).
F a i lu re  o r im p a i r m e n t  o f  PIP found  in R A , e s p e c ia l ly  c o m p l ic a te d  by 
vascu lit is , occurs secondary to the prescence o f an in h ib i to r  o f this process as 
described in this d isserta t ion . Studies on the genetics o f th is  inh ib i to r  o f PIP 
are needed to  delineate its re la t ionsh ip  to the o the r genetic  markers in RA . 
This could be carr ied  out by genetic fa m ily  studies in RA as we ll as 
a t te m p t in g  to clone the gene responsible fo r  the pu ta t ive  60kD inh ib i to ry  
molecule, u t i l is ing  ex is t ing  D N A technology. I t  would be in te res ting  to  see i f  
the gene coding fo r  the 60kD molecule described above was also to  be found 
w ith in  the m a jo r h is to c o m p a t ib i l i ty  complex.
Fu rthe r studies concern ing the nature of the 60kD (or gp60) molecule are 
required. Rad io labe lling  w i l l  a llow  fo r  experim ents to be set up to measure 
the m etabo lic  tu rnover o f  this molecule in normal and in disease states. The 
development o f radioimmunassays and/or ELISA w i l l  ascerta in  its ro le in 
disease by re la t ing  the levels measured to the c l in ica l features observed. 
Work on these m e tabo lic  studies of gp60 could be ca rr ied  out in i t ia l ly  in 
animal models o f a r th r i t is .  P a r t ic u la r ly ,  what is the  re la t ionsh ip  between gp60 
and rheum ato id  fac to rs  o f the various classes?
1. Does gp60 in fluence the binding of RF to  IgG?
2. Is gp60 made by the same cells as RF? This would require  tissue 
cu ltu re  experim ents to study the production o f RF by cells and to  look fo r  
concom itan t p roduction  o f gp60 under the same cond it ions as those which
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enhance RF production. Also what is the in fluence o f adding gp60 i ts e l f  to 
these RF producing cells in cu ltu re?
3. In v ivo studies could be carr ied  out to study the production  of gp60 in
the experim en ta l animal under conditions which are known to  s t im u la te  RF 
production  (eg l ipopolysacchride induced RF production  in m ice).
To conclude I have demonstra ted tha t  serum fac to rs  im pa ir  PIP in RA and
tha t  these are re la ted  to the e x tra -a r t ic u la r  m an ifes ta t ions o f  disease. I have 
explored the re la t ionsh ip  between PIP and rheum ato id  fa c to r  and studied the 
mechanism of im pa irm en t of PIP in RA serum and SF. I have demonstrated 
the presence o f a new molecule in serum and its  possible im p lica t io n  in the 
im pa irm en t o f PIP has been discussed in the l ig h t  of recent f indings.
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